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CHAPTER 1 
General introduction 

Human immunodeficiency virus types 1 and 2 (HIV-I and HIV-2), the causative 
agents of acquired immune deficiency syndrome (AIDS) in humans, are members 
of the Lentivirinae subfamily of the Retroviridae family. The lentivirus 
subfamily also includes related members from other species, like monkeys 
(simian immunodeficiency viruses [SIV]), cats (feline immunodeficiency viruses 
[FIV]), and the ungulates sheep, goats, horses and cattle. 
Structure of lentivirllses 
Mature lentiviruses are spherical to ellipsoid particles with a diameter of 
approximately 100 nm consisting of a lipid envelope surrounding a cone shaped 
core (Gelderblom et al 1989) (Fig. I). In HIV-I the core is formed by a 24 kd 
capsid protein (p24). It contains two identical strands of positive-sense genomic 
RNA closely associated with the nucleocapsid proteins (p7 and p9) and several 
copies of the reverse transcriptase. A membrane associated matrix protein p 17 is 
situated between the core and the envelope. In the envelope a 41 kd 
transmembrane glycoprotein (gp41) is anchored. The transmembrane protein is 
non-covalently attached to the 120 kd surface glycoprotein (gpI20). The other 
lentiviruses have a similar structure, with slightly different molecular weights of 
their proteins. 
Genome organisation 
The proviral positive strand RNA genomes of lentiviruses are approximately 
9500 bp in length and are t1anked by two long terminal repeats (L TR) (Fig. I). 
The genome contains three large open reading li'ames (ORF), gag, pol and ellv 
that encode structural and enzymatic proteins. Apart from these large ORFs the 
genome of the primate lentiviruses contains six small genes. Of these auxiliary 
genes tat and rev are essential and, lie!, vi!, vpr, and VPIl (vpx in HIV-2 and 
SIV) are nonessential for virus replication ill vitro (for reviews see: Fauci 1993 
and Gibbs 1994, Morrow 1994) 
LTR. The LTRs direct and control viral DNA and RNA synthesis and the 
integration of proviral DNA into the genome of the host cell. They contain a 
polyadenylation signal sequence, a negative regulatory element (NRE), an 
enhancer region (NF-KB binding region), Sp I binding sites and transacting 
responsive sequences (TAR). 
gag. The gag gene codes for a precursor protein of 55 kd which is cleaved 
into p17, p24 and pIS by the viral protease. 
gag-pol. The 3'-end of the gag gene overlaps the 5'-end of the pol gene 
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Fig. 1 Genome organisation and virion structure of HIV -l. Abbreviations: MA. matrix protein; 
CA, capsid protein; NC, nucleocapsid protein; PR, protease; RT, reverse transcriptase; IN, 
integrase; SUo surface glycoprotein gp120; TM. transmembrane protein gp4l. 
by a few hundred nucleotides. The pol gene, which has a reading frame different 
from the gag gene, is translated as a result of a frame shift of 5% of the 
ribosomes translating the gag-pol mRNA (Jacks 1988). By autocleavage a 10 kD 
viral protease is released from the resulting gag-pol precursor polyprotein ( 
Ratner 1985, Sanchez-Pescador 1985, Kramer 1986, Debouck 1987). This 
protease cleaves the polyprotein into a functional reverse transcriptase, RNase H 
and integrase (Farmerie 1987, Peng 1989). The same protease is also responsible 
for the cleavage of the Gag precursor protein mentioned above. 
ellV. The ellV gene codes for a glycoprotein (160 kD for HIV-I), which 
after endo-proteolytic cleavage forms the surface unit (SU) protein (gp120 for 
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HIV -1) and the transmembrane (TM) protein gp41 for HIV -1). In primate 
lentiviruses the env gene products have been shown to control many functions 
which are important for viral pathogenesis (for review: Levy 1993, Sattentau 
1996, Chirmule and Pahwa, 1996). 
tat. The tat gene (transactivator) consists of two exons in the env region of 
the genome. Its transcription into mRNA involves two splicing events (Arya S.K. 
1985; Sodroski1985). Tat is a nuclear protein of 15 kd that acts by enhancing the 
rate of transcription from the 5' LTR (Hauber1987, Kao1987, RubenI989), 
boosting the expression of viral genes 50 to 1000 times the level seen in HIV 
mutants lacking the tat gene. Its effect depends on a short sequence within the 
LTR, the trans acting responsive (TAR) sequence, that is included in the mRNA 
transcripts of every gene of the primate lentiviruses. 
rev. The Rev protein is encoded. by a spliced mRNA of which the first 
coding exon overlaps the tat gene and the second exon the ellv gene (Sadaie 
1988). It is a nuclear protein that binds to the Rev responsive element (RRE), 
which is present in viral mRNA before splicing. It facilitates translocation of full 
length or single spliced viral mRNAs from the nucleus to the cytoplasm ( Malim 
1989). These mRNAs encode structural proteins. At low concentrations of Rev 
the viral mRNAs are predominantly small and multiple spliced ( Emerman 1989, 
Felber 1989). These small mRNAs encode regulatory proteins. The concentration 
of the Rev protein therefore plays an important role in determining whether a 
lentivirus infection is latent or productive. 
lief The nef gene encodes a protein on the cell surface of infected cells. 
The protein is believed to increase viral load and hence to allow the virus to 
overcome the host immune response. It may act as a superantigen and a mitogen 
for T-cells (Torres 1996a, 1996b). 
vif Vif for virion infectivity factor is a small hydrophobic protein that is 
essential for cell free infection. 
vpr and vpx. These genes are related (Tristen 1990,1992). All the 
primate lentiviruses contain at least one homologue of vprlvpx. The 
SIV mac/HIV -2/SIV sm, group of primate lentiviruses is the only one to contain 
both vpr and vpx genes. The vpr and vpx products are both virion associated 
(Cohen 1990), but their functional roles have not been elucidated. However, they 
seem to playa role in replication of the virus ill vivo, as a single vpx deletion 
mutant and a vpr/vpx double mutant of SIVmac were slightly, respectively 
severely attenuated ill vivo. No attenuation was observed for a single vpr 
deletion mutant (Gibbs 1995). 
vpu. Viral protein U (Vpu) is a protein unique to HIV -1 and the SIV strain 
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found in chimpanzees. It is a cytoplasmic protein that facilitates assembly and 
export of virions and the degradation of CD4 in the endoplasmatic reticulum 
(Lenburg and Landau 1993, Raja 1994). Deletion of vpu had a significant effect 
of infectivity and moderate effects on pathogenicity in a SCID-1IU model system 
(Aldrovandi and Zack, 1996). 
Lentivirus replication cycle. 
Attachment of the primate lenti viruses to the target cell is achieved by the high 
affinity interaction between the SU part of the virus glycoproteins and the 
cellular surface antigen CD4 (Stein 1987). This binding alone is insufficient to 
allow entry of the virus into the cell and for nearly 10 years researches have 
tried to identify the HIV co-receptor. Recently a number of co-receptors have 
been identified that are responsible for bringing the surface membranes of the 
host cell and virus together to allow fusion. The first identified co-receptor for 
macrophage tropic (M-tropic) strains is the chemokine receptor CCR5 (Alkhatib 
1996a, 1996b , Deng 1996, Dragic 1996) and for T cell tropic (T-tropic) strains 
of HIV, a chemokine receptor named fusin ( also termed CXCR4 or LESTR) 
(Feng 1996 Science 272: 872-877). Other chemokine receptors that have been 
implicated as co-receptors for HIV -I are CCR3 and CCR2b (Doranz 1996 Cell 
85: 1149-1158, Choe 1996). The newly described co-receptors are all seven 
transmembrane receptors from the large family of G protein coupled receptors 
in man, which respond to chemokines. Chemokine receptor CCR5 binds 
RANTES, MIP-Ia and MIP-Ip what explains the inhibition of these chemokines 
on PBMC infection by HIV -1, HIV -2 and SIV observed by Cocchi et al (Cocchi 
1995 Science 270:1811-1815). The importance of the CCR5 receptor for HIV-l 
infection is further emphasised by the finding that individuals homozygous for a 
32-base-pair deletion in the CCR5 gene are highly resistant to infection with M-
tropic, but not T tropic viruses. This deletion produces a truncated version of 
CCR5 that is not expressed at the cell surface (for a review on host factors and 
pathogenesis of HIV see Fauci 1996). 
The structural changes induced in the SU protein by its primary interaction 
with CD4 and than with its co-receptor, trigger a conformational change in the 
TM protein. As a result the fusion peptide of the TM protein penetrates the target 
cell (Lifson 1986, Weissenhorn 1997, B inley 1997). The transmembrane domain 
and the fusion domain of the TM protein are than brought into close proximity, 
facilitating the coalescence of the viral and cell membranes and, ultimately, 
membrane fusion. Upon fusion the viral core containing the two identical 
genomic RNA strands, reverse transcriptase and RNase H, protease, and integrase 
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(Yarmus and Swanstrom 1985, Farnet and Haseltine, 1990), is released into the 
cell's cytoplasm. The single stranded RNA is here converted by the action of 
reverse transcriptase (DNA polymerase and RNase H together) into a double 
stranded DNA intermediate, flanked at both ends by long terminal repeats (LTR). 
Formation of the provirus is completed once the double stranded DNA 
intermediate is integrated into the host genome by the action of the viral 
integrase. Expression of the genes of this provirus is a complex process 
controlled by both host and viral factors. In the latent stage of the infection short 
double spliced mRNAs coding for the regulatory proteins reach the cytoplasm 
(Feinberg 1986, Malim 1989). Later in infection the long unspliced mRNAs 
coding for the structural proteins and replicative enzymes are dominant. During 
this lytic stage of the infection the capsid precursor protein and the gag-pol 
precursor protein become inserted into the cell membrane via the myristic acid 
attached to their N-termini (Yeronese 1988) where they co-assemble. The capsid 
precursor protein contains two copies of a viral RNA-binding motif, the so callcd 
cysteine-histidine box (Marie and Spahr, 1986). This cysteine-histidine box 
specifically recognises the 'I' packaging signal located at the 5'-end of the genomic 
RN A and ensures that the RNA is incorporated in the resulting closed spherical 
particles (Lever 1989). Assembled nucleocapsids bud through the cell membrane, 
which contains the already digested virus envelope glycoprotein. Late maturation 
events include the proteolytic cleavage of capsid protein and replicative enzyme 
precursors (Oroszlan and Luftig 1990). 
Pathogenesis 
HIY is a sexually transmitted and blood-borne pathogen. Infection with this virus 
can have a number of diverse manifestations ranging from subclinical 
abnormalities to opportunistic infections and malignancies that define the 
acquired immunodeficiency syndrome (AIDS), the end-stage of HIY infection 
(reviewed by Levy, 1993). From the very first description, AIDS has been 
associated with the depletion of CD4+ T-lymphocytes (Gottlieb 1981). The virus 
infects CD4+ T lymphocytes and cells of the monocytes/macrophage lineage, 
dendritic cells and certain glial cells. The mechanisms by which HIY causes 
immunodeficiency are not entirely clear, but they are driven by a persistent HIY 
infection (Pantaleo 1993, Embretson 1993). Increasing evidence suggests that the 
decliny in CD4+ lymphocytes that finally results in the collapse of the immune 
system is not solely due to lytic infection of these cells. Defective antigen 
presentation and inappropriate signalling by antigen presenting cells resulting in 
T cell anergy and priming cells for activation induced apoptosis contribute to the 
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lymphocytes (Stanley and Fauci 1993, Meyaard 1993, Oyaizu 1995). 
Animal models for HIV infection in man 
The ideal animal model for AIDS would be an inexpensive readily available 
laboratOIy animal that can be infected with HIV -1 and subsequently develops an 
AIDS-like disease. Apes like the chimpanzee (Pall troglodytes) and the gibbon 
(Hylobates spp.) have been shown to be susceptible to experimental HIV-I 
infection (Alter1984, Fultz J. Virol. 1986, Goudsmit 1988, Arthur 1989, Lusso, 
1988). However, these animals have not been shown to develop AIDS upon 
infection. This aspect, together with the endangered status, the high costs and the 
ethical objections against the use of animals so closely related to humans, makes 
these models unsuitable for extensive AIDS research. It has been shown that HIV-
I can replicate in severe combined immunodeficiency (SCID) mice, reconstituted 
with human lymphocytes or human foetal thymus and liver or lymph nodes 
(McCune 1988, Aldrovandi and Zack 1996). However, functional CD8+ human 
lymphocytes do not persist in these mice and HIV -1 spreads rapidly and ablate T 
cells rather than replicate in a chronic, low grade fashion (Mosier 1989). 
Nowadays the most widely used primate model for HIV infection in man is 
simian immunodeficiency virus (SIV) infection of macaques (reviewed ill Schultz 
and Hu, 1993). SIVmac, isolated from a rhesus macaque ( Macaca Mulalla) 
(Letvin 1985) and SIVsm from sooty mangabeys (Cercocebus atys) (Fultz, 
PNAS 1986) show remarkable similarities with the human immunodeficiency 
viruses in virus morphology, genome organisation, replication cycle, tropism and 
pathology of disease that they cause in their natural hosts. The SIV and HIV-l 
envelope glycoproteins are relatively distinct. Therefore chimeric SIVs carrying 
HIV-l tat, rev, VPll, and ellV genes were constructed. These so-called SHIVs are 
able to replicate, albeit poorly, in cynomolgus macaques (Macaca fasciclilaris) 
(Shibata 1991, Li 1992, Sakuragi 1992) and may offer a system for testing HIV-
I based vaccines. 
Of the non-primate animal models FIV infection in cats is by far the most 
promising and widely studied. Like HIV-I and SIV, FIV is T lymphotropic, 
causes a progressive loss of CD4 + T cells, can infect macrophages and astrocytes, 
and eventually causes severe immunodeficiency or AIDS in its natural host 
(Barlough 1991, Dow 1990, Hoffmann-Frezer 1992, Hopper 1989, Hurtrel 
1992, Pedersen Science 1987, Sparger E.E., (review) AIDS 1989, Yamamoto 
Am J Vet Res 1988, Torten 1991). Like in the clinical course of HIV infection in 
man, five different stages can be recognised in the clinical course of FIV 
infection in cats (Ishida 1990). In the acute phase after infection, experimentally 
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infected cats develop a transient low grade fever, neutropenia which may persist 
for some days up to several weeks and generalised Iymphoadenopathy which can 
persist for several months (Pedersen [review] 1989, Yamamoto 1988). This 
phase is followed by the asymptomatic (AC) phase, which can last for years. The 
similarities of FIV infection of cats with HIV-I infection of man render it an 
attractive small animal model, that is relatively inexpensive and poses less ethical 
problems than the use of primates. However, it also has a number of drawbacks. 
Of these probably the most important one is that, unlike the primate lentivilUses, 
FIV does not use CD4 as the primary receptor. 
Anti-viral immunity 
The immune system can combat viral infections by a number of specific and non-
specific strategies. The specific immune response can be divided in antibody and 
cell mediated immunity, which both 'may exert their functions systemically and at 
mucosal surfaces. 
Antibody mediated immunity 
The effector molecules of humoral immunity are the immunoglobulins (lgs or 
antibodies) secreted by activated B cells. They can prevent virus infectivity by 
binding to specific antigens at the surface of vilUses (virus neutralisation), or by 
activating the complement system which can lead to viral cytolysis and uptake by 
macrophages. Once a virus has released its genetic information into the cytoplasm 
of a host cell, leading to the production of viral protein, antibodies can limit 
virus replication by causing lysis of the infected cell, either by utilising the 
complement pathway or through antibody-dependent-cellular cytotoxicity 
(ADCC). 
Naive B cells bear membrane bound IgM and IgD molecules on their 
surfaces with specificity for certain antigenic epitopes. The B cells proliferate 
upon encounter of the corresponding epitope (clonal expansion) creating many 
progeny B cells with antibodies having identical antigenic specificity. These B 
cells than differentiate into either effector (plasma) cells or memory B cells. 
During B cell proliferation B cells undergo a process called class switching 
whereby the class of antibody produced changes (for review on class switching 
see Snapper and Mond 1993). Different classes of immunoglobulins have 
different effector functions. For example, the pentameric structure of IgM makes 
it very suitable to activate the complement system by the classical pathway, IgG 
can target viruses for lysis by FcR bearing macrophages and secretory IgA 
antibodies playa major role in the mucosal immune response. 
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Antigenic stimulation of B cells alone is usually not enough to induce B 
cells to proliferate. This requires also cytokines secreted by activated T helper 
lymphocytes. 
T-cell mediated immunity and antigen presentation 
Contrary to B cells that can recognise free antigen, T lymphocytes (T cells) have 
receptors that recognise peptide fragments of degraded proteins associated with 
major histocompatibility complex (MHC) proteins (Townsend 1989). Different 
classes of T cells exist and can be distinguished by the type of cluster 
differentiation marker (CD) that they carryon their surface (Knapp 1989). CD4-
CD8+ T cells interact with peptides presented in association with MHC class I 
molecules (Norment 1988), whereas CD4+CD8- T cells recognise peptides bound 
to MHC class II molecules (Gay 1987). Exogenously delivered proteins are 
endocytosed by specialised antigen presenting cells like macrophages, dendritic 
cells or B lymphocytes. In the acidic endosomes the proteins are reduced and 
proteolytic ally cleaved into peptides (Van Noort 1991, Vidard 1991 ). The 
endosomal processing and class II MHC molecule biosynthetic pathways intersect 
(Peters 1991, Harding 1991) and the peptides bind to the a and b subunits of the 
class II molecular complex, displacing the invariant chain. The peptide loaded 
class II MHC complex is then expressed on the cell surface. 
Proteins delivered to the cytosol of cells, e.g. following a viral infection, 
are processed by the endogenous pathway. In this pathway proteins are 
proteolytically degraded into pep tides by proteasomes (Brown 1991, Martinez 
and Monaco 1991, Goldberg and Rock 1992), and transported by transporter 
molecules (TAPI and TAP2) to the lumen of the endoplasmatic reticulum, where 
they are further degraded. In the ER, newly synthesised MHC I heavy chains and 
p2-microglobulin are assembled into heterodimeric MHC class I molecules 
through the activity of accessory proteins such as p88. Each of these units can 
bind a peptide and the peptide-loaded MHC class I heterodimers are transported 
to the cell surface. 
The different pathways of antigen processing may not be totally separate. 
For example, Jarquemada et al. have demonstrated that the endogenously 
produced influenza A virus matrix protein can probably gain access to 
endosomal/lysosomal compartments via an intracellular route, leading to the 
processing and presentation in a class II-restricted manner. Increasing evidence 
also suggests that their is an alternative route for particulate antigens that results 
in a class I restricted presentation of these antigens (for review see Rock 1996). 
Peptides presented in the context of class I molecules will induce CD8+ 
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cytotoxic T-Iymphocytes (CTL) which can specifically kill virus infected cells, 
whereas peptides presented in association with class II MHC molecules will 
induce CD4+ T-helper (Th) cells. Different types of CTL and Th cells exist and 
they can mediate different types of immune responses through the action of their 
cytokines. A response that is often referred to as a type 1 response, 
preferentially mediates cellular immune responses, like delayed type 
hypersensitivity (DTH) responses and CD8+ CTL responses, whereas a type 2 
response provides help for antibody production (Cher and Mosman, 1987, Boon 
1988., Del Prete 1991, 1994, Parronchi 1991). 
Mucosal imlllunity 
The mucosal immune system is anatomically and functionally divided into 
separate regions. These include areas where antigens are encountered, processed 
and initial B- and T-cell triggering occurs (called inductive sites) and areas where 
immune cells actually function ( called effector sites) (McGhee et al. 1992 ). In 
hurnans the major inductive sites are probably the Peyer's patches of the 
gastrointestinal tract and the tonsils in the upper respiratory tract, with the 
lamina propria and salivary/mammary glands constituting the effector sites in the 
ga~trointestinal and respiratory tracts, respectively. Following oral entry, 
antigens may be taken up from the small intestine by the specialised microfold or 
"M" cells. These cells can even take up whole bacteria, and transport them to the 
follicle beneath, known as Peyer's patch. The induction of T- and B-cell 
responses to the antigens occurs here (inductive sites) and is followed by 
migration of the induced lymphocytes to the mesenteric lymph nodes. These 
lymphocytes then travel via the efferent lymphatics to the thoracic duct, where 
they enter the blood circulation. Later, cells migrate to various effector sites in 
the gastrointestinal, respiratory and genitourinary tracts. This is known as "the 
common mucosal immune system (reviewed by Brandtzaeg 1989, McGhee 1992, 
Kiyono 1995, Abreumartin 1996). IgA plasma cells initially stimulated by 
cognate Band T cell interactions in gut-associated lymphoid tissue (GALT) 
secrete local antibody that is specifically taken up by epithelial cells, transported 
to the mucosal surface, and released with a part of the receptor as secretory IgA 
(Bergmann and Waldman, 1988, Dahlgren et al 1989). Secretory IgA can protect 
against pathogens that replicate at or enter via mucosal surfaces (Michetti et al. 
1992, Walker et al 1992). 
The major route of entry of HIV is the mucosa of the urino-genital tract 
and the rectum. The Langerhans cells in the genital mucosa express CD4 and may 
be the first host cells were HIV replication will take place. Langerhans cells are 
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not present in the rectal mucosa (Hussain 1995) and it is thought that the target 
for HIV in rectal transmission may be colorectal or ileal epithelial cells. The 
importance of an adequate mucosal immune response to lentiviruses has been 
highlighted by studies in which vaccinated animals that were protected against a 
parental challenge failed to be protected when they we challenged via their 
mucosa (Sutjipto 1990). 
Approaches for the development of lentivirus vaccines. 
An effective profilactic HIV vaccine is urgently needed, especially for use in the 
third world. The ideal vaccine should be safe, confer long-lasting protection with 
a minimum of vaccinations, be inexpensive to produce and stable without cooling. 
Virtually all classic and new vaccine approaches are being studied for their 
effectiveness in the control of lentivirus infections, which by itself is indicative 
for the huge problems encountered. The most intensively explored approaches 
are listed here: 
Live alfellllafed vaccines 
Vaccines based upon live attenuated viruses are generally still the most effective 
vaccines. They have enabled the eradication of small pox and are expected to 
enable or facilitate the eradication of poliomyelitis and measles in due time. Since 
attenuated viruses replicate ill vivo they induce MHC class I restricted CTL 
responses. Furthermore, all the viral proteins can be presented to the immune 
system, thus inducing a wide spectrum of humoral and cell mediated immune 
responses, thereby reducing the risk of emerging escape mutants. The most 
impressive protection of macaques against SIV infection so far, has been obtained 
by vaccination with a live attenuated SIVmac239, which had a deletion in the lief 
gene (Daniel et al Science 1992). Despite the potential advantages of live, 
attenuated viruses as vaccines there are a number of concerns about their safety. 
For example, an attenuated virus may revert to its virulent form in vivo, as has 
been shown for the lief deletion mutant SIVmac32H (pCS) (Dittmer 1995). 
Modern recombinant DNA techniques can now rednce this risk by the 
introduction of defined deletion mutations, but these deletions do not rule out the 
possibility that recombination ill vivo with other (persistent) viruses will create 
more virulent viruses. Because infection with nef-deleted viruses persists for live, 
(temporary) loss of cellular immune competence due to intercurrent illness or 
due to ageing could result in an increased level of viral replication, which might 
result in the development of disease. Indeed, a SIVmac-lIef deletion mutant that 
protected adult macaques against wild type SIVmac infection was pathogenic in 
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protected adult macaques against wild type SIVmac infection was pathogenic in 
neonates (Baba 1995). The integration of provirus in the host genome. poses 
another problem in the development of live attenuated lentivituses. 
Inactivated whole virus vaccines 
These vaccines are based on complete viruses and can therefore contain several 
antigens which may favour induction of a protective immune response thereby 
reducing the risk of the emergence of escape mutants. However, they may contain 
undesirable antigens that induce an autoimmune response or enhance infection. 
They also generally fail to induce MHC class I restricted CTL responses, which 
may be essential in the clearance of lentivirus infections (for review: Gotch 
1996). In the FlV -cat system, vaccination of cats with paraformaldehyde fixed T 
cells (FL-4 cells) persistently infected with FIV and with parafonnaldehyde 
inactivated FlY derived from the same cells, proved to be protective against 
homologous and to a lesser extent heterologous challenge (Yamamoto 1991, 
1993). In the SlY-macaque system, vaccination with whole inactivated virus 
induced partial protection against challenge with PBMC from a SIVmac infected 
macaque (De Vries, 1994). Earlier reported protection against challenge with 
cell-free virus after immunising with inactivated whole SIVmac was almost 
certainly mediated by the immune response to cellular proteins incorporated into 
both the immunogen and the challenge viruses (De Vries 1994, Stott 1991). 
Subunit vaccines 
Subunit vaccines are based on the principle of using selected well-defined 
antigens. They do not pose the safety risks of live attenuated or whole inactivated 
virus vaccines, because they are non-infectious and the composition of the vaccine 
may be well defined and controlled. This makes it possible to include only those 
antigens that are important for the induction of protection. Antigens that may 
induce adverse effects like autoimmune reactions or enhancement of infection can 
be left out. Unfortunately subunit vaccines per se are generally poorly 
immunogenic when administered alone. They usually also fail to induce class I 
restricted CTL responses. Therefore a large number of adjuvant formulations 
(e.g. alum, muramyl-dipeptide, Qui! A) or carrier vehicles (e.g. iscom, 
liposomes, protein cochleates) have been developed which potentiate their 
immunogenicity (Vaccine Design, The subunit and adjuvant approach, 1995). 
However, most adjuvants have not been released for human use. A discussion of 
all adjuvants and adjuvant and adjuvant systems is outside the scope of this thesis. 
However, one of these, the immune stimulating complex (iscom), shows 
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The iscom is a cage-like structure with a diameter of 30-40 nm into which 
antigens can be incorporated (Morein 1984). It consists of glycosides of the 
adjuvant Quil A, cholesterol, the antigen, and in most cases phospholipids. Most 
viral membrane proteins with their hydrophobic anchor sequences are readily 
incorporated during iscom preparation. Proteins lacking hydrophobic 
transmembrane sequences can be incorporated by linking them to a hydrophobic 
carrier molecule such as palmitic acid ( Reid 1992). Alternatively, proteins can 
be treated with low pH to expose hydrophobic stretches in the molecule that are 
normally hidden (Morein 1990, Heeg 1991). The iscom is a highly effective 
antigen presentation form for viral antigens. It is a potent inducer of Band T cell 
responses, including MHC class I restricted CTL responses, leading to solid and 
long-lasting immunity against many viral infections (for review see 
Rimmelzwaan and Osterhaus 1995). When administered by the intranasal route, 
iscoms can induce mucosal immune responses in the lung, including specific IgA 
and CTLs. The induction of CD8+ CTLs by iscoms is most likely a result of 
entry into the endogenous pathway of antigen processing and presentation. This 
was shown in vitro by the stimulation of a CD8+ CTL clone specific for the 
fusion (F) protein of measles virus (MV) by F protein incorporated in iscom, but 
not by purified protein or UV inactivated MV. This stimulation was insensitive to 
the action of chloroquine, which inhibits the exogenous pathway of processing by 
raising the pH of the endosomal compartment. In addition, the presentation of F 
protein by iscom to CD8+ T cell clones was abrogated when a TAP negative 
antigen presenting cell was used (Van Binnendijk 1992). 
Macaques immunized with iscom containing envelope and core protein and 
Nef peptides of SIVmac developed virus neutralising antibodies and MHC class I 
restricted CTL (Hulskotte, Virology 1996). Unfortunately, this was insufficient 
to protect the macaques against a cell-free SIVmac challenge. A vaccine 
consisting of a mixture of iscom prepared from inactivated whole SIVmac (32H) 
grown in a human T-cell line, a gpl20-enriched is com preparation and p27 
protein failed to protect macaques against cell-free SIVmac produced in PBMC 
from a macaque, but did protect two out of four macaques against intravenous 
challenge with PBMC from a SIV infected macaque (Osterhaus 1992, De Vries 
1994). Interestingly, the protected monkeys shared a MHC class I allele with the 
PBMC donor monkey, suggesting that SIV specific CTL played a role in the 
observed protection (Heeney 1994). 
Virus like particles and self-aggregatillg proteins. 
Certain proteins that spontaneously associate into virus-like-particles (VLP) are 
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Certain proteins that spontaneously associate into virus-like-particles (VLP) are 
also evaluated as carriers of viral proteins. One approach is the Ty:VLP system 
(Mellor 1985) wherein a foreign DNA sequence is fused in-frame to the TY A 
gene. Following expression in yeast the VLP are formed which can then be 
purified and used for immunisation experiments. Using this system a MHC class I 
restricted CD8+ CTL response was induced against the principle antibody 
neutralising domain, V3, of HIV -I (Layton 1993). 
The hepatitis B virus core antigen (HBcAg) and surface antigen (HBsAg) 
are examples of self-aggregating viral proteins that are evaluated as potential 
carriers for foreign antigens (Francis et a!. 1990). HBcAg spontaneously self-
aggregates into characteristic 27 nm particles. Chimeric core particles can be 
created by the insertion of peptide sequences onto the N- or C-termini of HBcAg 
(Clarke, 1987 and Stahl, 1989). Fusions of the V3 domain from HIV -1 to either 
the N- or C-terminal of HBcAg, resulted in the induction of neutralising 
antibodies to HIV-I (Von Brunn 1993) and specific MHC class I restricted CD8+ 
CTL responses were induced upon immunisation with the V3 domain fused to 
HBsAg (Schlienger 1992). 
Live, recombinallf viral and bacterial carriers. 
Several viruses and bacteria have been evaluated as potential live carrier systems 
to present heterologous antigens to the immune system. Some of the viral vectors, 
like attenuated vaccinia virus (Andrew 1991 ) and adenovirus (Johnson 1988 ) 
replicate in vivo, whereas others, like poliovirus minireplicons (Burke 1988; 
Evans 1989; Dedieu 1992) and avipox virus (Radaelli 1994), are engineered to 
have a restricted or abortive replication. Since they all infect host cells, both 
humoral and cell-mediated immunity, including class I restricted CTL responses, 
can be induced. A chimeric influenza virus has been used to induce neutralising 
slgA against HIV -I after intranasal immunisation, which was detectable for more 
than a year (Munster 1995). A combined vaccination scheme using a live vaccinia 
virus expressing the SIV envelope protein followed by a boost with purified 
protein protected macaques against a challenge with SIVmne (Hu 1992), but 
failed to protect against challenge with SIVmac (Giavedoni 1993). Some viral 
carriers like influenza and poliovirus can only accommodate relatively small 
inserts, limiting the number of heterologous Band T cell epitopes that can be 
presented. Live viral carriers may pose similar safety risks as live attenuated 
viruses, like the generation of more virulent viruses from the carrier by 
mutations or recombination in vivo. 
The most widely studied bacterial carriers are BCG (Bacilllls Call1letfe-
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Guerill) and attenuated Sal mall ella strains. BCG has been used as an attenuated 
vaccine against Mycobacterium tuberculosis infections for many years. It is an 
avirulent derivative of M.bovis and is the most widely used live human vaccine. 
BCG has been administered to about a billion people within the first months of 
life with remarkable few side effects. Its adjuvant qualities have been well 
documented. Killed BCG included in Freund's adjuvant stimulates cellular 
immunity against other included antigens. The safety of BCG and its strong 
adjuvant properties prompted researchers to develop it as a live carrier for 
heterologous antigens (Stover 1991). BCG expressing the principal neutralising 
domain of the envelope of HIV induced VN antibodies in mice and was able to 
protect against HIV infection in a hu-SCID mouse model (Honda 1995 ). 
Of the attenuated Salmollella strains used as live carriers, the am mutants 
have received most attention. The aro genes encode enzymes of the prechorismate 
pathway, which is the sole route of biosynthesis of several key aromatic 
metabolites. Mammals do not possess an equivalent pathway and must extract the 
aromatic components from their diet. The concentration of these aromatic 
compounds in mammals is insufficient for Salmollella amA, C or D mutants, 
resulting in a self-limiting infection. S. typilimurium aroA mutants are highly 
attenuated in mice, yet proved to be excellent single dose vaccines against 
salmonellosis (Hoi seth and Stocker, 1981). Salmollella typilimurium aroA strains 
have been used successfully to present heterologous bacterial (Clements 1986, 
Poirier 1988), viral (Charbit 1993, Schadel 1994, Tite 1990) and protozoal 
(Aggarwal 1990, Sadoff 1988, Yang 1990) antigens to the immune system of 
mammals. Systemic humoral and cellular responses, including class I restricted 
cytotoxic T lymphocytes (CTL), and mucosal humoral responses have been 
shown to result from vaccination with recombinant Salmollella strains (Aggarwal 
1990, Flynn 1990, Gao 1992, Turner 1993, pfeifer 1993). The induction of local 
as well as systemic immune responses following oral administration most likely 
depends on their ability to proliferate in the GALT as well as in the liver and 
spleen. Induction of a mucosal immune response may act as a first line of defence 
against pathogens like HIV -1, of which the major port of entry are the mucosae 
of the urogenital and gastro-intestinal tract •. S. t)'pilimurium amA expressing the 
Gag protein of SIV induced specific secretory IgA responses and systemic CTL 
responses, but failed to induce specific serum antibodies, following oral 
administration (Valentine 1996). 
A potential disadvantage of bacterial carriers is their inability to glycosilate 
proteins. Also, the conformation of viral proteins expressed by bacteria is not 
necessarily identical to their natural conformation in the virus. These drawbacks 
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may reduce the range of virus neutralising epitopes presented to the immune 
system. 
The induction of local and systemic immune responses, the low production 
costs and the ease of (oral) administration make attenuated Salmollella strains 
attractive vaccine candidates. However their development as live carriers for 
heterologous antigens, has been hampered considerably by problems with 
instability of expression or poor production levels caused by the toxicity of the 
antigens for the producing Salmollella strains. A number of strategies have been 
developed to ensure stable expression of the heterologous antigens, like 
chromosomal integration of the gene encoding the heterologous antigen (Hone 
1988, Strugnell 1990) or linkage of an essential gene to the expression plasmid 
(Nakayama 1988, Curtiss 1989). Although these approaches have proven to be 
useful for the stable expression of a number of antigens, they may result in over-
attenuation of bacteria expressing antigens at toxic levels. Another approach is 
the use of promoters that are induced ill vivo. This kind of promoters may delay 
antigen expression till the bacteria reaches tissues relevant for the induction of 
protective immunity, resulting in much better humoral responses compared to a 
constitutive promoter (Chatfield 1992). However, also this strategy does not 
allow the production toxic antigens during the complete route of infection nor 
will it allow further growth of the bacterial population once antigen expression 
reaches toxic levels. For the induction of antibodies against the B subunit of the 
heat labile toxin (LTB) of E.coli the initial amount of antigen produced appeared 
to be of more importance than the stability of expression (Cardenas 1993, 1994). 
For the induction of class I restricted CTL responses abundant as well as stable 
antigen expression have both been shown to be of importance (Turner 1993, 
Wick 1993). 
Nucleic acid immullisatioll 
Nucleic acid immunisation, also referred to as genetic or naked DNA (or RNA) 
immunisation, is a novel immunisation strategy that shows considerable promise 
for vaccine development. It involves the induction of a specific immune response 
to an antigen expressed ill vivo following the introduction of its encoding 
polynucleotide (DNA or RNA) (for a review see Shiver 1996). Because the 
foreign antigen is synthesised by the host cells, it is able to induce specific MHC 
class I restricted CTL responses, but without the risk of inadvertent infection. 
The heat stability and the relative simple quality control are other advantages of 
nucleic acid vaccines over other types of vaccines. Nucleic acid immunisation 
against influenza has induced broad cross-protection with antigenically distinct 
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SHIV challenge has been obtained with a nucleic acid vaccine that induced 
neutralising antibodies and specific CTL responses (Boyer 1996). A theoretical 
risk with nucleic acid vaccines is tumour induction as a result of DNA integration 
into the genome, but so far studies have failed to demonstrate DNA integration. 
Specific problems in lentivirus vaccine development 
A number of lentivirus characteristics hinder the development of safe and 
effective vaccines against these viruses. Lentiviruses have a high mutation rate 
due to low fidelity of the lentivirus reverse transcriptase and the absence of 
proofreading activity. This results in the constant generation of mutants that 
escape from surveillance either by VN antibodies or specific T -cells. Following 
integration of the proviral DNA into the host genome lentiviruses can remain in a 
quiescent state, invisible for the immune system. The initial site of infection is 
usually at the mucosae of the genital tracts or the intestine where the virus can 
replicate in the dendritic cells. To limit viral replication in this initial stage of 
infection the induction of an effective mucosal immune response will be 
necessary. Unfortunately most vaccine strategies pursued currently do not induce 
mucosal immune responses. Another problem in the immunologic control of 
lentivirus infection is that they destroy or interfere with the functioning of T-
helper cells which have a key role in the immune system. This may not be a 
problem for vaccines inducing sterilising immunity, but it may pose a major 
obstacle for the development of vaccines that merely limit viral replication. 
Outline of this thesis 
As described above, attenuated recombinant Salmonella strains have potential as 
vaccine candidates against lentivirus, but their development has been seriously 
hindered by problems with instability or poor expression levels of toxic 
heterologous antigens. Therefore, a major aim of this thesis was to develop a 
generally applicable expression system for the abundant and stable production of 
heterologous antigens in Salmonella vaccine strains. This expression system 
should allow constant production of heterologous antigen, even if their levels are 
toxic for the producing bacteria. The construction of such an expression system 
and its evaluation using heterologous bacterial, viral and parasitic antigens, are 
described. Furthermore, it is used to generate a FIV -Gag producing Salmonella 
strain, of which the immunogenicity is evaluated in cats. In a more extended 
study the immunogenicity and effectiveness of an experimental vaccine based on 
FlV-Env and Gag producing Salmonella strains is tested in the FlV/cat model. To 
compensate for the lack of glycosilation of bacterially produced proteins, this 
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vaccine was also tested in combination with an iscom preparation containing 
glycosilated FIV envelope protein. Finally, the potential of iscom preparations 
containing glycosilated envelope protein and a bacterially produced b-
galactosidase-Env fusion protein mixed with Quil A as an adjuvant, are evaluated 
as potential FIV vaccine candidates. The results of the studies described in this 
thesis are summarised and discussed in the last chapter. 
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Salmonella strains have great potelllial as live-carriers of heterologous antigens to induce 
immunity against a variety of infectiolls diseases. However, the amoullt of heterologous 
antigen required to induce an adequate immune response may be toxic for the bacterium 
and result lit cell death, overattelluotioll or loss of expression of the heter%golls anligen. 
To solve this problem all expression veclor was developed with a strollO promoter located 
011 a DNA/ragment which is inverted at random. Aflligell is Dilly expressed ill olle particular 
orienlation oJlhe promoter. Thus a bacteria! populatioll harbouring the plasmid will cOllsist 
oj a sllbpopulatioll II'hich does 1I0t prodllce heterologous antigen, and is thereJore I/ot 
affected ill groll'th, persistence and dfssemination within the host. Further, this 
1I01l-producing poplllatioll will cOlltinuously segregate antigen-producing bacteria. To 
evaluate the system, CtxB was used as a model antigen. Analysis oj the plasmid DNA 
isolatedJrm;, Salmonella revealed a selection against the promoter orientation/hat directs 
transcription oj the ctxB gene. In spite oj this, the vector was stably maintained in vivo 
and induced CtxB-specific lOA and IgG ill mice. These results indicate that this kind oj 
expression vector lJlay offer a solution to the problem oj unstable expression oj Joreign 
antigens ill live bacterial vaccine strains. 
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Attenuated Salmonella strains expressing heterologous 
antigens have been shown to be able to induce mucosal, 
humoral and cell-mediated immunity against these 
antigensl. With respect to cell-mediated immunity, both 
class I and II MHC-restricted cytotoxic T cells directed 
against heterologous antigens have been detected2- 4• 
Furthermore, in animal models protective immunity has 
been induced,with a number of Salmonella-recombinant 
strains against bacterial, viral and protozoal infections4- 6 • 
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Live Salmollclla vaccine strains have been accepted for 
use in humans. An oral human typhoid vaccine based 
on SalmOllclla /yphi strain Ty21a, a galE mutant, has 
been licensed in many countries after it was shown to be 
efficacious in field trials7• Other more defined attenuated 
Salmonella strains have been constructed, such as aroA 
and c),a, crp mutants. These strains have been shown to 
be safe and immunogenic in a number of animal models. 
Salmonella strains attenuated by oro mutations have been 
shown to be safe even in immune-suppressed animals l • 
S. /yplli aroA, purA and S. typhi aroC,D strains have 
undergone phase 1 clinical trials in humans8.9. 
Clearly, Salmol/ella strains have great potential as live 
carriers to induce immunity against a variety of infectious 
diseases. However, the amount of heterologous antigen 
required to obtain an adequate immune response is often 
toxic for the bacterium, and this forms a major obstacle 
to the use of recombinant Salmol/ella strains. In order 
to solve this problem, an expression system was 
developed, based on an invertible promoter, which results 
in high-level expression of the antigen of interest in only 
a minor part of the bacterial population 10. If the amount 
of antigen produced is toxic for the bacterium, it will 
stop growing, but the nOll-producing part of the 
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population will continue to grow and segregate new 
antigen producers. Here we describe the construction of 
this expression "'ector and its evaluation in a mouse 
model using the D subunit of cholera toxin (CtxB) as a 
model antigen. 
MATERIALS AND METHODS 
Bacterial strains, plasmids and media 
Escherichia coli strain DH5a (BRL Life Technologies, 
Breda, The Netherlands) was used as a host for all 
plasmid constructions, Before introduction into the 
Salmol/ella typhimuriu1tl vaccination strain SL326111, 
plasmids were passaged through the restriction-deficient, 
modification-proficient S, typhimltrium strain SL5283, All 
bacteria were grown in NZCYM12 aerobically at 31QC, 
unless indicated otherwise. Ampicillin was used at 
100Jlgml- 1• 
DNA manipulations 
Isolation of plasmid DNA, preparation of DNA 
fragments and ligations were carried out using standard 
methods12. Plasmids were introduced into bacteria by 
electroporation using the Biorad Gene Pulser (Bio-Rad, 
Richmond, CA, USA) as follows: overnight cultures were 
diluted 1: 100 in NZCYM and grown aerobically at 31"C 
to mid-log phase. The cells were subsequently harvested 
by centrifugation and washed twice with ice-cold distilled 
water. Finally, the cells were resuspended to 1010. 
cells ml- 1 in distilled water containing 10% (w/v) 
glycerol, frozen in dry ice and stored at _10°C until use. 
For electroporation, DNA was precipitated, resuspended 
in distilled water and subsequently mixed with 109 cells 
in an ice-cooled cuvette and electroporated at 2.5 kY, 
25 JIF and 200 n. Immediately after electroporation 
I ml of NZCYM was added and the cells were 
subsequently incubated aerobically for 30 min at 37°C. 
Aliquots were plated on NZCYM~agar plates containing 
ampicillin and incubated at 31°C. 
Immunization of mice and in (,Iro stability of pYZ17 
For oral immunization, bacteria from logarithmically 
growing cultures were harvested by centrifugation, 
washed in phosphate-buffered saline (PBS) and resuspen-
ded to a cell concentration of 2 x 1010 cells ml- 1 in 10% 
NaHC03• Subsequently, 6-week-old female Balb/c mice 
received two successive oral immunizations with 1010 
bacteria at days I and 4 followed by two successive 
booster immunizations with the same number of bacteria 
at days 32 and 36. At days 11, 18,25,32 and 60 two mice 
per group were bled and their spleens and guts were 
removed. Gut-washes were obtained by washing the 
complete gut-segment distal from the stomach with 1 ml 
PBS, centrifuging the samples for 10 min at 10000 
rev min -1 and collecting the supernatants. Gut-washes 
and sera were stored at -20°C until tested by ELISA. 
The spleens were homogenized and the stability ofpYZ11 
was determined by comparing the number of viable 
bacteria that could be recovered on McConkey agar 
plates with and without ampicillin (l00,ugml- 1). 
Essentially the same procedure was followed for 
intraperitoneal (i.p.) immunization, except that bacteria 
were suspended in PBS to a cell concentration of 2 x 106 
cells ml- t, and mice were immunized with 106 bacteria 
intra peritoneally (Lp.) at days 4 and 32. 
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ELISA 
p-/ac/amase ELISA. p-Iactamase (TEM R +, Boeh-
ringer Mannheim, Germany) was diluted in 0.1 M 
phosphate buffer, pH 8.1, to a protein concentration of 
2,5 Jig 001- 1 and adsorbed onto 96-well high-binding 
microtitre plates (Costar E.I.A.fR.I.A. plate HB, Cam-
bridge, USA) by overnight incubation at 4°C. After 
washing with demineralized water containing 0.05% 
Tween-80, plates were blocked with PBS containing 5% 
fetal calf serum (FCS), 5% NaCI and 0.1 % Tween-20. 
Plates were washed with 0.05% Tween-80 containing 
demineralized water and each well was incubated with 
100 JII dilutions of the sera or gut-washes. After 
incubation for 1 h at 3rC, the plates were washed twice 
and the wells were incubated with goat anti-mouse IgG 
or 19A HRP-conjugates (Southern Biotechnology Inc., 
Birmingham, UK) diluted 8000 times. Binding of the 
conjugate was detected by addition of loo,ul of a 
TMBjDONS-based substrate solution to each well. After 
IOmin at room temperature, lOOJd 2M H2S04 was 
added to stop the colour reaction. The absorbance at 
450 nm was determined in a Titertek Multiscan (Titertek. 
ICN Biomedicals, Amsterdam, The Netherlands). The 
titre was defined as the highest dilution of test samples 
at which the A450 was higher than the mean A450+ three 
times s.d. of the corresponding samples from Balb/c mice 
immunized identically with SL3261 without pYZ11, 
LPS-ELISA. The ELISA for LPS differed from the 
p-Iactamase ELISA only in the coating step, which was 
performed in 0.11 M acetate buffer, pH 5.5, containing 
5.0I1gml-1 S. /),phimllrillm LPS (Sigma, cat. no. L6511, 
Axel, The Netherlands) and the anti-IgG and IgA 
HRP·conjugate dilutions employed (1:4000). The titre 
was defined as the highest serum dilution at which the 
A4~O was higher than the mean A450 + three limes 
standard deviation (s.d.) of preimmune sera. 
CtxB-ELlSA. CtxD (List Biological Labs, Campbell, 
CA, USA) was diluted in PBS to a concentration of 
5.0 Jig 001- 1 and adsorbed to the microtitre plates. The 
used anti-IgG and IgA conjugates were diluted 10000 
and 4000 times respectively. All the other conditions were 
as described for the p-lactamase ELISA. 
Western blot analysis of recombinant bacteria 
Overnight cultures were diluted ten limes in NZCYM 
and incubated aerobically until the absorbance of the 
culture at 550 nm reached 1.0. Aliquots of bacteria were 
pelleted, resuspended in 100 JII sample buffer l3 and boiled 
for 20 min. Samples of IOpl were separated on 15% 
SDS-PAGE and subsequently transferred to nitro-
cellulose. After blocking with 0.5% Tween-80 in PBS for 
30 min the blots were incubated at room temperature 
with a goat-anti·CtxB serum (List Biological Labs, 
Campbell, CA, USA) diluted 500 times in PBS containing 
0.5% Tween-80 and 0.5% low-fat milk powder. After 
washing three times over a period of 30 min in PBS 
containing 0.5% Tween-SO, the blot was incubated for 
1 h at room temperature with horseradish peroxidase-
conjugated protein A (Amersham, Den Bosch, The 
Netherlands) diluted 2500 times with 0.5% Tween-80 in 
PBS, After three washings, the blot was developed in a 
TMBjDONS-based substrate. 
RESULTS 
Construction and characterization of pYZ17 
Plasmid pYZ17 is an expression plasmid with an 
invertible promoter based on the bacteriophage Mu Gin 
system. The Gin invertase of phage Mu initiates 
spontaneous G segment inversion on phage Mu genome, 
which takes place between two 34 bp inverted repeat (IR) 
sequences t4• The size of the invertible segment is not a 
crucial factor in the inversion process, a G segment as 
small as 40 bp is still inverted. and the left (L) and right 
(R) IR sequences are equivalent in terms of their roles in 
the recombination process and can therefore substitute 
for each other15, Based on these observations, an 
invertible promoter can be constructed by inserting a 
promoter fragment between two identical IR sequences. 
Plasmid pYZI7 is a derivative of pYZ16a (Van and 
Meyer, manuscript in preparation), which has the 
following features; a promoteriess DNA fragment coding 
for phage Mu Gin invertase, a clts857 gene fragment 
coding for temperature-sensitive lambda cI repressor, a 
fd transcriptional terminator downstream and an rrnB 
Tl transcriptional terminator upstream of c1ts857 
fragment, a promoterless cholera toxin subunit B 
fragment sequence, origin of replication and ampicillin 
resistance gene from pBR328, Plasmid p YZ17 (Fig lire I) 
was constructed by introducing an XIIOI IR-PL-IR 
module into the single X/wi site on pYZ16a. To construct 
the IR-PL-IR module, the lambda leftward promoter PL 
was isolated from pLC2833 16 as an ",250bp Xhall 
fragment and ligated at both ends with a synthetic IR 
sequence flanked by Bell/X/wi sites: 5'-GATCATTTA-
CCGTTTCCTGTAAACCGAGGTTTIGGAT AAC·3'. 
After ligation, the IR-PL-IR module was inserted into 
pYZ16a. In the resulting plasmid, pYZ17, antigen (CtxB) 
expression can only occur in one orientation of the PL 
promoter (designated the 'ON' orientation). Besides a 
correct orientation of the PL promoter, expression of 
CtxB requires the bacteria containing pYZ17to be grown 
at temperatures higher than 28°C to inactivate the 
thermosensitive repressor of PL' 
Expression of CtxB was analysed on Western blots, 
after growing strain SL3261 harbouring pYZ17 at 28 and 
37°C. As expected, CtxB could not be detected when 
bacteria were grown at 28°C, but was clearly induced at 
37°C (Figllre 2), 
If there is no selection against a particular orientation 
of the PL promoter, one expects that in a bacterial 
population habouring pYZI7, 50% of the plasmids wiII 
contain the PL promoter in the 'ON' orientation. Howe .. 'er, 
if transcription driven by the PL promoter in a particular 
orientation (most probably the ON orientation) is 
detrimental, the percentage of plasmids with this 
orientation will be smaller than 50%. To estimate the 
fraction of pYZ17 molecules in the bacterial population 
which contained PL in the ON orientation, plasmid DNA 
was isolated from bacteria grown at 28 and 37°e, and 
subsequently digested with EeaRL Plasmid pYZ17 
contains two EeaRI restriction sites (Figure J), one of 
which is located between the two inverted repeats (IR) 
just downstream of the PL promoter. Digestion of pYZI7 
with EeaRI should result in fragments of 5.0 and 1.9 kb 
for plasmids containing the PL promoter in the 'OFF' 
orientation and 4.7 and 2.2 kb for the ON orientation. 
Analysis of EeoRI-digested pYZ17 DNA derived from 
bacteria grown at 37°C revealed that a small fraction of 
TI 
fd T 
EcoRI 
EcoRI 
IR PL IR 
pYZ17 
(6.9 kb) 
Figure 1 Plasmid pVZ17 containing an Invertible promoter lor CbtB 
expressIon. PL, leftward promoter 01 bacteriophage lambda; IR, Inverted 
repeat; n, frnB nlranscription terminator; fd T, transcription terminator 
fd T; amp, ampk!llin reslstan<;e gene; g{n, Invertase gene; elts, phage 
lambda temperature-sensitive repressor protein gene; elxB cholera toxIn 
B subunit gene, The two EcoRI sites which can be used to determIne 
the orientation of the Pl promoter afe Indicated. Shown Is pYl17 with 
the Pl promoter In the OFF orientation 
-.. ·.·OtxB 
12 
Figure 2 ClxB expressIon by SL326I(pVZI7) at 28 and 37'e. Total cell 
Iysates contaInIng equal quantities of bacteria were subjected 10 
SOS-f'AGE, followed by Western blotting using a ClxB--specilic serum. 
Lane I, SL3261 grown aI37'C; lane 2, SL3261(PVZ17) grown at 28'C; 
lane 3, SL3261(PYlI7) grown at 37'C 
pYZ17 plasmids contained PL in the ON orientation, 
suggesting that PL"driven transcription towards the etxB 
gene is selected against (Figure3). Unexpectedly, when 
cells were grown at 28°C most pYZI7 molecules were 
also found to contain the PL promoter in the OFF 
orientation. This suggests that even the low transcription 
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level from the PI. promoter at 28°C is sufficient to select 
against the oN-form of pYZI7. 
Immunogenlcity and stability of SL3261 (pYZ17) 
To determine whether pYZl7 was stably maintained 
ill vivo, mice were infected Lp. with SL3261(pYZI7), and 
bacteria were recovered from the spleens after 1,2 and 
3 weeks to determine the fraction of SL3261 cells still 
containing pYZI7 (Figllre4). During this period, pYZI7 
appeared to be completely stable. Five bacterial colonies 
recovered from the spleens were tested for expression of 
CtxB, and turned out to produce the same amount of 
CtxB as the original strain used for infection (results not 
shown). 
ON 
1 2 
6.6 kb 
4.4 
2.3. 
2.0 
1.4 
Figure 3 Restriction analysis 01 pYZI7, derived from strains grown al 
28 or 37'C. Plasmid DNA was isolated from Sl5283(pYlI7) grown at 28 
or 37'C, digested with EcoRI and subjected to electrophoresis on a 1% 
agarose gel. Fragmenls characteris\lc for plasmlds containing the PL 
promoter In ON and OfF orientation are Indicated 
10',------------------. 
..... eeks 
Figure 4 Stabilily of pYl\7 In vivo; lOS C(llls of strain Sl3261(pYlI7) 
were administered I.p. to Balblc mice. After 1, 2 and 3 weeks, mice were 
killed and the number of bacteria present In the spleen still containing 
pYZ17 was compared with the total number of bacteria by plating on 
McConkey agar plates with (hatched bars) and without (filled bars) 
ampicillin, respectively. Represented are the geometric means (bars) 
and the cotfesponding maximum numbers of colony·formlng unils 
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The immunogenicity ofSL3261(pYZI7) was determined 
in mice after oral and i.p. immunization. After oral 
immunization, CtxB·specific IgG and IgA could be 
detected in serum (Figure Sa and b, respectively). 
Furthermore, IgA could also be detected in gut washes 
(Figure6a), indicating that, besides a systemic immune 
response, a mucosal immune response was induced. The 
IgG titres remained high for up to 4 weeks after 
immunization. The IgA titres reached their maximum 
value within 1 week after immunization. During the 
following weeks these tit res decreased, but they were 
restored by a booster at week 4. 
In contrast to the oral immunization, no CtxB·specific 
antibodies could be detected after Lp. immunization 
(Figure 5). The difference in immune response against 
CtxD observed after oral and i.p. immunization could be 
due to the nature of CtxB, which is known to be a very 
effective mucosal immunogen I1 •18• The immunization 
with CtxD by the oral route may be inherently more 
effective than immunization by the i.p. route. Alternatively 
the Lp. immunization could have been less effective 
because a lower number of cells was administered than 
in oral immunization. To discriminate between these 
possibilities, the antibody responses of the orally and i.p. 
immunized mice against two other bacterial antigens 
were compared. These antigens were lipopolysaccharide 
(LPS) and p·lactamase, which are expressed on the 
surface and in the periplasmic space of SL3261(pYZI7), 
respectively. Both oral and i.p. immunization resulted in 
the appearance of LPS-specific JgG and IgA in serum 
(Figure 7a and b, respectively). Furthermore, both routes 
of immunization induced a LPS·specific secretory IgA 
response (Figure 6b). Both oral and i.p. immunization 
resulted in a p·lactamase·specific IgG response in serum 
(Figllre8), although the i.p. route was clearly more 
effective than the oral route. Specific IgA against 
p·lactamase could not be detected in the sera or in the 
gut washes after oral or i.p. immunization (results not 
shown). 
These results indicate that for LPS and p·lactamase 
i.p. immunization was at least as effecti\'e as oral 
immunization. Thus the difference between the response 
against CtxB after oral and i.p. immunization is most 
probably due to the fact that CtxD is much more 
immunogenic when presented orally than when presented 
parentally. 
DISCUSSION 
Attenuated Salmonella strains have great potential as 
carriers for the delivery of heterologous antigens to the 
immune system. However, construction of Salmonella· 
recombinant strains expressing the heterologous antigen 
at levels high enough to induce protective immunity 
without affecting the ability of the strain to invade and 
persist in the host, is a major problem. Expression of 
(high levels of) heterologous antigens may be detrimental 
or toxic for the bacteria, resulting in loss of expression 
in vivo l9 ,2o or overattenuation, In particular, loss of 
expression due to plasmid segregation has been a 
problem 2l. For this reason much effort has been put into 
developing systems which increase the stability of the 
DNA expressing the heterologous antigen. Curtiss et 
af.22-24 have developed a host-vector system in which 
the antigen expressing DNA is located on a plasmid 
which contains a gene, coding for aspartate 
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Agure 5 Antibody response to Ctx8 in sera after oral (filled bars) and I,p. (hatched bars) Immunilation of mice with Sl326I{pVZI7). Sl326I(pYZI7) 
was administered to Balbfc mire at weeks (fand 4. Every week, two mice of both groups were bled and their anO-CtxB serum titres were determined. 
Represented are geometric means (bars) and the corresponding maximum lilres. The arrow Indicates the booster Immunimtion. (a) Anti-CtxB IgG 
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Figure 6 Igl\ response of four times diluted gut·washes after oral (filled bars) and I.p. (hatched bars) immunization of mire with Sl3261{pYlI7). 
Sl3261(pVZI7) was administered to Balbfc mice at weeks 0 and 4. Every week, Iv;o mice of both groups were killed a!ld their gut washes were lested 
tn ELISA. Represented are geometric means (barS) and the corresponding maximum A4!>O values. The arrow Indicates the booster Immunization. 
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FIgure 7 Antibody response to lPS In sera after oral (filled bars) and !.p. (hatched bars) Immunization 01 mice with Sl3261(pYl17J. Sl3261(pYZ17J 
was administered to Balbfc m!ce at weeks 0 and 4. Every week. two mice 01 both groups were ble<! and their anti-lPS serum tilres were determined. 
Represented are geometric means (bars) and the corresponding maximum titres. The arrow Indicates the booster Immunization. (a) Anti-LPS 19G 
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FIgure 8 19G response to p.laclamase In sera after oral (filled bars) 
and I.p. (halched bars) Immunization of mice with Sl3261(pYlI7}. 
SL3261(pYl17J was administered to Balbfc mice at weeks 0 a!ld 4. Every 
week. two mice 01 both groups were bled and their anti-p'!aclamase 
serum mres were determined. Values shown are geometric means with 
their maximum titres. The arrow Indicates the booster Immuniution 
p-semialdehyde dehydrogenase, which is essential for 
growth of the host strain. The stability of the 
antigen-expressing DNA may also be increased by 
integrating it into the chromosomeJ.2s.26. Although these 
systems have proven to be very useful for the stable 
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expression of a number of antigens, they do not allow 
expression of antigens at levels which inhibit cell growth, 
because this will inevitably result in mutational 
alterations to reduce expression B • This is a major 
problem, because many heterologous antigens are toxic 
for S. lyphinlllrifllll due to different codon usage or the 
presence of toxic (e.g. hydrophobic) sequences. 
Deliberate reduction of the expression to a level high 
enough to induce an adequate immune response and low 
enough not to affect the fitness of the carrier strain is 
another strategy to obtain stable antigen expression. 
However, this balance between the immunogenicity and 
toxicity will depend on the nature of the antigen and will 
have to be determined anew every time another antigen 
is used. For some antigens this approach will be 
ineffective because, to induce an adequate immune 
response, they require expression at levels that are toxic 
to the producing vaccine strain. 
We have developed a vector for stable expression of 
antigens, based on an invertible PL promoter. The essence 
of the vector is that it directs expression of an antigen 
in only a minor part of the bacterial population. If 
production of the antigen is lethal, the antigen-producing 
bacteria will stop dividing. However, the non-producing 
part of the population will continue to grow and segregate 
antigen-producing cells due to inversion of the PL 
promoter. In this way, dissemination and invasion of the 
total bacterial population will not be affected by antigen 
production (Figure 9). 
To evaluate our system, we used CtxB as a model 
antigen. A plasmid, designated pYZ17, was constructed 
in which expression of the clxB gene is controlled by an 
invertible PL promoter. It appeared that pYZ17 was 
stably maintained ill vitro and ill vivo. Analysis of pYZI7 
isolated from SL5283 revealed that the copy number of 
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FIgure 9 Model illustrating the course 01 an infection with Sl3261 
expressing foreign antigens due to promoter inversions. Circles irldicale 
bacteria that do (e) and do not (0) produce antigen. In this figure 
it is assumed thai In every generation, 25% althe bacteria will produce 
toxic amounts 01 antigen due 10 inversion 01 the Pl promoter and stop 
growing. After oral administration the bacteria will slart to colonize the 
gut-associated lymphoid tissue (GALn. The bacteria that produce the 
foreign antigen will stop growing and may even lyse. The noo-producing 
bacteria will continue the InfectiOn and may colonize the lymph nodes, 
spleen and rIVer Without being affected by production 01 the anfrgen. 
During the Infection antigen-producing cells will constantly be 
generated due to inversion of the PL promoter 
the ON plasm ids was substantially lower than the copy 
number of the Off plasm ids. The apparent low copy 
number of pYZI7·0N may be caused by effects at the 
level of cell growth and/or plasmid replication. If the 
production of CtxB inhibits cell growth, bacteria 
containing higher numbers of pYZ17·0N will be 
outgrown by bacteria containing lower numbers of this 
plasmid. However, the observation that the ON/Off ratio 
is not affected by the large difference in CtxB production 
at 28 and 37°C, nor by deletion of the ctxB gene (result 
not shown) indicates that this effect is of minor 
imparlance. The alternative explanation for the low copy 
number ofpYZ17,oN, i.e, an effect on plasmid replication, 
seems more likely, For example, transcription from the 
PL promoter in the ON orientation may interfere with 
plasmid replication. A similar fhenomenon has been 
described byStrueber and Dujard 1. The observation that 
the growth temperature does not affect the ON/Off ratio 
suggests that even the leaky transcription at 28°C is 
sufficient to interfere with plasmid replication. We are 
currently addressing these questions. 
In spite of the low copy number ofpYZ17·oN, strains 
isolated from the spleens of mice still produced CtxB. 
Apparently pYZ17'ON is stably maintained in the 
bacterial population due to continuous replenishment 
from pYZ17·0ff. Furthermore, strain SL3261(pYZI7) 
was able to induce an immune response against CtxB. 
The induced CtxB.specific IgG and IgA titres in the 
serum and the presence of IgA in gut washes 
demonstrated that CtxB was efficiently presented in the 
immune system after oral administration of the S. 
typhimllrium strain SL3261 harbouring pYZ17 to Balb/c 
mice. The i.p. route turned out to be ineffective to induce 
an immune response against CtxB. This phenomenon 
does not generally apply to other antigens as 
demonstrated by the fact that antibodies to LPS and the 
pYZ17-encoded p-Iactamasc were induced more efficiently 
by the i.p, than by the oral route. Others have also found 
that i.p. immunization in general induces stronger 
immune responses than oral administration of recomb in· 
ant Sa/mOl/ella strains2S• The CtxB·pentamer binds 
specifically to the Gr-.n gangliosides that are abundantly 
present on mucosal epithelial cells t7•1S• This results in a 
very efficient presentation of CtxB to the immune system 
by the oral route. We speculate that the amount of CtxB 
expressed by SL3261(pYZl7j was too low to induce 
humoral responses after i.p. immunization. In fact, using 
an improved invertible promoter system that results in 
much higher CtxB levels, specific antibodies were also 
induced byi.p. immunization (manuscript in preparation). 
At present we are evaluating the immune responses to 
a number of HIV·l and FIV-antigens expressed in 
SL3261 by this improved invertible promoter system. 
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Continuous high level production of heterologous 
antigens in a Salmonella vaccine strain for the 
induction of local and systemic immune responses 
Edwin J. Tijhaar, Jos A. Karlas Yan Zheng-Xin, Thomas F. Meyer, Albeit 
D. M. E. Osterhaus and Frits R. Mooi 
ABSTRACT 
In this report we describe a system that allows the stable production of 
heterologous antigens in Salmonella strains at levels that are toxic for the 
producing bacteria. The system is based 011 flVO plasm ids. One plasmid contains 
the T7 RNA polymerase gene under the control of a strong promoter that is 
located on a DNA fragment which is inverted at random. When the promoter 
inverts to the ON position it directs expression of T7 RNA polymerase which in 
turn directs expression of a gene under the control of a T7 promotel~ present on 
a second plasmid in the same bacterium. The essence of the system is, that the 
promoter that controls expression of the T7 RNA polymerase gene, inverts with 
a frequency that results in antigen production at high, toxic, levels in a minor 
part of the bacterial population Therefore, the major part of the popUlation will 
not be affected by production of the heterologous antigen and will continuously 
segregate new antigen-producing bacteria. 
Using this two plasmid system much higher levels of the Cholera toxin B 
subunit (CtxB) were expressed compared to a one plasmid system, in which ctxB 
expression was under direct control of the invertible promoter. The higher 
expression resulted in enhanced CtxB specific IgO and IgA responses in mice. 
A series of invertible promoter plasm ids was constructed which revealed 
different expression levels of genes under control of a T7 promoter. Although 
expression of an HIV-J env gene fragment was toxic for the producing bacteria, 
most of the plasmid combinations were stably maintained in vivo. Only the 
combination that resulted in the highest level of antigen production was unstable. 
Plasmid combinations which were found to be stable in vivo were also stably 
maintained after invasion of a cell line by S.typhimurium. Salmonella strains in 
which production of the maltose binding protein (MBP) was controlled by the 
invertible promoter system, induced much higher MBP-specific antibody titers 
after oral administration to mice, compared to strains in which MBP production 
was dependent on a fixed promoter. 
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INTRODUCTION 
Attenuated Salmonella strains have been used successfully to present 
heterologous bacterial (8, 9, 18, 22), viral (6, 26, 33, 36) and protozoal (1, 40) 
antigens to the immune system. Mucosal, humoral and cellular responses against 
such antigens have been demonstrated. The potential of Salmonella strains to 
induce class I restricted cytotoxic T lymphocytes (CTL) to the heterologous 
antigens has been demonstrated in vitro (18, 19,37) as well as in vivo (I, 12, 13, 
14, 35 ). Clearly, recombinant Salmonella strains have great potential as live 
vaccines against infections diseases. However, construction of Salmollella-
recombinant strains expressing the heterologous antigen at levels high enough to 
induce protective immunity without affecting the ability of the strain to invade 
and persist in the host, is a major problem. Production of (high levels of) 
heterologous antigens may be detrimental or toxic for the bacteria, resulting in 
over-attenuation or instability of the expression vector ill vivo. Especially loss of 
expression due to plasmid segregation has been a problem (17). To solve these 
problems we have devised a phase variable expression system, which causes a 
vaccine strain to split up spontaneously into two sUbpopulations: antigen and 
non-antigen producers. While antigen production may have negative effects on 
plasmid stability and the fitness of the host strain, these effects do not occur in 
the non-producing population. Unhindered by antigen production, the non-
producing population may disseminate within the host, and segregate antigen-
producers so that antigen may be presented to the immune system in different 
tissues. This expression system is based on the G DNA segment inversion system 
of bacteriophage Mu, that controls phage infectivity ( 16, 20). In phage Mu the 
inversion of the G gene segment results from a site-specific recombination 
between two short inverted repeats mediated by the invertase Gin. One 
possibility to establish a phase variable expression system, was to replace the G 
segment between the two short inverted repeats by a promoter, making this 
promoter invertible. When this invertible promoter is positioned in front of the 
gene of interest, it will only direct expression in one orientation. 
Using the Cholera toxin B subunit (CtxB) as a model antigen, we 
demonstrated that a Salmonella typhimlirilllll aroA strain harbouring the 
invertible promoter plasmid p YZI7, stably expressed the ctxB gene and was able 
to induce high antibody titers to CtxB in mice after oral administration (31, 38, 
39). However, no antibodies to CtxB were induced after intraperitonial (Lp.) 
administration. We hypothesized that the production of CtxB in S.typhimllrillm 
was too low to induce specific antibodies when the bacteria were administered by 
the Lp. route. 
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Here we describe an improved expression system that combines the ability 
of the invertible promoter plasmids to express toxic antigens with the high 
expression that cim be obtained by the T7 RNA polymerase system (23, 28, 29, 
30). Using this improved expression system, much higher levels of CtxB could 
be produced, resulting in enhanced immune responses. Furthermore, using the 
lIlalE gene, we demonstrate that the system is able to induce much higher specific 
antibody responses than a comparable system that uses a fixed promoter. 
MATERIAL AND METHODS 
Bacterial strains, plasmids and media 
Escherichia coli strain DHSo: (BRL Life technologies, Breda, The Netherlands) 
was used as a host for all plasmid constructions. Before introduction into the 
S.t),philllllrilllll vaccination strain SL3261 (IS), plasmids were passaged through 
the restriction deficient, modification proficient S.typhilllllrilllll strain SLS283, a 
galE503 derivative of LBSOOO (3, 2S). All bacteria were grown in LB 
aerobically at 370 C, unless indicated otherwise. Ampicillin was used at 100 
!lg/ml in LB agar plates and 200 !lg/ml in liquid media. Kanamycin was used at a 
concentration of SO !lg/ml in agar plates and liquid media. 
DNA manipulations 
Isolation of plasmid DNA, preparation of DNA fragments and ligations were 
carried out using standard methods (24). Plasmids were introduced into bacteria 
by electroporation as previously described (31). 
Construction of plasmids 
The vectors used in this study are represented in Figure 1. Plasmid pYZ17 has 
been described previously (31, 38). Relevant features are; the invertible PL 
promoter flanked by two inverted repeats, gill encoding the invertase which 
binds to the inverted repeats and drives the inversion of the DNA fragment with 
the PL promoter, and the cI857 gene, encoding the temperature sensitive 
repressor for PL. Finally, pYZI7 contains the cholera toxin B subunit encoding 
ctxB gene, the transcription of which is dependent on the orientation of PL. 
Vector pYZ17GP .(38) (this plasmid was previously designated pIPl (32» is 
similar to p YZ17, except that it contains a different ori and that ctxB has been 
replaced by the gene coding for T7 RNA polymerase. The vectors p YZ17GP and 
pYZ27bGP (previously designated pIP3 and pIP2, respectively (32» are 
identical to p YZ17GP except for the orientation of gill and cI857. The vector 
p YZ27bGP differs only from p YZ27GP by an additional nucleotide between the 
S9 
PL promoter and the GTG start codon for gill (Yan, unpublished). The vector 
pYZ17 inverts its PL promoter with a higher frequency than pYZ27b (38), the 
plasmid from which p YZ17bGP was derived. 
To construct derivatives of pYZ27bGP and pYZ27GP that would be 
maintained at lower copy numbers, the p15A ori, which results in an 
intermediate copy number, was replaced by the ori of the low copy number 
plasmid pSCI01. Therefore the part of pSClOllocated between nucleotides 4581 
and 6240 (numbering according to Bernardi and Bernardi (2)), which contains 
the ori and the partitioning (par) locus, was amplified by PCR using the primers 
5'-CAGGATCCAGTCTGAA TGACCTG-3' and 5'-ACCGGA TCCAAGAGCCA 
TAAGA-3'. After treatment of the PCR fragment with Klenow fragment it was 
inserted into the Sma! site of pUCI9 to generate pUCSc. This vector was 
digested with EcoR! followed by filling-in with Klenow fragment and Pst! 
digestion to excise the fragment containing the pSC101 ori. Finally, the fragment 
was inserted in the PstI site and Klenow fragment filled-in Nile! site of 
p YZ27bGP and p YZ27GP to generate pIP4 and pIP5, respectively. 
The pYZ27GP, pYZ27bGP and pIP-plasmids were used in combination 
with plasm ids that contain the gene for a model antigen under the control of a T7 
promoter. Two of such plasmid, pT7ctxB and pET3xa-env (Fig. 1 ), were 
constructed for this study. Plasmid pT7ctxB was obtained by cloning the BglII-
Sal! fragment of pYZI7, containing the promoterless ctxB gene, into the BamHI 
and Sal! site of pT7-5 (30). Plasmid pET3xa-env was obtained by cloning the 
Bg/II-Bg/II fragment of the ellv gene of HIV-l lIIB, coding for amino acids 279 
to 473, into the BamHI site of pET3xa (28). This resulted in a fusion between 
gene-lO and ellv sequences, providing efficient translation signals for ellv. 
Construction of pETMALp, which contains the malE gene under control of a T7 
promoter, has been described previously (32). 
Effect of different plasmids on host strain viability at 370 C 
At 37 oC, but not at 28 oC, the cI857 repressor is inactive, resulting in strong 
transcription from the PL promoter which will result in the high level 
expression of the model antigen. To assess how this may affect cell viability, a 
single colony of a particular strains was spread on a plate containing the 
appropriate antibiotics and grown at 25 oC for 16 hours. Subsequently, the 
bacteria were harvested and resuspended in PBS to a concentration of about 100 
to 500 bacteria/150 Ill. Aliquots of 150 III were plated in duplicate on plates 
containing the appropriate antibiotics. One half of the plates was incubated at 28 
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Fig. 1. Schematic representation of the plasmids used in this study. Transcription of the ctxB 
gene in pYZl7 is under direct control of the invertible PL promoter. In the pIP-vectors the 
invertible promoter controls transcription of the T7 RNA polymerase gene, which in its turn 
directs transcription of a gene located on a second plasmid under control of the PT7 promoter 
(e.g. pT7-ctxB or pET3xa-env). The PL promoter of pGPI-2 that controls the expression ofT7 
RNA polymerase is fixed. Plasmids pYZ27bGP and pYZ27GP have previously also been 
designated pIP2 and pIP3. respectively. Vectors pYZ27GP and pIPS are identical to pYZ27bGP 
and pIP4. respectively. except for an additional adenine about 50 nucleotides in front of the GTG 
start codon for gill. Arrows indicate the transcriptional orientation. Abbreviations: PL. leftward 
promoter of bacteriophage lambda; ffi, inverted repeat; TI, rrnB Tl transcription terminator; T2. 
transcription terminator fd T; gin. invertase gene; cI857, phage lambda temperature sensitive 
repressor protein gene; Ap, ampicillin resistance gene; Kant kanamycin resistance gene; ctxB, 
cholera toxin B subunit gene; T7pol. T7 RNA polymerase gene; PT7. gene-IO promoter of 
bacteriophage T7; ColE!. ColEl origin of replication; p15A. pl5A origin of replication. 
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oC and the other half at 37 oc. The viability at 37 0C was defined as: (CFU at 37 
oC / CFU at 28 oc) x 100 %. 
Plasmid stability in media without selective antibiotics. 
For each strain a single colony was plated on plates containing the appropriate 
antibiotics. After growth at 25 0C for 16 hours bacteria were harvested and 
resuspended in LB without antibiotics. The cultures were diluted to an OD600 of 
0.1, and subsequently duplicate samples were grown aerobically at 37 0C. 
During the experiment the bacteria were kept in logarithmic growth phase by 
dilution with medium of 37 0C. At several time points samples were plated on 
media with or without the appropriate antibiotics, followed by incubation at 28 
0C. The plasmid stability of the recovered bacteria was defined as: ( CFU on 
plates with antibiotics / CFU on plates without antibiotics) x 100 %. 
Immunisation of mice and in vivo plasmid stability. 
For immunisation, bacteria producing CtxB or the Env-fusion protein were 
grown at 370C in the presence of ampicillin and kanamycin. Bacteria were 
harvested by centrifugation at an OD600 of 0.6 to 0.8, washed in PBS and 
resuspended to a cell concentration of 1010 cells/ml in 10% NaHC03 for 
intragastric intubation or 2x 107 cells/ml in PBS for intraperitonial (Lp.) 
immunisation. Subsequently, 0.5 ml of the bacterial snspensions were 
administered by the oral or i.p. route to six week old female Balb/c mice. An 
identical booster immunisation was given at four weeks after the primary 
immunisation. Blood samples were obtained by retro-orbita puncture of 
anaesthetized mice. Gut-washes were obtained as described previously (31). Sera 
and gut-washes were stored at -20 0C until tested in an ELISA. 
Immunization with bacteria producing MBP was performed essentially as 
described above, except that bacteria containing the fixed promoter plasmid 
pGPI-2 were grown at 28 oC to repress MBP production and mice received 
3xl08 bacteria in a volume of 0.3 ml of PBS via intragastric intubation. 
To determine plasmid stability ill vivo, mice were injected Lp. with 0.5 ml 
PBS containing 107 bacteria. Each construct was tested in two mice. One week 
after administration the mice were sacrificed and their spleens were removed. 
The spleens were homogenized and plasmid stability was determined by 
comparing the number of CFU that could be recovered on McConkey agar plates 
with and without ampicillin + kanamycin. 
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Assay for plasmid stability of bacteria grown in eukaryotic cells 
The mouse cell line P815 (American Tissue Culture Collection) was cultured in 
RPMI 1640 (Gibco) supplemented with 10 % (v/v) FCS, 2 mM L-glutamine, 
penicillin (100 Vim!) and streptomycin (100 flg/ml) at 37 °C. Prior to infection 
P815 cells were washed two times in RPMI 1640 without any additives. Bacteria 
from logarithmical growth cultures were harvested by centrifugation and washed 
two times with RPMI 1640. About 108 bacteria were added to 106 P815 cells in 
a total volume of I ml RPMI 1640. Subsequently, cells were incubated for 2 
hours at 37 oC, during which period they were resuspended every 20 minutes. 
Finally the cells were washed three times in RPMI and suspended in 10 ml 
culture media supplemented with gentamicin (50 flg/ml) to kill extracellular 
bacteria. After incubation for I and 3 days at 37 oC, cells from I ml of culture 
were harvested, washed two times in PBS and lysed in 350 fll PBS containing 1% 
Triton x-IOO to release intracellular bacteria. The bacteria were plated on media 
without antibiotics and colonies were allowed to form at 28 oc, Subsequently, 
about 50 colonies of each sample were tested for resistance on plates containing 
the appropriate antibiotics. The plasmid stability was expressed as the percentage 
bacteria that was still resistant to the relevant antibiotics. 
ELISA 
The CtxB and LPS ELISA's were performed as previously described (3 I). The 
MBP ELISA was essentially performed as described previously (32), but mice 
antibodies were detected with anti-mouse Ig HRP linked F(Ab')2 fragment from 
sheep (Amersham, Cat. No. NA931O) diluted 1:2000. 
SDS-PAGE 
For SOS-PAGE, overnight bacterial cultures were diluted 20 times in LB 
containing the appropriate antibiotics and incubated aerobically until they 
reached an 0.0.600 of 0.6. Aliquots of bacteria were pelleted, resuspended to an 
0.0.600 of 10 in sample buffer and boiled for 20 min. Samples were subjected 
to SOS-PAGE, followed by fixation and Coomassie brilliant blue staining. 
Western blotting 
Oetection of CtxB by Western blotting was performed as previously described 
(31). For detection of Env fusion protein by Western blot analysis, SOS-PAGE 
was immediately followed by transfer of the proteins to nitrocellulose. After 
blocking with PBS containing 0.5 % Tween-80 and 0.5 % low fat milk powder, 
the blots were incubated for one hour at room temperature with a biotinylated 
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mouse monoclonal antibody directed to the hypervariable V3-loop of gpl20 of 
HIV-I strain IIIB, diluted in the same buffer. After washing 3 times in PBS 
containing 0.5 % Tween-80 during a period of 30 min., the blot was incubated 
for I hour at room temperature with a HRP-streptavidin conjugate diluted 2000 
times in PBS containing 0.5 % Tween-80. After 3 washings, the blot was 
developed in a TMBIDONS based substrate. 
RESULTS 
Construction and evaluation of an improved phase variable 
expression system. 
In p YZI7 (Fig. 1 ) transcription of ctxB is under direct control of the invertible 
PL promoter. On average, in a single CtxB producing cell only a fraction of the 
PL promoters will be in the plus orientation and thus only a fraction of the ctxB 
copies will be expressed. We hypothesized that production of CtxB could be 
increased if a single promoter inversion in a particular cell would result in 
transcription of all ctxB copies within that cell. To obtain this situation, we 
combined the invertible promoter system with the efficient T7 RNA 
polymerase/promoter expression system (28, 29, 30). The bacteriophage T7 
RNA polymerase is about 8 times more active than E.coli RNA polymerase (5) 
and less stringent with respect to template structure (11). It directs highly 
specific transcription from a conserved 23-bp sequence (4), which is not 
recognized by polymerases of E. coli or S.typhillllll'iulIl strains. 
We cloned the ctxB gene downstream of the T7 promoter, so that 
production of CtxB became dependent on the presence of T7 RNA polymerase. 
The resulting plasmid, pT7ctxB (Fig. I), was used in combination with 
pYZ27bGP (Fig. I), which contains the T7 RNA polymerase gene under control 
of the invertible PL promoter. In this configuration a single promoter inversion 
would result in production of T7 RNA polymerase, which in turn would direct 
transcription of all the ctxB genes present in a particular bacterium. 
The production of CtxB in S.typhillllll'illlll strain SL3261 harbouring 
p YZ17 or the two-plasmid system, was compared (Fig. 2 ). As anticipated, much 
higher levels of CtxB were produced by SL3261 harbouring the two-plasmid 
system compared to SL3261(pYZ17). 
Immune responses against CtxB expressed by SL3261 carrying the 
one or two plasmid system. 
To investigate whether the higher CtxB-production obtained by the two-plasmid 
system resulted in the induction of higher titers of CtxB-specific antibodies, mice 
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Fig. 2 CtxB Production by the single- and two-plasmid system. Bacteria were grown at 370 C 
and equal amounts of ceUs were subjected to SDS-PAGE. Subsequently CtxB was detected by 
Western blotting. Lane I, SL3261(pYZI7); Lane 2, SL3261(pT7ctxB + pYZ27bGP). 
were immunised orally or i.p. with SL3261(pYZI7) or SL3261(pT7ctxB + 
p YZ27bGP). Both strains were able to induce CtxB-specific serum IgG and IgA 
after oral administration (Fig. 3A and B), but the titers were much higher in 
mice immunised with SL3261(pTIctxB + p YZ27bGP). This strain also induced 
the highest mean level of CtxB-specific sIgA in gut washes after oral 
administration (Fig. 3C). Intraperitoneal administration of SL3261 (p YZI7). 
induced a considerable CtxB-specific IgG response in a few mice, but most mice 
developed only low or undetectable (<100) antibody titers. In contrast 
SL3261(pTICtxB + pYZ27bGP) induced considerable anti-CtxB IgG responses 
in almost all i.p. immunised mice (Fig. 3A). As expected for the i.p. route, the 
mean serum IgA titers and especially the mucosal IgA responses were very low 
in mice (Fig. 3B and C), irrespective of the used bacterial strain. 
Thus in all cases cells harbouring the two-plasmid system were able to 
induce higher levels of CtxB-specific antibodies compared to cells harbouring 
the one-plasmid system. 
Construction of plasm ids with different inversion frequencies 
When a toxic level of antigen is defined as the level that prevents cell division, a 
bacterial population containing the two-plasmid system can only increase in size 
if the percentage of bacteria expressing toxic level of antigen is smaller than 
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Fig. 3 CtxB-specific antibodies after immunization with SL3261(pYZI7) (open triangles) or 
SL3261(pT7ctxB + pYZ27bGP) (filled triangles). Mice were immunized orally or 
intraperitoneally in week 0 and received a booster at week 4 (indicated by the arrow). Individual 
responses are indicated by triangles, with the mean antibody response of each group represented 
by a horizontal bar. A. Serum IgG titer; B. Serum IgA titer; C. Secretory IgA response. Titers in 
panel A and B were determined as described in Materials and Methods, In panel C responses are 
presented as the OD450 value of 16 times diluted gut washes. 
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50%. The percentage of bacteria producing a toxic level of antigen is determined 
by the inversion frequency, defined as the number of inversions of the PL 
promoter per cell per generation, and by the toxicity of the expressed antigen. 
Thus the inversion frequency may have to be adapted to different antigens. 
Therefore a series of invertible promoter vectors were constructed that were 
expected to reveal different inversion frequencies (Fig. 1). Based on their 
derivation, it was expected that the inversion frequency of the PL promoter in 
pYZI7GP, pYZ27bGP and pYZ27GP would decrease in the order pYZI7GP, 
p YZ27bGP, P YZ27GP. The different inversion frequencies of these plasmids is 
probably due to the different levels of transcription of gill. Another way to 
affect the invertion frequency is by reducing the plasmid copy number. Plasmid 
copy number may affect the inversion frequencies in at least two ways. First, 
because of the reduced number of invertible promoter fragments present in a 
single cell. Secondly, because the production of Gin will probably be less, due to 
a gene-dose effect, and lower levels of Gin have been shown to result in a 
reduced inversion frequency (2 I). A lower copy number of the plasmids with 
the invertible PL promoter was achieved by replacing the p15A ori in pYZ27GP 
and pYZ27bGP by the ori and par region of the low copy number plasmid 
pSC 10 1. This resulted in a copy number that is two to three times lower than 
that of the parental plasmids (results not shown). The par region of pSC10l 
ensures equal distribution of the plasmid copies over the daughter cells during 
cell division (34). 
In previous experiments (unpublished) we used vectors in which 
expression of a 580 bp ellv fragment from HIV -1 was under direct control of an 
inducible, fixed, promoter. Induction of expression appeared to be toxic for the 
producing bacteria, resulting in rapid plasmid loss. We wanted to determine 
whether high level, stable expression of this gene fragment could be 
accomplished with the two-plasmid system. Therefore pET3xa-env (Fig. 1) was 
constructed. This plasmid contains a gelle- JO-ellv fusion under control of a T7 
promoter and is compatible with the plasmids that contain the T7 RNA 
polymerase gene under control of the invertible PL promoter. 
Strain SL5283 containing p YZ27bGP and pET3xa expressed high levels of 
gene-IO protein (Fig. 4A). The production level of the gene-IO-env fusion 
protein was lower, but a band corresponding to the predicted molecular mass of 
53 kD was clearly visible on a Coomassie stained SDS-PAGE gel of total 
bacterial lysates (Fig. 4B ). The identity of the protein band was confirmed by 
Western blotting using a monoclonal antibody specific for the V3-100p of gp120 
(result not shown). 
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Fig. 4. Production of gene-I 0 and the gene- IO-env fusion protein by SL5283 carrying the two-
plasmid system. Total cell Iysates of bacteria grown at 370 C were subjected to SDS-PAGE 
followed by fixation and staining of the gels. A. Lane I, molecular weight markers; Lane 2, 
SL5283; Lane 3, SL5283(pET3xa); Lane 4, SL5283(pET3xa + pYZ27bGP); B. Lane I, 
molecular weight markers; Lane 2, SL5283; Lane 3, SL5283(pET3xa-env); Lane 4, 
SL5283(pET3xa-env + p YZ27bGP). 
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123456 
Fig. 5. Production of a gene-I O-env fusion protein by SL3261 strains carrying pET3xa-env in 
combination with different invertible promoter vectors. Strains were grown at 370C in the 
presence of appropriate antibiotics. Subsequently, equal amounts of bacteria were subjected to 
SDS-PAGE followed by Western blotting using a monoclonal antibody specific for the V3-loop 
of Env. Lane I, SL3261(pET3xa-env); Lane 2, SL3261(pET3xa-env + pYZI7GP); Lane 3, 
SL3261(pET3xa-env + pYZ27GP); Lane 4, SL3261(pET3xa-env + pYZ27bGP); Lane 5, 
SL326I (pET3xa-env + pIP5); Lane 6, SL3261(pET3xa-env + pIP4). 
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A higher inversion frequency will result in a higher percentage of antigen 
producing cells in the bacterial population and this will be reflected by a higher 
amount of antigen produced by the total population. Production of the gene-lO-
env fusion protein by strain SL3261 containing pET3xa-env in combination with 
the different invertible promoter vectors, was compared on Western blot (Fig. 
5). Of the vectors containing a pl5A ori, the highest production of the fusion 
protein was obtained by pYZ17GP, followed by pYZ27bGP and finally 
pYZ27GP. As expected pIP4 exhibited a higher production level of the fusion 
protein than pIP5 and both plasmids revealed lower production levels than their 
higher copy number counterparts pYZ27bGP and pYZ27GP, respectively. 
Stable antigen production with the two-plasmid system 
To asses the importance of the invertible promoter system for stable antigen 
production, the effect of expression of the gene-IO-Env fusion protein by the 
invertible promoter plasmids was compared with a fixed promoter. The viability 
of strains with pET3xa-env in combination with pGPI-2, which has a fixed 
promoter, or one of the invertible promoter plasmids, was determined by 
comparing plating efficiencies at 28 0C (to repress the PL promoter) and 37 oC 
(Table I). The viability of strain SL5283 with pET3xa-env or pGPI-2 only, was 
slightly affected (i.e. respectively 92% and 86%). However bacteria containing 
both plasm ids could only be recovered at 28 oC, demonstrating that expression 
of the gene-lO-env gene fragment is toxic for the producing bacteria. When 
pET3xa-env was combined with an invertible promoter vector (i.e. p YZI7bGP), 
viability at 37 oC was comparable to strains harboring either one of these 
plasmids (i.e. - 90%). In contrast to strain SL5283(pGPI-2), strain 
SL3261(pGPI-2) was not able to grow at 37 oc. At present we are unable to 
explain the different behaviours of these strains. Comparable amounts of 
colonies were recovered at both temperatures from SL3261 containing pET3xa-
env in combination with each of the pIP-vectors. Clearly the pIP system can be 
used to produce antigens at toxic levels in a bacterial population. 
Assessment of stability ill vivo. 
Mice were infected by the i.p. route, and after one week the percentage of 
bacteria in the spleens that had stably maintained their plasmid combination, was 
determined (Table 2). The combination of pET3xa-env and p YZI7GP was 
unstable. Only 7 % of the bacterial colonies isolated from mice to which 
SL3261(pET3xa-env + pYZI7GP) was administered contained both plasmids. 
Moreover, 10 of these colonies were tested and all failed to express the gene-lO-
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Table 1. Effect of different plasmids on the host strain viability at 370 C. 
Strain 
SL5283(pET3xa-env) 
SL5283(pGPI-2) 
SL5283(pET3xa-env + pGPI-2) 
SL5283(pET3xa-env + p YZ27bGP) 
SL3261(pGPI-2) 
SL3261(pET3xa-env + pGPI-2) 
SL3261(pET3xa-env + pYZI7GP) 
SL3261 (pET3xa-env + p YZ27bGP) 
SL3261(pET3xa-env + pYZ27GP) 
SL3261(pET3xa-env + pIP4) 
SL3261(pET3xa-env + pIP5) 
Viability at 370 ca 
92±6% 
86 ± 11% 
0% 
90 ± 26% 
0% 
0% 
69 ± 10% 
75 ± 14% 
98 ± 8% 
85 ±7% 
102 ± 13% 
(l Equal amounts of bacteria grown at 280 C in the presence of the appropriate antibiotics were 
plated in duplicate on plates containing the appropriate antibiotics. One half of the plates was 
incubated at 280C and the other half at 370C, The viability is defined as: [(CFU at 370C I CFU at 
280C) x 100%]. Represented is the mean viability at 370C ± SD of several independent 
experiments. 
Env fusion (Table 2). All the other invertible promoter vectors were essentially 
stable in combination with pET3xa-env and all the recovered bacteria that were 
tested still produced the fusion protein at equal levels compared to the original 
strains (not shown). 
Growth of bacteria within eukaryotic cells may resemble the natural 
growth conditions of S.typhimll/'illm in mammals more closely than growth in 
liquid cultures. Therefore, the plasmid stability of the Salmonella strains with the 
different plasmid combinations was determined after intracellular growth in 
P81S cells. In this test all the combinations with pET3xa-env were stably 
maintained in SL326 I except for the combination of p YZl7GP with pET3xa-env 
(Table 3). So, the plasmid stability obtained by this test correlates with the 
stability found in mice (Table 2). 
Immunogenicity of strains with an invertible or fixed PL promoter 
The ability of strains harboring the two-plasmid system with an invertible or a 
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Table 2. Stability of plasmids ill vivo. 
Strain 
SL3261(pET3xa-env + pYZI7GP) 
SL3261(pET3xa-env + pYZ27bGP) 
SL3261(pET3xa-env + pYZ27GP) 
SL3261(pET3xa-env + pIP4) 
SL326l(pET3xa-env + pIP5) 
Stability 
plasmidsa 
7%C 
95% ±5% 
103% ±7% 
101%±16% 
102% ± 4% 
expressionb 
0/10 
9/9 
5/5 
5/5 
5/5 
a Mice were infected intraperitonially with the indicated strains, and after one week the percentage 
bacteria that was still resistant to both ampicillin and kanamycin was determined in the spleens of 
two mice for each strain. Represented is the mean plasmid stability ± the difference with 
individual values. b Gene-IO-env expression of individual ampicillin and kanamycin resistant 
colonies was tested by Western blot analysis using a monoclonal antibody specific for the V3-100p 
of Env. Indicated is the number of antigen-expressing colonies/number of tested colonies. C From 
only one of the two mice inoculated with this strain enough colonies were recovered on plates 
containing both ampicillin and kanamycin to allow a reliable determination of plasmid stability. 
Table 3. Plasmid stability in P815 cells 
Strain 
SL326l(pET3xa-env + pYZ17GP) 
SL3261(pET3xa-env + pYZ27bGP) 
SL3261(pET3xa-env + pYZ27GP) 
SL326l(pET3xa-env + pIP4) 
SL3261(pET3xa-env + pIP5) 
Plasmid stabilitya 
I day 
2±2% 
95 ± 8% 
98 ±2% 
100±0% 
100 ± 0% 
3 days 
2±3% 
82 ± 5% 
94±6% 
96 ±2% 
99± 1% 
a P815 cells were infected with the different bacterial strains and cultured in the presence of 
gentamicin to kill extracellular bacteria. After I and 3 days the percentage intracellular bacteria still 
resistant to both ampicillin and kanamycin was determined. Represented is the mean plasmid 
stability ± SD of several independent experiments. 
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Fig. 6. Production of MBP by SL3261 strains containing the invertible or fixed promoter 
system. Bacteria were grown in the presence of appropriate antibiotics. Subsequently, equal 
amounts of bacteria were subjected to SDS-PAGE followed by fixation and staining of the gels. 
Lane I, molecular weight markers; Lane 2, SL3261(pETMALp + pYZ27GP) grown at 37 oC; 
Lane 3, SL3261(pETMALp + pIP5) grown at at 37 oC; Lane 4, SL326I (pETMALp + pGPI-2) 
grown at 28 0C; Lane 5, SL3261(pETMALp + pGPI-2) grown at 28 oC and subsequently 
induced for 2 hours at 37 °C. 
fixed PL promoter to induce an immune response in mice was compared. 
Unfortunately, the gene-IO-Env fusion protein expressed by SL3261 was poorly 
immunogenic in Balb/c mice (results not shown), making this antigen unsuitable 
for comparative studies. The B subunit of cholera toxin is less suitable for these 
studies too, as this protein is a strong mucosal antigen by itself. Like most 
proteins, the maltose binding protein (MBP) is not immunogenic by itself when 
administered orally (unpublished results), but immunisation by the oral route 
with Salmonella strains producing this antigen does induce MBP specific 
antibodies (32). Therefore, MBP was used as a model antigen in these 
experiments. Plasmid pETMALp (Fig. I) contains the gene coding for the 
maltose binding protein (malE) under control of the T7 promoter. The strains 
SL5283 and SL3261 containing pETMALp in combination with pGPI-2 (which 
contains a fixed PL promoter) were not able to grow at 37 OC, indicating that 
the amount of MBP produced was toxic at this temperature (not shown). SL3261 
strains containing pETMALp in combination with pYZ27GP, pIP5 or the fixed 
promoter plasmid pGPI-2, produced large amount of MBP (Fig. 6). As 
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Fig. 7. Induction of MBP-specific antibodies by strains containing the two plasmid system with 
an invertible or fixed promoter. Mice were immunized orally with SL326 I (pETMALp + pGPI-2) 
(filled bar); SL3261(pETMALp + pYZ27GP) (hatched bar) or SL3261(pETMALp + pIPS) (open 
bar), and antibody liters were determined 3 weeks post-infection. Each group contained 10 mice, 
with data presented as the mean titre + SD 
expected, pIP5 revealed a lower production level of MBP than its higher copy 
number counterpart pYZ27GP. The production level obtained with 
SL3261(pETMALp + pYZ27GP) cultured at 37 oC was comparable with that of· 
SL3261(pETMALp + pGPI-2) induced for 2 hours at 37 0C. 
Three weeks after a single oral administration of the different MBP 
expressing strains, all mice had developed MPB specific antibodies. The average 
anti-MBP titers induced by oral immunisation with SL3261(pETMALp + pGP1-
2 ) was nearly 40 times lower than the titers induced by the strains with the 
invertible promoter (Fig. 7). 
DISCUSSION 
Much effort has been put into the development of vectors for the stable 
production of heterologous antigens in S. fyphillluriulII strains. Although 
chromosomal integration expression cassettes (12, 27), or linkage of an essential 
gene to the expression plasmid (10, 17) have proven to be very useful for the 
stable production of a number of antigens, these approaches will not allow stable 
production of antigens at levels that prevent cell growth. The use of promoters 
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that are induced in vivo is another approach that has been followed with some 
success. A more sophisticated kind of inducible promoter, delays toxic 
expression until the bacteria arrive in cells and tissues relevant for the immune 
system (7). This kind of promoters represent a significant improvement, but 
they too do not allow the production of toxic antigens during the complete route 
of infection nor will they allow further growth of the bacterial population once 
antigen production reaches toxic levels. 
The essence of the phase variable expression system is, that it directs 
production of (toxic levels of) antigen in only a minor part of the bacterial 
population, allowing the non-producing bacteria to disseminate and segregate 
new producers. The two plasmid system described in this paper is an 
improvement of the previously described one plasmid system (31, 38, 39) in 
which the gene of interest is under direct control of an invertible PL promoter. 
In the two plasmid system the invertible promoter controls the expression of T7 
RNA polymerase gene, which in turn directs transcription of a gene under 
control of a T7 promoter, present on a second plasmid in the same bacterium. 
Therefore a single promoter inversion results in transcription of only one gene 
copy in the one plasmid system, but multiple gene copies in the two plasmid 
system. With the two plasmid system much higher levels of CtxB could be 
expressed compared to the one plasmid system (Fig. 2). This resulted in much 
stronger anti-CtxB IgG responses after oral and i.p. administration and higher 
specific serum and secretory IgA responses after oral administration (Fig. 3). 
The two plasmid system can be used to produce antigens at toxic levels. 
This was demonstrated for the gene-lO-Env fusion protein. When production of 
the Env fusion protein was dependent on a fixed, temperature inducible, PL-
promoter no colonies were recovered at the permissive temperature. However, 
when expression of the Env fusion protein was under control of the invertible 
PL_promoter, a comparable number of colonies was recovered at permissive and 
non-permissive temperatures (Table I). 
The level of Env fusion protein (Fig. 5) and MBP ( Fig. 6 ) production 
obtained with the two-plasmid system is probably a reflection of the percentage 
bacteria that is producing antigen due to a promoter inversion. Replacement of 
the pl5A ori of the invertible promoter plasmids by the ori of the low copy 
number plasmid pSC 10 I, resulted in invertible promoter plasm ids that revealed 
a considerably lower antigen production level (Fig. 5 and 6). In vivo all 
invertible promoter vectors were essentially stable in combination with pET3xa-
env, except for pIPI which directs the highest production levels (Table 2). The 
extreme instability of the plasmid combination with pIPI might be the result of 
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toxic antigen production in close to or more than 50% of the bacteria. 
Plasmid stability ill vitro can differ dramatically from ill vivo stability. 
The different growth rates of S.typhilllllrilllll ill vitro and ill vivo may affect the 
plasmid stability in different ways. The longer generation time ill vivo may 
result in an increased inversion frequency due to the longer time available for 
Gin to mediate the recombination event that results in promoter inversion. This 
will result in considerable plasmid loss when the inversion frequency approaches 
a level that prevents further expansion of the population. The restricted number 
of cell divisions ill vivo will, on the other hand, limit the loss of plasmids. We 
have found that the plasmid stability after growth of S.typhilllllrilllll in cell lines 
correlates with ill vivo stability (Table 2 and 3 ). Thus, an indication of plasmid 
stability ill vivo may be obtained before animal experiments are initiated by 
determining the stability in cell lines. 
Although satisfactory plasmid stability and expression levels of the Env 
fusion protein were obtained with a two plasmid system, we were not able to 
show the induction of Env-specific serum antibodies. A number of other studies 
also failed to demonstrated the induction of specific serum antibody responses 
against heterologous antigens produced by S.typhillllll'illlll vaccine strains, but 
showed the induction of specific helper T cells and class I restricted CTLs (1,27, 
36). Although not tested in the framework of this study, the phase variable 
expression system may have its merits for the generation of class I restricted 
CTL responses, as it allows abundant and stable production of antigens. Both 
these factors are of importance for the generation of class I restricted CTL 
responses ( 35, 37). Using MBP as a model antigen, we demonstrated that 
strains with the invertible promoter plasm ids are able to induce a much stronger 
antibody response compared to strains with the fixed promoter plasmid pGPI-2, 
even though comparable production levels of MBP were obtained ill vitro. 
Production of high levels of MBP was lethal for the bacteria and presumably 
strains with the invertible promoter, but not strains with a fixed promoter, are 
able to infect the GALT and the systemic lymphatics efficiently, thereby 
presenting much larger amounts of antigen to the immune system. 
The phase variable expression system can be further improved by 
replacing the antibiotic resistance genes, by essential genes that have been deleted 
in the carrier strain (17). This will make it more acceptable for use in live 
bacterial vaccines and has the additional advantage that it may further stabilise 
the expression system. 
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SUMMARY 
The genes, Tams!-! and Tamsl-2, encoding the 30-and 32-kDa major merozoite surface antigens of Theileria m/ll/llata 
(Ta), have recently been cloned and characterized. Both genes encode a protein of 281 amino acids (aa) containing a 
putative hydrophobic N-terminal signal peptide. Another hydrophobic stretch is predicted at the C terminus which 
probably functions to anchor the protein in the membrane of the merozoite and piroplasm. Here, we report the successful 
expression of both Tallls!-! and Tamsl-2 in ESc/lerichia coli (Ec) using gene fragments lacking both hydrophobic 
domains. Attempts to produce high amounts of the entire recombinant (re-) protein, or a fragment containing the N 
terminus only, were unsuccessful. This is presumably due to the toxicity of these re-proteins. The internal part of both 
genes was also expressed in SalmOl/ella typhillmrillll/ (Sr) aroA vaccine strain SL3261. We employed a dual-plasmid 
expression system based on an invertible promoter and selected the most stable SI construct in vitro using liquid cultures 
and a macrophage-like cell line. The re-Tams!-! protein produced in Ee, as well as in Sr, was recognized by monoclonal 
antibody (mAb) 5EI specific to the 30-kDa protein. Both re-Tams!-l and re-Tams!-2 were recognized by Ta immune 
calf serum. 
Cor"'5pomf~llc<, to: Dr. F. Jongejan, Department of Parasitology and 
Tropical Veterinary Medidne, Faculty of Veterinary Medicine, Utrecht 
University, p.o. Box 80165, 35t18 TD Utr~ht, The Netherlands. Tel. 
(31-30) 2532568; Fax (31-30) 2540784; 
e-maH: FJongejan@:pobOX-ruu,nl 
• Present address: School of Biologica.! and Medical Sciences, 
University of St. Andrews, Ir.ine Building, S1. Andrews K'J.'16 Q.AL, 
Scotland., UK. Tel. (44·l3H) 463397. 
Abbreviations: A, absorbance (I cm); aa, amino acid(s); Ab, antibody(-
it's); Anb, antibiotic(s); Ap, ampicillin; aroA, gene encoding 
3.enolpnm)·hhikimate-5-phosphate synthetase; bp, base pair(s); 
DHFR, gene encoding dihydrofolate reductase; DMEM, Dulbe.:co's 
mo<.iifiej Eagle's medium; Ec, Eschakhia coli; FBS, fetal bovine serum; 
Gin, invertase; HEPES, N-2-hydroxyethylpiperaline-N'-1.ethanesul. 
fonic acid; Hiso·tag, 5i-<; consecutive His residues; IPTO, isoprop}IIl·D· 
thiogalactopyranoside; ISCOM, immunostimulating complex; kb, kilo-
base(s) or 1000 bp; Km, kanamycin; lac!. gene encoding the lac repres· 
sor, LB, Luria-Bertani(medium); mAb,monoeional Ab; Nj·NTA, nickel 
nitrilo·tri-acetic acid; nt, nucleotide(s); p, plasmid; PL- leftward major 
promoter of bacteriophage t.; PAGE, polyacrylamide-gel e!~trophore­
sis; PBS, phosphate.buffered saline (137 mM NaCI,I2.7 mM 
KC!j1O mM Na2HPO,/1.8 mM KH2PO. pH 7.4); PCR, polymerase 
chain reaction; PoHk, Klenow (large) fragment of El' DNA polymerase 
I; reo, recombinant; St, Salmonella tJphimllrillm; 5DS, sodium dodec}1 
sulfate; Tn, Th<'ileria all/llIlala; Tams/-/ and Tanis/-!, genes encoding 
Tamsl-l and Tamsl-2; Tamsl-I and Tamsl-2, 30- and 32-kDa major 
merozoite surface antigens of Ta, re.;;pecti\'eJ}~ (J, denotes plasmid. 
carrier state. 
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INTRODUCTION 
Theileria a/lll!llata (Ta) is a tick-borne protozoan para· 
site, which causes tropical theileriosis in cattle. The dis· 
ease is distributed from Southern Europe and Northern 
Africa, through the Middle East into Central Asia 
(Uilenberg, 1981). Tropical theileriosis is characterized 
by a Iympho-proliferative and a -Iympho-destructive 
phase, usually accompanied by a marked anaemia. Ta 
enters the bovine host during tick feeding as sporozoites, 
which rapidly invade mononuclear leukocytes. Here, they 
mature into macroschizonts and induce proliferation of 
the host cell. Macroschizonts develop ultimately into 
merozoites, which are released from the leukocyte and 
invade erythrocytes to develop into piroplasms (for a 
review, see Tait and Hall, 1990). 
Tropical theileriosis is currently controlled by chemo-
therapy and vaccination using attenuated macroschizont-
infected lymphoid cell lines, and by tick control using 
acaricides. Although attenuated Jive vaccincs are being 
used. with success in endemic areas, their application has 
a number of drawbacks. Therefore, considerable effort is 
currently undertaken to identify and produce immuno-
genic antigens by re-DNA techniques. Such antigens, if 
shown protective, could provide a basis for a subunit 
vaccine against tropical theileriosis. 
The merozoite stage is invasive and thus a potential 
target for a protective immune response. A recent study 
identified a molecule of 30 kDa on the surface of Ta 
(Ankara stock) merozoites (Glascodine et ai., 1990). This 
molecule is a major polypeptide of merozoites and piro-
plasms and strongly recognized by immune scra from 
cattle infected with Ta. It has a variable molecular mass 
in different parasite lines of clonal origin (Dickson and 
Shiels, 1993). 
Recently, the genes Tallls]-] and Tams1-2 encoding the 
30- and 32-kDa major Ta merozoite surface antigens 
(Ankara stock), respectively, have been cloned and char-
acterized by sequence analysis (Shiels et aI., 1994; 1995). 
In order to assess the potential of these molecules for use 
in diagnosis and as components in a multi-unit 
re-vaccine, this study was carried out to express the 
Tams]·] and Tamsl-2 genes in Ee and the St aroA vac· 
cine strain SL3261. 
RESULTS AND DISCUSSION 
(a) Cloning and expression of both Tamsl-l and Tamsl-2 
inEc 
The nt sequences encoding the 30- and J2-kDa major 
merozoite surface antigens translate into polypeptides of 
281 aa each. They are 88% idc·ntical at the aa level. Both 
proteins exhibit a strong hydrophobic N terminus (aa I 
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through 24) characteristic ofa signal peptide and a strong 
hydrophobic C terminus (aa 261 through 281) character· 
istic as anchor peptide (Shiels et ai., 1994; 1995). TalliS]'] 
and Tamsl-2 DNA was cloned in frame with a stretch of 
six His residues (His6-tag) at the N terminus of expression 
vector pQEIO (QIAGEN Inc., Chatsworth, CA, USA). 
peR primers were chosen to facilitate the cloning of the 
genes and specific fragments thereof (Fig. 1). These frag-
ments included: (i) the complete gene (primers A and D), 
(ii) the complete gene lacking the region coding for the 
hydrophobic N terminus (primers B and D), (iii) an 
internal gene fragment without the sequences coding for 
both hydrophobic domains (primers B and C), and (ir) 
the complete gene lacking the region coding for the 
hydrophobic C terminus (primers A and C). 
Whole cell extracts of uninduced and induced Ee 
M15[pREP4)[pETamsl-l). -[pETamsl-2). -[pETamsl-
1 +] and [pETams1-2+] (Fig. 1) were analysed by SDS-
PAGE, followed by Western blotting using mAb 5E1 
specific to the 30-kDa protein and Ta immune calf 
serum (Fig. 2). Upon induction by IPTG, Ee 
1H5[pREP4][pETamsl-1] and ·[pETamsl-2] synthe-
sized large amounts of re-protein (Fig. 2A, lane 6 and 8. 
respectively). These proteins could not be detected in 
uninduced cells (Fig. 2A, lanes 5 and 7, respectively), or 
in the vector-only control (Fig. 2A, lane 2). The presence 
of the hydrophobic C terminus resulted in a considerable 
reduction in the production of re-protein (Fig. 2A, lanes 
10 and 12 arrow), These re-proteins exhibit a similar 
mobility when compared to the re-proteins lacking the 
hydrophobic domains (Fig. 2A, compare lanes 6 and 8 
with lanes 10 and 12), This may be due to charge differ-
ences which cause ~his aberrant mobility when perform-
ing SDS-PAGE. Attempts to express gene fragments 
containing the region encoding the hydrophobic N termi-
nus ,vere unsuccessful; presumably due to toxicity of the 
encoded protein. The mAb 5El recognized both 
re-Tamsl-! but not the re-Tamsl-2 proteins (Fig.2B, 
lanes 6 and 10), whereas Ta immune calf serum reacted 
with all re-Tamsl-1/Tams!-2 proteins (Fig. 2e, lanes 6, 
8, 10 and 12). The observed reactivity of 5El with the 
Tamsl-l re-antigens was an unexpected result. This is 
because, previollsly, treatment of native antigen by mild 
periodat~ oxidation significantly reduced detection by the 
Ab (Dickson and Shiels, 1993), indicating that it recog-
nizes an epitope conferred by modification of the poly-
peptide by carbohydrate (Woodward et aJ., 1985). The 
same was shown for the re-Tamsl-1 proteins (c. d'O. and 
FJ., unpublished data). Possession of this epitope on the 
Tams!-1 re-polypeptides implies that either they are 
being modified in a prokaryotic expression system or that 
a secondary structure of the polypeptide chain, which is 
insensitive to SDS-PAGE, is altered by mild treatment. 
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Fig. I. Construction of expre5:Sion cassettes for Ec and St aroA. peR of Tmn.sJ-l and Tamsl-} DNA using primers B 
(S'·AGOATGAAAAGAAAAAAGAAGGAAAAAAAAGACGTIG and C (5'·GTCGACAACTGGTITGTAATC) or Band 0 
{S'·GGGTTTTAAAGGAAGTAAAGG) resulted in 700- and 780-bp (ragments, respecth-ely, corresponding \Iith aa 25 to 259 and aa 2S to 281, 
respectively .. Protruding ends. were filled-in by PCllIk and ligated into pQEIO Yector digested with BamIlI and treated ",ilb PolIk. The re;;ulting 
plasmids were wrified by nt sequence ana[y.sis (Sanger el aI., 1917) and used to transform Ec MI5[pREN] which resulted in 
MI5[pREN][pETamsI.l]. -[pETamsI-2], [pETamsl-1 +] and {pETamsl·2+]. respectively. In addition, the fragment generated with primer> B 
and C was ligated into pEnh vector digested with BamHI and treated with Pollk. Resulting plasmids pSTamsl-1 and pSTamsl-2 were verified by 
nt sequence analysis and used to transform St aroA SL3261 (Holseth and Stocker, 1981). SP, signal peptide; AP, anchor peptide; pIo, Ec phage TS 
regulated promoter containing two lac operator sequences; His6 , six consecutive His residues; T7, Ec phage T7 regulated promoter. 
Expression of the gene encoding mouse DHFR from plas-
mid pQE16 served as a control for expression. Neither 
the His6-tag nor the re-DHFR protein reacted with mAb 
SEI (Fig. 2B, lane 4) or immune calf serum (Fig. 2e, lane 
4). Pre-immune serum taken from the same animal did 
not react with the re-proteins (data not shown). 
(b) Purification of re-Tamsl-l protein from Ec 
His6-tagged re-Tamsl-! protein was purified under 
native conditions according to the manufacturer's 
instructions (QIAGEN). Fig. 3 shows SDS-PAGE and 
Western analysis of the purified re-Tams!-l and 
re-Tamsl-2 proteins together with Ta piroplasm extract 
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Fig..2. Expression of Tamsl·' and Tamsl-l gene fragments by Ec transfonnants. (A) Gel stained \\ilh Coomassie brilliant blue. Lanes: 1 and 2, 
uninduCt'd and induced Er M1S[pREN][pQEIO]; 3 and 4, uninduced and induced MIS[pREN)[pQEI6); 5 and 6, uninduced and induced 
MIS(pREP4)[pETamJi-l): 7 and S, uninduced and induoxd MIS(pREN][pETamsl-2J; 9 and 10, uninduced and induced 
MlS(pRENJ[pETamsl-I+); 11 and 12, uninduced and induced MIS[pREN][pETamsl-2+]. (8) Western blot usingmAb 5EI. (C) Western blot 
using Ta immune calf serum. Methods: Single colonle, of Ec Iransformants were grown for 16 h al 37'C in LB containing 100 JIg Ap/ml and 25)1& 
Km/ro!. A small aliquot was usOO to inoculate 10 mJ of LB+Ap + Km medium and the bacteria were allowed to grow at 3TC while shaking. Whm 
the ,u[lure rea(hed an Aw;o"", of 0.7 an 1 m[ aliquot was ",ithdrawn as 'uninduced' sample, and subsequently 2 mM [PTG was added to induce 
upression.lnduclion was continued for 4 h, al .... hich poinl a 250 fll aliquot was y,ithdrawn as 'induced' sample. Cells were pelleted by centrifugation 
{or I min at lO000xg and resuspended in 5O~1 of 50S-PAGE sample buffer (SOmM Tris·Hel pH 6.8/1% jl.mercaptoethanolj2% SOSIO.l% 
bromophenol blue/IO'! .. glycerol). All samples y,~ere heated at 9ST for 10 min, centrifuged as described above and 10 ,.d aliquots of the supernatant 
was separated by 0.1% SDS-12% PAGE (Sambrook el a1 .. 1989). 
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Fig.3. Purification of re·Tamsl·1 and fe-Tamsl·2 from Ec trans-
formants. (A) Gel stained with Coomassie bril1iant blue_ Lanes: I, piro· 
plasm e.,tfact; 2, fe-Tamsl-I; 3, re·Tamsl·2. (8) Western blot using mAb 
SEI. (e) Western blot using Ta immune ,alfserum.l\fethods: Column-
purified re-Tamsl_1 and fe·Tamsl·2 (2 llg) were separated by 505-
PAGE (see legend to Fig. 2). As a control, purified piroplasms from 
infected boyine erythroC)tes was used. 
as a control. The mAb SEt recognized the 30·kDa pro· 
tein in piroplasm extract (Fig.3B, lane I). The weak 
signal may be due to a low amount of available epitope 
for the mAb to react with. Ta immune calf serum detected 
the 30J32-kDa doublet as well as an array of other poly-
peptides (Fig. 3C, lane 1). Pre-immune serum laken from 
the same animal did not react with piroplasm extract 
(data not shown). Re-Tamsl-I protein is recognized 
by mAb SEt (Fig. 3B, lane 2) and both the re-Tamsl-I 
and re-Tamsl-2 proteins were recognized by Ta immune 
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calf serum (Fig. 3C, lanes 2 and 3, respectively). Plasmids 
pETarnsl-l and pETamsl-2 (Fig. 1) were verified by nt 
sequence analysis. They both encode a polypeptide of 
approximately 34 kDa. Therefore, the difference in mobil-
ity of the re-proteins seen on SOS·PAGE is presumably 
due to small differences in aa composition (Fig. 3A, com· 
pare lanes 2 and 3). 
(c) Cloning and expression of both Taml-l and Tamsl-2 
in Sf aroA 
In Ec the Tamsf-f and Tall/sf-2 gene sequences lacking 
the sequences that code for the N- and C terminus were 
,yell expressed. Therefore, these partial gene sequences 
were selected to be expressed in the St aroA vaccine strain 
SL3261 (Hoiseth and Stocker, 1981). 
To obtain stable, high leyel expression we made use of 
a dual plasmid system based on an im'ertible promoter 
(Tijhaar et aI., 1994; Tijhaar et aI., submitted); as origi-
nally proposed by Podhajska et al. (1985). In this system 
the gene of interest is cloned downstream from the phage 
T7 promoter, so that expression becomes dependent on 
the presence of T7 RNA polymerase. The polymerase is 
encoded by a second plasmid present in the same bacte-
rium. Transcription of the T7 RNA polymerase gene is 
controlled by a temperature inducible A. PI. promoter that 
inyerts at random. This inversion is the result of recombi-
nation between two inyerted repeats that border the)., PL 
promoter by site-specific reeombinase Gin. The T7 RNA 
polymerase gene is only expressed in one orientation of 
the promoter. The essence of the system is that the pro-
moter inverts only in a minor part of the bacterial popula-
tion. Therefore, expression of (toxic Ie\'els of) antigen will 
be directed only in this part of the population, allowing 
the major non-producing pa.rt to disseminate and segre-
gate new producers, thereby ensuring the continued pro-
duction ofre-antigen in the immunized host until SL3261 
is cleared. 
Both Tamsl-! and Tams!-2 gene fragments were 
cloned downstream from the phage T7 promoter in 
expression vector pET3b (Novagen, Madison, WI, USA) 
to yield plasmids pSTamsl-l and pSTamsl-2, respectively 
(Fig. I). Co-transformation of either St SL3261 
[pSTamsl-1] or -[pSTamsl-2] cells with one of the four 
pIP. plasmids, namely pIP2 (also called pYZ27bGP), 
pIP3 (also called pYZ27GP), pIP4 or pIP5 (Tijhaar et at, 
submitted), generated Sr SL326! [pSTamsl-lJ[pIP] and 
SL3261 [pSTamsl-2J[pIP], respectively. Plasmids pIP2 
to pIP5 provide the T7 RNA polymerase gene under 
control.of an invertible A PL promoter. They were con-
structed in such a way that the inversion frequency 
decreases from pIP2 to pIP5, resulting in a diminished 
percentage of the bacterial population producing 
re-protein. The percentage of the population producing 
re-protein may be of influence to the plasmid stability. 
Whole cell extracts of the different SL3261 constructs 
grown al 37°C to induce PL, were analysed by SDS-
PAGE and Western blotting using mAb 5El and Ta 
immune calf serum (Fig. 4). As expected, the negative 
controls SL326l [pET3b], -[pSTamsl-IJ, -[pSTamsl-2] 
and -[pET3b][pIPS] did not show detectable expression 
of heterologous genes (Fig. 4A, Band C lanes 1 to 4, 
respectively). In contrast, SL3261 [pSTamsl-l] in combi-
nation with the different pIP constructs produced sub· 
stantial amounts of re-Tamsl-! protein (Fig. 4A, lanes S 
10 8). Similar results were obtained for pSTamsl-2 
(Fig.4A, lanes 9 to 12). The mAb 5El reacted with 
re-Tamsl-! protein only (Fig. 4B, lanes 5 10 8), whereas 
immune calf serum recognized both re-proteins (Fig. 4C, 
lanes S to 12). Plasmids pSTamsl-l and pSTamsl-2 
(Fig. 1) were verified by nt sequence analysis. Both 
translated products encode a polypeptide of approxi-
A B 
mately 31 kDa. The difference in mobility on SDS-PAGE 
between the fe-Tams!-! and re-Tamsl-2 proteins was 
seen in different independent experiments and is probably 
due to small differences in aa composition (Fig. 4A, com-
pare lanes S 10 8 with lanes 9 to 12). 
(d) Plasmid stability in St aroA SL3261 
To determine the stability of the different plasm ids in 
liquid cultures, the transformed St SL3261 strains were 
grown for 16 and 32 h at 3TC in the absence of Ap and 
Km. Aliquots from individual cultures were taken and 
subsequently grown on plates for 16 h at 37°C in the 
presence or absence of both antibiotics (Anb) (Table 1). 
T,yo general observations could be made: (i) when com-
paring the re-Tams!-l with the re-Tamsl-2 producing 
bacteria after 32 h of growth in LB, the bacterial popula· 
tion producing re-Tams!-l protein had a reduced ability 
to stably maintain both plasmids of the dual·plasmid 
expression system (Table I, column 3); (ii) when compar· 
ing the effect of the different pIP plasm ids in both the 
fe-Tams!-1 and re-Tamsl-2 producing bacterial popula-
tions, the bacteria bearing pIPS showed the highest 
degree of stable maintenance ofbolh pIP and pSTamsl-1 
or pSTamsl-2 (TableI, column 3). All pJasmids were 
stably maintained when grown for 32 h at 3TC in the 
presence of Anb (data not shown). 
More relevant is the in vjyO stability of the different 
plasmid combinations. The in vivo plasmid stability has 
been shown to correlate well with the plasmid stability 
after growth of SL3261 strains in eukaryotic cell lines 
(Tijhaar el al., submitted). We, therefore, infected the 
macrophage cell line J774.16 (Ralph et at, 1975) with 
different SL3261 strains and subsequently determined the 
stability of the plasmids after a 48 h period of growth at 
37°C (Table I). Again, two general observations could be 
made: (0 the bacterial population producing re-Tamsl-2 
protein maintained both their plasmids more stably than 
SLJ261[pIP2][pSTamsl-l] or -[pIP5][pSTamsl-l] 
(Table I, column 4); (U) when comparing both bacterial 
c 
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Fig.4. Expression of Ta11l51·1 and Tamsl·} gene fragments by Sf aroA SL3261 Iransformants, (A) Gel stained \\ith Coomassie brilliant blue. Lanes: 
I, SLJ261 (pEnb]; 2, SL326! [pSTamsl·1 J; 3, SL3261 [pSTamsl-2]; 4, SL326t [pEnb][pIP5]; S to 8, SL3261 [pSTams!·! ][pIPl to piPS]; 9 10 
12, SL326I[pSTamsl.2][pIPl to piPS], (8) Western blot using mAb SEt (C) Western blot using Ta immune calf serum. Methods: Single colonies 
were grown overnight a137'C in S ml L8 medium containing 100].lg Ap/ml and 25 JIg Kmjml. Samples were taken for 50S· PAGE (s~ legend 10 Fig. 2). 
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TABLE I 
Plasmid stability in SI t1roA SL3261 
SI aroA Plasmid stability 
SL3261 [plasmids]' 
L brothb 1174.16 "lIs< 
16h(%) 32h ('Yo) 48h(%) 
(I) (2) (3) (4) 
[pSTamsl-l][pIP2] 
" 
17 26 
[pSTamsl-l][pIP3] 78 
" 
NO 
[pSTamsl-l][pIN] 56 33 NO 
[pSTamsl-l][pIP5] 
" " 
5\ 
[pSTams!-2][pIP1] 
" 
53 45 
[pSTam.s!-2][pIP3] 89 56 NO 
[pSTamsl-2][pIN] 92 95 NO 
[pSTams!-2][pl P5] 100 9S 92 
• Plasmids (';lrried by this host are descri~d in Fig. I. 
b Bacteria were grown in LB for 16 h at 37'C in the absence of both 
Ap and Km (16 h time point). Aliquots were taken for another 16 h of 
growth (32 h time point). Afler both time points, aliquots of appropriate 
dilutions were taken for grO\;th on plates at 37'C in the pre;ence 
(100 Ilg Ap/ml and 2511g Km/ml) or absence of Anb. Colonie; were 
counted and the pla.smid stability of the different strains was defined 
as: ({num~r of re,istant baCleria:total num~r of bacteria) x 100%]. 
< 1174.16 ceHs, a continuolls macrophage-like ce\lline deri\'ed from 
a reticulum eel! $arcoma (Ralph et ai., 1975), was grown in D~IEM 
supplemented with 10% FBSj20 mM HEPES/2 mM L-
glutaminej4.5 mglml D·glucose/J.25 Ilg fungizone/ml, further refered to 
as OMEM complete medium. Macrophage; (S x 101) were allowed to 
adhere 10 each well of a 6-\\'ell plate. An aliquot of an o\'ernight SL3261 
culture was serial diluted with OM EM and bacteria were added to each 
well at a ralio of approximately 1 bacterium per macrophage. The cells 
were incubated for 1 h at 37'C to permit phagocytosis. Free bacteria 
were remowd by three washes with PBS and subsequently killed by 
incubation for 2 h at 37'C in OMEM complete medium supplemenled 
with 150 j.lg gentamicin/ml. The medium was replaced by DMEM com-
plete medium, supplemented "ilh 20).lg gentamicinfml. Wells were 
sampled at 43 h post infection by washing the "US 3 x v.ith PBS and 
lysing with PBSjl% Triton-XIOO. Aliquots of appropriate dilutions 
were grown on plate, for 16 h at 37'C in the prc.sence and absence of 
Anb. The plasmid stability was eJ:pressed as descri~d above. NO, 
not done. 
populations producing re-Tamsl-l or re-Tamsl-2, the 
bacteria bearing pIP 5 showed the highest degree of stable 
maintenance of both pIPS and pSTams1-1 or pSTamsl-2 
(TableI, column 4). 
Clearly, the re-Tamsl-l protein has a negative effect 
on the stability oCthe plasmid combinations in St SL3261. 
This is probably due to a higher degree of toxicity of the 
re-Tams1-l protein compared to re-Tamsl-2. The bacte-
ria bearing pIPS maintained their plasmids more stably 
than bacteria bearing pIP2. This may be due to the fact 
that pIPS has a different origin of replication that results 
in a lower plasmid number per bacterium and therefore 
a lower percentage ofre-protein producing cells resulting 
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ill a lower selection pressure against the plasmids (Tijhaar 
et aI., submitted). 
(e) Conclusions 
(I) Provided that they lack both the N- and C-terminal 
hydrophobic domains, the genes encoding the 30- and 
32-kDa Ta major merozoite antigens can readily be 
expressed ill Ec and St SL3261. When both Tams!-I and 
Talllsl-2 contained their signal sequences, no detectable 
expression could be obtained. The presence of hydro-
phobic N-ter·minal sequences is presumable highly toxic 
to the expression bacteria. Low-level expression is 
obtained from the constructs containing the hydrophobic 
C terminus. 
The purified re-Tams!-1 and Tamsl-2 proteins can 
now be incorporated into immunostimulating complexes 
(ISCOl\·ls) (l\-1orein et a!., 1987) for immunization trials 
in cattle that are subsequently challenged· with Ta. 
Successful immunization trials using ISCO~-Is have been 
reported for other protozoan parasites such as 
Trypa/Josoma entzi (Araujo et al., 1991), Toxoplasma 
gondii (Lunden et aI., 1993) and Eimeria faiciforlllis 
(Kazanji et aL, 1994). 
(2) When infected macrophage-like cells (J774.16) were 
grown for 48 h at 37°C, St SL3261[pSTamsl-l][pIPS] 
and SL3261 [pSTamsl-2][pIPS] retained their plasmids 
with the highest degree of efficiency. These are therefore 
the strains of choice for delivering both Ta merozoile 
re-proteins in future vaccination trials in cattle. 
. It has been shown that immunization using live attenu-
ated Salmollella spp. as carriers of foreign antigens 
induces humoral as well as cellular immune responses 
(Smith et aI., 1984; for a review, see Cardenas and 
Clements, 1992~ Coulson et aI., 1994). 
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ABSTRACT 
Salmonella typhimurium aroA strains (SL3261), expressing high levels of the 
Gag protein of feline immunodeficiency virus (FIV) fused with maltose binding 
protein (SL3261-MFG), were constructed using an invertible promoter system 
that allows the stable expression of heterologous antigens at levels toxic for 
bacteria. A SL3261 strain expressing the B subunit of cholera toxin by a similar 
system (SL3261-CtxB) served as a control in FIV-immunization experiments. 
Cats immunized once orally or intraperitoneally with SL3261-MFG or SL3261-
CtxB all developed serum antibodies to SL3261 lipopolysaccharide and against 
maltose binding protein or the B subunit of cholera toxin, respectively. Two 
intraperitonial immunizations with SL3261-MFG also resulted in the 
development of Gag specific serum antibodies. Two oral immunizations with 
SL3261-MFG primed for a Gag specific response, which was demonstrated upon 
FIV challenge. All challenged cats became infected and no significant differences 
in viral loads were found between SL3261-MFG and SL3261-CtxB immunized 
cats. 
INTRODUCTION 
Feline immunodeficiency virus (FIV) infection of cats shows many similarities 
with human (HIV) and simian immunodeficiency virus (SIV) infections. It 
infects its natural host persistently, is T lymphotropic, causes a progressive loss 
of CD4+ T cells, can infect macrophages and astrocytes, and eventually causes 
severe immunodeficiency or feline AIDSI-6. Because of these similarities, FIV 
infection of cats is considered a useful small-animal model for the evaluation of 
vaccine strategies relevant for controlling HIV -1 infection of humans. 
In the search for effective lentivirus vaccines different strategies like 
inactivated complete virus7, subunits8-12, peptides l3 , live attenuated virus I4-17, 
viral carriers I8-20, bacterial carriers21 , 22 and nucleic acid immunizations23 , 
24 are being explored. In the FIV -cat system, vaccination of cats with 
paraformaldehyde fixed T cells (FL-4 cells) persistently infected with FIV and 
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Fig, 1 The two plasmid invertible promoter system. PL, leftward promoter of bacteriophage 
lambda; IR, inverted repeat; T 1, rrnB T 1 transcription terminator; gin, invertase gene; elS87. 
phage lambda temperature sensitive repressor protein gene; Kan, kanamycin resistance gene; Ap, 
ampicillin resistance gene; malE, gene coding for maltose binding protein; T7pol, T7 RNA 
polymerase gene; PT7, gelle-lO promoter of bacteriophage T7. The invertible promoter of pIP 
controls transcription of the T7 RNA polymerase gene, which in turn directs transcription of a 
gene located under control of the PT7 promoter on a second plasmid (e.g. pETMALp, 
pETMALgag (not shown) or pT7ctxB (not shown)). In this study four different pIP-vectors 
(pIP2, -3, -4 and -5) were used. The vector pIP3 (=pYZ27GP) differs from pIP2 (=pYZ27bGP) 
by having an additional adenine in the untranslated leader sequence of the gill gene. The vectors 
pIP4 and pIP5 are derivatives from pIP2, respectively pIP3, in which the p15A origin of 
replication(ari) that results in an intermediate copy number, is replaced by the ari and partitioning 
(par) region of the low copy number plasmid pSC I 01. The par region ensures equal distribution 
of the plasmid over the daughter cells during cell division. 
with paraformaldehyde inactivated FIV derived from the same cells, proved to 
be protective against homologous and to a lesser extent heterologous 
challenge25, 26. In the SIV -macaque system, vaccination with whole inactivated 
virus induced partial protection against challenge with PBMC from a SIVmac 
infected macaque27. Earlier reported protection against challenge with cell-free 
virus after immunizing with inactivated whole SIVmac was almost certainly 
mediated by the immune response to cellular proteins incorporated into both the 
immunogen and the challenge viruses27, 28. To date, the most effective 
protection of macaques against SIV infection has been obtained with live 
attenuated SlVI4, 29, However, safety issues are still a major subject of 
debate l7 , 
Live recombinant carriers like pox-viruses, BCG and attenuated 
Salmonella strains are being evaluated as alternative approaches for lentivirus 
vaccine development. Attenuated Salmonella strains have been used successfully 
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to present heterologous bacterial30, 31, vira132-34 and protozoal35-37 antigens 
to the immune system of mammals. Systemic humoral and cellular responses, 
including class I restricted cytotoxic T lymphocytes (CTL), and mucosal 
humoral responses have been shown to result from vaccination with recombinant 
Sallllonella strains35, 38-41. 
The development of Salmonella bacteria as carriers for heterologous 
antigens has largely been hampered by problems with stability of expression or 
production levels caused by the toxicity of the antigens for the producing 
Sallllonella strains. Especially expression of non-bacterial antigens may cause 
problems due to different codon usage or the presence of toxic (e.g. 
hydrophobic) sequences. Therefore we42-4S developed a system that allows the 
stable expression of antigens at levels toxic for individual bacteria. The system is 
based on an invertible promoter that controls the expression of T7 RNA 
polymerase. A single promoter inversion results in expression of T7 RNA 
polymerase, which in turn directs expression from genes located under the 
control of a T7 promoter present on another vector in the same cell (Fig. 1). 
The key feature of the system is that the promoter controlling the T7 RNA 
polymerase expression inverts with a frequency that results in toxic levels of 
antigen expression in only a sub-population of the bacteria. Therefore the major 
part of the bacterial popUlation will not be affected by expression of the 
heterologous antigen and will continuously segregate new antigen-producing 
bacteria. 
Here we describe the use of this invertible promoter system to express 
high levels of FIV core protein as a fusion with the maltose binding protein 
(MBP) in the S.typhilllllriulIl aroA vaccine strain SL326! and the use of this 
strain to induce specific immunity in cats. 
MA TERIAL AND METHODS 
Bacterial strains, plasmids and media 
Escherichia coli strain DHSo: (BRL Life Technologies, Breda, The 
Netherlands ) was used as a host for all plasmid constructions. Before 
introduction into the S.typililllllrilllll aroA vaccination strain SL326!46 plasmids 
were passaged through the restriction deficient, modification 
proficient S. typhilllllrilllll strain SLS283, a galE503 derivative of LB500047 , 
48. 
Strain BL2!DEpLysS49 is a lysogen of the E.coli strain BL2! that 
contains a copy of the T7 RNA polymerase gene in the chromosome under 
control of the IPTG inducible lacUVS promoter50 and the pLysS plasmid which 
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codes for T7 lysozyme; a natural inhibitor of T7 RNA polymerase. Strain 
BL2lDEpLysS was used to express genes under the control of a T7 promoter. 
The T7 RNA lysozyme, encoded by pLysS, reduces the basal activity of T7 RNA 
polymerase in uninduced cells, thereby allowing the establishment of target genes 
whose basal expression would otherwise have been toxic to the cells. The vector 
pLysS confers resistance to chloramphenicol and is compatible with plasmids 
containing a ColE I origin of replication49. All bacteria were grown aerobically 
at 370 C in Luria broth (LB), unless indicated otherwise. Ampicillin was used at 
100 J.lg/ml in LB agar plates and 200 J.lg/ml in liquid media. Kanamycin and 
chloramphenicol were used at concentrations of 50 J.lg/ml and 35 J.lgiml, 
respectively, in agar plates as well as in liquid media. 
Construction of the plasmids pYZ27bGP (=pIP2), pYZ27GP (=pIP3), 
pIP4 and pIP5 has been described previously43, 45. The vectors pET3xa49 and 
pMal-p were purchased from Invitrogen and New England Biolabs, respectively. 
DNA manipulations 
Isolation of plasmid DNA, preparation of DNA fragments and ligations were 
carried out using standard methods51 . Plasmids were introduced into bacteria by 
electroporation as previously described44. 
Construction of plasmids used in this study 
To increase the copy number of pET3xa49 the rop gene, which negatively 
regulates plasmid copy numbers of ColE! based plasmids, was removed by 
cleavage with BglII and PvuII, followed by blunting of the ends with T4 DNA 
polymerase and religation of the plasmid. From the resulting plasmid, designated 
pET3xa 1, a number of inconvenient restriction sites were removed by cleavage 
with EcoRI and EcoRV followed by blunting with T4 DNA polymerase and 
religation. The resulting plasmid was designated pET3xa2. The malE gene, 
which codes for precursor maltose binding protein (preMBP), was obtained by 
PCR using pMal-p ( cat #800-61, New England Biolabs, Inc., Beverly, MA, 
USA) as template and the oligo nucleotides 5'-CGAGCATA TGAAAAT AAA 
AACAGGTGCACG-3' and 5'-GAATTCAGGCCTACCCTCGATGGATCC-3' as 
amplimers. The first amplimer was designed to introduce a NdeI site (underlined 
at the position of the ATG start codon of //la/E. The second amplimer 
overlapped partially with the multiple cloning site (MCS) of pMAL-p, so that the 
PCR product would contain the 5'-part of the MCS, which includes a unique 
KpnI site. The PCR product was cleaved with NdeI and KpllI and cloned into the 
corresponding sites of pET3xa2 to generate pETMALp (Fig. 1). In this plasmid 
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transcription of the malE gene is under the control of the 1'7 promoter. 
The vector pETMALgag was constructed by replacing the small Nco 1-
BamHI fragment of pETMALp (Fig. 1) by the NeoI-BamHI fragment of pMAL-
gag, which contained the 3'-end of the malE gene in frame with the complete 
coding part of the gag gene of the molecular FIV clone 19k!. In pETMALgag, 
transcription of the malE-gag fusion is under the control of the 1'7 promoter. 
Western blot analysis of bacteria 
For Western blot analysis SDS-PAGE was immediately followed by 
transfer of the proteins to nitro-cellulose. Blots were incubated for 30 minutes at 
room temperature with blocking buffer (BB) [0.5 % Tween-20 and 0.5% low fat 
milk powder in PBS]. Subsequently, the blots were incubated for one hour at 
room temperature with serum of an experimentally infected SPF cat (cat 89176), 
diluted 100 times in BB. After washing 3 times over a period of 30 minutes in 
PBS containing 0.5% Tween-20, the blot was incubated for 1 hour at room 
temperature with a biotinylated anti-cat IgG monoclonal (Sigma Immuno 
Chemicals, clone CT-21, caLm. B-226) diluted in BB. After washing, the blot 
was incubated for 30 minutes at room temperature with alkaline phosphatase 
conjugated ExtrAvidin (Sigma Immuno Chemicals, caLnr. E2636) diluted in BB. 
Finally the blot was washed three times, soaked for 10 minutes in substrate 
buffer (O.IM Tris pH9.5, O.lM NaCl, 0.05M MgCI2) and developed in substrate 
buffer containing Nitro Blue Tetrazolium (NBT) and 5-Bromo-4-Chloro-3-
Indolyl Phosphate (BCIP). 
Detection of antigen expression by electron microscopy. 
To obtain an indication of the percentage of bacteria of strain SL3261-
MFG4 (Table I) that, due to a promoter inversion, expressed the MBP-Gag 
fusion protein, bacteria were grown in the presence of ampicillin and kanamycin 
until they reached the logarithmic phase. Subsequently, the bacteria were spun 
down (13.000 rpm) for 2 minutes, washed once with ice cold PBS and fixed with 
4% paraformaldehyde in 0.1 M NaCacodylate (pH7.4). Then the bacteria were 
transferred to 2% gelatine, impregnated in 2.3 M sucrose and frozen in liquid 
nitrogen. Finally ultra thin cryosections were made. The cryosections were 
subjected to immunogold labelling using the Gag specific moAB 2-1152 diluted 
100x in PBS containing 0.5% BSA and 0.1 % gelatine, and protein A conjugated 
to gold particles with a diameter of 10 nm (Aurion, Wageningen, The 
Netherlands, nr. 110.111) diluted 20x in the same buffer. The sections were 
stained and embedded into methyl cellulose according to the method of 
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Tokuyasu53. Subsequently, the sections were analysed by transmission electron 
microscopy (Phillips EM400). Bacteria were arbitrarily classified according to 
the amount of labelling. For this determination only complete longitudinal cross 
sections of bacteria were used. 
Plasmid stability of bacterial strains during growth in thymocytes. 
The assay for determination of plasmid stability of SL3261 strains after invasion 
of eukaryotic cells was essentially performed as described previously45. In 
short, thymocytes derived from a specified pathogen free (SPF) cat were 
stimulated for 3 days with Concanavalin A, washed and subsequently maintained 
in culture medium ( RPMI 1640 [Gibco) supplemented with 10% (v/v) FCS, 2 
mM L-glutamine, penicillin [l00 IVlml], streptomycin [100 J.lg/ml], L-glutamine 
[2mM) and IL2 [100 IV/ml, Cetus) at 370 C I 5% C02. About 108 bacteria from 
logarithmic phase cultures were added to 106 thymocytes in a total volume of 1 
ml RPMI 1640 without any additives. After 2 hours incubation at 370 C the cells 
were washed and subsequently maintained at 370C/5%C02 in 10 ml culture 
media containing gentamicin (50 J.lg/ml) to kill extracellular bacteria. After 24 
hours the plasmid stability was determined by lysing the thymocytes and 
comparing the number of CFUs that could be recovered on plates without and 
with the appropriate antibiotics. 
Immunization and FIV challenge of cats. 
For immunization, bacteria from logarithmically growing cultures were 
harvested by centrifugation, washed, and resuspended in PBS. Subsequently, six 
months old specified pathogen free (SPF) cats, without detectable antibody levels 
against Salmonella LPS or CtxB, received 4 ml of 2.5x108 cells/ml by the 
intraperitoneal (i.p.) route or 10 ml of 5xl0l0 cells/ml directly into the stomach 
to simulate oral administration. This "oral" immunization was performed with 
anaesthetized cats using a syringe connected to a thin tube that reached into the 
stomach. Just prior to oral administration of the bacteria, gastric juices were 
neutralized by administration of lOml 10% NaHC03 using the same device. , 
Two cats were immunized with SL326l expressing Gag, one cat by the 
oral route and the other by the i.p. route. The primary immunization (week 0) 
was performed with SL3261-MFG4, whereas the secondary immunization (week 
9) was performed with equal amounts of strains SL3261-MFG2 and SL326l-
MFG4 (Table 1). As a control, two cats were immunized with the CtxB 
expressing strain SL326l-CtxB (Table 1) at week 0 and 9. Again, one cat was 
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Table! SL3261 strains used in this study. 
Strain 
SL3261 
SL3261 (pETMALgag) 
SL3261-MFG2 
SL3261-MFG3 
SL3261-MFG4 
SL3261-MFG5 
SL3261-CtxB 
Plasmids 
no 
pETMALgag 
pETMALgag + plP2 
pETMALgag + plP3 
pETMALgag + plP4 
pETMALgag + plP5 
pT7ctxB + plP2 
a MFG: fusion protein of Maltose binding protein and FLY-Gag. 
h CtxB: B subunit of cholera toxin. 
Heterologous antigen 
no 
no 
MFGa 
MFGa 
MFGa 
MFGa 
CtxBb 
immunized by the oral route and the other by the i.p. route. Eighteen weeks 
after the primary immunization all cats were challenged intramuscularly with 30 
ID50 of the molecular FlV clone 19k154. Serum samples were taken at 1,2,3, 
4, 5, 9, 10, 13 and 15 weeks after the primary immunization, immediately prior 
to FlV challenge and 4, 7, 10, 14, 19,24,28,33 and 67 days post challenge. 
Detection of FIV infection. 
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized 
blood and cultured in limiting dilutions as previously described54 to enumerate 
percentages of FIV infected cells. The presence of FlV antigen in culture 
supernatants was detected with a FlV antigen capture ELISA as previously 
described55. 
ELlS As 
LPS-ELISA. The detection of S. ryphilllllrilllll LPS specific antibodies was 
essentially performed as previously described44. The incubation step with HRP 
conjugated anti-mouse antibody was replaced by an incubation for 90 minutes at 
370 C with a biotinylated anti-cat IgG monoclonal antibody (Sigma lmmuno 
Chemicals, clone CT-21, cat.nr. B-226) diluted 1:1000, followed by incubation 
for one hour at 370 C with a streptavidin-biotin-HRP complex (cat.nr. RPNI051, 
Amersham ) also diluted 1: 1000. The titer was defined as the highest dilution of 
test samples at which the O.D.450 was higher than the mean O.D.450 + 3 times 
S.D. of pre-immune sera. 
CrxB -ELISA. The ELISA for the detection of CtxB specific antibodies 
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differed from the LPS ELISA in the coating step, which was performed in PBS 
containing S.O I!g/ml CtxB (List Biological Labs, Campbell, CA, USA) and the 
dilutions of the biotinylated anti-cat IgG monoclonal antibody (1:2000) and the 
streptavidin HRP-conjugate (I:2S00). In addition the ELISA-buffer in which the 
cat sera were diluted, was supplemented with 1% SL3261 sonificate prepared 
from a SO times concentrated o/n bacterial culture to reduce background 
reactions. The titer was defined as the highest dilution of test samples at which 
the O.D.4S0 was at least three times higher than that of the corresponding serum 
dilution of the control cat immunized in a similar way with SL3261 expressing 
MBP-Gag instead of CtxB. 
MBP-ELISA. The ELISA for the detection of MBP specific antibodies was 
performed identical to that for CtxB except that for the coating step 3.0 I!g/ml 
MBP was used. The MBP was isolated from strain DHSa(pMALc) by affinity 
chromatography with maltose-Sepharose using a commercially available kit 
(Protein Fusion and Purification System, cat #800, New England Biolabs, Inc., 
Beverly, MA, USA). The titer was defined as the highest dilution of test samples 
at which the O.D.4S0 was at least two times higher than that of the 
corresponding serum dilution of the control cat immunized in a similar way with 
SL3261 expressing CtxB instead of MBP-Gag. 
Gag-ELISA. Antibody titers against p17 and p24 core proteins were 
determined using a commercially available ELISA (FIV-p24/pI7 antibody test 
kit, cat. nr. F 1002-ABO I, European Veterinary Laboratory B V., Woerden, The 
Netherlands). 
RESULTS 
Expression of FlV -Gag 
For use in the two plasmid invertible promoter system (Fig. I), the malE gene 
was placed under the control of the T7 promoter. The resulting plasmid, 
designated pETMALp (Fig. I), was transferred to the E. coli strain 
BL2lDEpLysS which contains on its chromosome the T7 RNA polymerase gene 
under control of the IPTG inducible lacUVS promoter. 
IPTG-induction of the T7 RNA polymerase gene in BL2IDEpLysS-
(pETMALp) resulted in the expression of the malE gene (Fig. 2). A prominent 
band with a Mw corresponding to preMBP, as well as a weaker band with a Mw 
corresponding to MBP from which the signal sequence had been cleaved-off, 
were visible on a Coomassie Blue stained SDS-PAGE gel. 
100 
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Fig. 2 Expression of MBP by BL2IDEpLysS(pETMALp). Five hours after the addition of I 
mM !PTG to logarithmically growing bacteria, cells were harvested and total bacteriallysates were 
subjected to SDS-PAGE followed by staining of the gel. Lanes: 1. molecular weight markers; 2. 
BL2IDEpLysS; 3. BL2IDEpLysS-(pETMALp). Numbers on the left refer to the molecular sizes 
of the marker proteins in kDa. 
To obtain high expression levels of the gag gene of the molecular clone 
FlY 19k1, it was cloned in frame with the malE gene of pETMALp and the 
resulting plasmid was designated pETMALgag. The plasmid pIP2 
(=pYZ27bGP) (Fig. I) contains the T7 RNA polymerase gene under control of 
an invertible PL-promoter. S.fyphimlll'ilim strain SL3261, harbouring, 
pETMALgag in combination with pIP2, designated SL3261-MFG2, expressed 
high amounts of the MBP-Gag fusion protein (Fig. 3A). The presence of the 
Gag-moiety of this fusion protein was confirmed by Western blotting which 
shows the full-length MBP-Gag band and a number of break-down products 
(Fig. 3B). 
Inversion frequency and plasmid stability 
Previously45 it had been demonstrated that pIP3, which differs from pIP2 by 
having an extra nucleotide in the untranslated leader sequence of gin, reveals 
slightly lower expression levels of genes under the control of a T7-promoter 
than pIP2. The vectors pIP4 and pIP5 are lower copy number derivatives of 
pIP2 and pIP3, respectively, which reveal significantly lower expression levels 
than the parental plasmids. The pIP-vectors were analyzed by SDS-PAGE (Fig. 
4A) and Western blotting (Fig. 4B). Three individual clones were tested for each 
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Fig. 3 Expression of MBP-Gag by SL3261 containing the two-plasmid invertible promoter 
system. Cells were grown at 370 C, lysed and subjected to SDS-PAGE. Lanes: 1. SL3261; 2. 
SL3261-MFG2. (A) Coomassie-blue stained SDS-PAGE gel; (B) Western blot using serum of an 
experimentally FIV -infected SPF cat. The arrow indicates the position of the full-length MBP-Gag 
fusion protein. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Fig. 4 Expression of MBP-Gag by different SL3261-MFG strains. Total celllysates of bacteria 
grown at 370 C are shown. For each strain three individual clones were analysed. Lanes: 1. 
SL3261; 2. SL3261(pETMALgag); 3-5. SL3261-MFG3; 6-8. SL3261-MFG2; 9-11. SL3261-
MFG5; 12-14. SL326IMFG4; (A) Coomassie-blue stained SDS-PAGE gel; (B) Western blot 
using serum of an experimentally FIV-infected SPF-cat. The arrow indicates the position of the 
MBP-Gag fusion protein. Only the relevant part of the SDS-PAGE and WB is shown. 
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Fig. 5 Percentage immunogold labelled bacteria lIsing a Gag specific monoclonal antibody. 
Logarithmically growing bacteria were fixed, immunogold labelled and analysed by transmission 
electron microscopy. Bacteria were classified according to the amount of goldparticles/cell: 0 
(striped); 1-3 (black); more than 3 (dotted). 
of the plasmid combinations. The highest MBP-Gag production was obtained for 
SL3261-MFG2, followed by SL3261-MFG3 and SL3261-MFG4, which reveal 
comparable expression levels, and finally SL3261-MFG5. 
The plasmid stability of SL3261 strains after growth in eukaryotic cell 
lines gives an indication of the ill vivo plasmid stability45. Therefore the plasmid 
stability of the SL3261-MFG strains was determined in cat thymocytes cultured 
ill vitro (Table 3). In this invasion assay pETMALgag alone was stably 
maintained in SL3261, but the combinations of pETMALgag with p YZ27bGP 
(=pIP2), and pYZ27GP (=pIP3) were not. The majority of the bacteria 
harbouring one of these combinations lost one or both plasmids within 24 hours. 
Furthermore, the bacteria that still contained both plasmids, appeared to be 
mutants that did not express the fusion protein. In contrast, the combinations of 
pETMALgag with pIP4 or pIP5 were relatively stable and all the tested bacteria 
still expressed the MBP-Gag fusion protein. 
Of the two stably expressing strains the highest expression levels were 
obtained with SL3261-MFG4. To obtain an indication of the percentage of the 
cells, that expressed the MBP-Gag fusion protein in this strain, bacteria from 
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Table 2. Immunization schedule of cats with SL3261 strains expressing heterologous 
antigens. 
Immunizations Challengea 
Cat (no) Strain Route (week) (week) 
SL3261-CtxB oral o and 9 18 
2 SL3261-CtxB Lp. o and 9 18 
3 SL3261-MFG oral o and 9 18 
4 SL3261-MFG i.p. o and 9 18 
aChallenge was performed Lm. with 30 cat ID50 of the molecular clone FIV 19k!. 
logarithmic growth cultures were fixed, immunogold labelled on ultra-thin 
cryosections and analysed by means of transmission electron microscopy. 
Bacteria were arbitrary classified according to the amount of labelling (Fig. 5). 
Of the cells of the negative control strains SL3261 and SL3261-CtxB, 94% and 
92% were not labelled, respectively. The remaining 6% and 8% respectively, 
were labelled with only one to three gold particles. Of strain SL3261-MFG4 
53% of the cells were not labelled, 30% contained one to three gold particles and 
17% contained more than 3 particles, with an average of 10.5 
particles/bacterium. Taking the 7% background labelling of the control strains 
into consideration, the percentage cells from strain SL3261-MFG4 expressing 
MBP-Gag is approximately 40% (=30-7+ 17) of the total population. 
Immunogenicity of SL3261·MFG and SL3261·CtxB in the cat 
Two cats were immunized with SL3261-MFG4 and two cats with strain SL3261-
CtxB, which previously induced high titers of CtxB specific antibodies in 
mice45 . Within each group one of the cats was immunized orally and the other 
one intraperitoneally (Lp.) (Table 2). All animals developed antibodies to S. 
typhimurilllll LPS within one week after the first immunization (Fig 6A). After 
administration of SL3261-CtxB, high anti-CtxB serum titers were induced (Fig 
6B). After the primary immunization with SL3261-MFG4, considerable anti-
MBP IgG titers were induced in the intraperitonially immunized cat (Fig 6C). 
The orally immunized cat developed a weak specific IgG response after the first 
immunization, but the second immunization at week 9 resulted in a considerably 
increased response. 
After the primary immunization with SL3261-MFG4, no antibodies 
specific for the Gag-moiety of the MBP-Gag fusion protein could be detected. 
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Fig. 6 The IgG antibody titers in cat sera immunized with recombinant S.typhimllrium vaccine 
strains and challenged with FlV. Cats were immunized orally (open symbols) or intraperitonially 
(closed symbols) at week 0 and 9 with SL3261-MFG (circles) or SL3261-CtxB (triangles). Eight 
weeks after the booster immunization the cats were challenged intramuscularly with a dose of 30 
cat IDSO FlV. (A) LPS-specific antibody titer; (B) CtxB-specific antibody titer; (C) MBP-specific 
antibody titer; (D) core proteins pI7/p24-specific antibody titer. 
This strain was selected for the primary immunization, because the plasmids in 
this strain were relatively stable in the invasion assay (see Table 3). The second 
immunization was performed with equal amounts of SL326l-MFG4 and 
SL326l-MFG2. Although the plasmid combination of SL326l-MFG2 was not 
stably maintained in the invasion assay, it was incorporated in the second 
immunization because it expressed higher levels of MBP-Gag. The idea was that 
SL326l-MFG2 would present a higher amount of MBP-Gag early in infection, 
while SL326l-MFG4 would give a lower but more stable expression. One week 
after the second immunization Gag -specific antibodies were detected in the 
serum of the cat immunized by the i.p. route (Fig. 6D). No Gag-specific 
antibodies were detected in the serum of the orally immunized cat. 
To determine whether immunization with SL326l-MFG had induced 
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Table 3. Stability of recombinant SL3261 strains in cat thymocytes cultured ill vitro. 
Strain 
SL3261 (pETMALgag) 
SL3261-MFG2 
SL3261-MFG3 
SL3261-MFG4 
SL3261-MFG5 
Stability 
plasmidsa 
99.5 ± 0.5% 
17 ±2% 
7 ±2% 
71 ± 21% 
79 ± 19% 
expressionb 
012 
012 
4/4 
3/3 
a Cat thymocytes were infected with the different bacterial strains and cultured for 24 hours ill the 
presence of gentamicin to kill extracellular bacteria. The plasmid stability was determined by 
lysing the thymocytes and comparing the number of CFU on LB-agar plates with and without all 
the appropriate antibiotics. 
b Number of MBP-Gag expressing colonies 1 total number of tested colonies harbouring both 
plasmids. 
Table 4. Detection of FlY in cat PBMCs after challenge. 
lnununization: 
strain/route 
SL3261-MFG/oral 
SL3261-MFG/i.p. 
SL3261-CtxB/oral 
SL3261-CtxB/i.p. 
presence of FlY at day (p.c.): 
4 7 10 14 19 
+ + 
+ + 
+ 
+ 
24 60 
+ + 
+ + 
+ + 
+ + 
PBMC were stimululated with 10 ltg/ml ConA for three days, washed and maintained in culture 
medium containing 100 IU/ml r-JL-2. The presence ofFIV-antigen was detected using an antigen 
capture ELISA. 
protective cellular immune responses, all cats were challenged intramuscularly 
with 30 ID50 of the homologous molecular clone FlV 19k I, eighteen weeks after 
the first immunization. Between 14 to 19 days post challenge (p.c.) all the 
animals had developed a persistent viraemia (Table 4). No significant differences 
in viral load were observed between the cats immunized with SL3261-MFG or 
SL3261-CtxB (Table 5). Both cats immunized with the SL3261-MFG strains 
developed an anamnestic response to Gag as antibody titers to Gag started to rise 
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Table 5. Viral load after FlV challenge. 
Infected cells per 106 PBMC (days p.c.): 
Inununization: 
antigen/route ~--------------------------------------
SL3261-MFG/oral 
SL3261-MFG/Lp. 
SL3261-CtxB/oral 
SL3261-CtxB/Lp. 
14 
Nf 
<12.5 
<12.5 
<12.5 
19 
12.5 
Nf 
Nf 
Nf 
33 67 
58 75 
133 375 
79 150 
79 112 
two weeks earlier in these cats than in the cats immunized with SL3261-CtxB 
(Fig. 6d). 
DISCUSSION 
In the present paper we have shown that the S.typhilllllrilllll strain SL3261 can be 
used efficiently as a vector to present heterologous antigens to the feline immune 
system. Cats immunized with SL3261-MFG developed a Gag specific immune 
response, but were not protected from intramuscular challenge with the 
homologous molecular clone FlY 19k1. 
The development of candidate vaccines based on recombinant Sallllonella 
as live carriers, has largely been hampered by the inability to stably express 
heterologous antigens at levels that are toxic for the producing bacteria. 
However, we previously45 described a two plasmid invertible promoter system 
which may solve this problem. The system is based on the pIP-vectors which 
contain the T7 RNA polymerase gene under control of a promoter that inverts at 
random. When the promoter inverts to the ON position, T7 RNA polymerase is 
expressed which in turn directs expression of the gene of interest that has been 
positioned under the control of a T7 promoter on a second plasmid. The system 
can be stably maintained when a pIP vector is used that results in toxic antigen 
expression in only a minor part of the bacterial population. 
In the present study we used the invertible promoter vectors pIP2 
(=pYZ27bGP), pIP3 (=pYZ27GP), pIP4 and pIPS to express the Gag protein of 
FlY as a fusion product with MBP. S.typhimlirilllll aroA strains SL326l-MFG 
(Table 1) expressed high levels of the MBP-Gag fusion protein. The highest 
expression levels were obtained with SL326l-MFG2 followed by SL326l-MFG3 
and SL326l-MFG4, which revealed similar expression levels, and finally 
SL326l-MFG5. Of the different SL326l-MFG strains, only SL326l-MFG4 and 
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SL3261-MFG5 stably maintained their plasmids after invasion of a cat thymocyte 
cell line (Table 3). Although SL3261-MFG3 and SL3261-MFG4 expressed 
similar amounts of the MBP-Gag fusion protein, indicating the presence of 
comparable percentages of antigen expressing bacteria, a striking difference in 
plasmid stability between both strains was observed. The higher plasmid stability 
of SL3261-MFG4 compared to SL3261-MFG3, is most likely the result of the 
partitioning (par) region present on plP4 which is absent on p1P3. This pa r 
region ensures equal distribution of the plasmid copies over the daughter cells 
during cell division, what greatly enhances plasmid stability56. 
lmmunogold labelling of SL3261-MFG4 demonstrated that about 40% of 
the bacteria expressed MBP-Gag (Fig. 5). This does not mean that all these 
expressing bacteria actually contain a pIP plasmid with the PL promoter in the 
ON position. It may be speculated that a number of these cells have been derived 
from cells that divided after a promoter inversion occurred, but before antigen 
expression reached a level that prevented further cell divisions. 
The S. typ hi III II ri II III vaccination strain SL3261 appeared to be 
immunogenic in cats. After Lp. as well as after oral immunization, high specific 
antibody titers to S.typhilllurilllll LPS were induced. Moreover, SL3261 can also 
be used as a vector to present heterologous antigens to the immune system of 
cats, as high serum antibody titers were induced to CtxB and MBP. The 
responses to FlY Gag were considerably weaker. A second immunization was 
necessary to induce detectable Gag specific serum antibodies upon i.p. 
immunization. After two oral immunizations no Gag-specific antibodies were 
detected, but the immune system had clearly been primed for Gag protein 
recognition, as after flY challenge Gag-specific antibodies could be detected two 
weeks earlier than in the control cats. It is unlikely that this is the result of 
enhancement of FlY infection, as we observed with other FlY vaccine 
candidates57 , since the FlY loads of this cat at 33 and 67 days post challenge 
were even lower than those of the control cats. It should be stressed that the 
specific antibody responses were mainly determined as a marker to demonstrate 
that the heterologous antigens expressed by SL3261 are presented to the immune 
system of cats, since it cannot be expected that antibodies against the internal Gag 
proteins would neutralize FlY. In general S. typhimllriulIl preferentially induces 
cellular immune responses, including cytotoxic T cell responses35-38, 40 which 
may contribute to protective immunity58. No FlY specific T cell responses were 
determined in the framework of these experiments. However, if indeed Gag 
specific T helper and CTL responses were induced by these immunizations, they 
were apparently not sufficient to protect the cats against the homologous 
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challenge with 30 CID50 FIV. 
We are currently investigating the immune responses and priming 
effects in cats, immunized with SL3261 strains expressing the Gag and envelope 
proteins of FIV in order to generate a more complete immune response to FIV 
proteins that will hopefully result in protection. 
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ABSTRACT 
Two experimental feline immunodeficiency virus (FIVj vaccines were tested, 
either alone or in combination, in four groups of cats (A-D). One vaccine 
(SL3261 -FIV) was composed of live attenuated Salmonella typhimurium aroA 
(SL3261) strains expressing the capsid (Gag) and part of the envelope (Env) 
proteins of FIV. The other \Vas composed of FIV-Gag and -Env proteins 
incorporated into imml!ne stimulating complexes (iscom-FIV). Cats of group A 
were immunized four times with SL3261 -FIV and of group B twice with 
SL3261 -FIV fol/owed by two immunizations with iscom-FIV. Cats of group C 
were immunized twice with SL3261 expressing the B subunit of Cholera toxin 
(SL3261 -CtxB), followed by two immunizations with iscolll-FIV. Cats of group 
D, which served as negative controls, received SL3261 -CtxB twice fol/owed by 
two immunizations with iscom in which the Gag and Env proteins of simian 
immunodeficiency virus (SIV) had been incorporated (iscom-SIV). Two weeks 
after the last immunization all cats were challenged. At this time cats immunized 
with iscom-FIV (groups Band C) had shown strong plasma allfibody responses 
to Gag and Env, while these responses had been weak or undetectable in the cats 
immunized four times with SL3261-FIV. Seven weeks after FIV-challenge, Env-
specific antibody responses had increased considerably in cats of all the groups 
except the one immunized four times with SL3261 -FIV. The mean viral loads in 
the cats of this group, proved to be lower than those of the other groups at all 
time POillfS, indicating partial protection. 
INTRODUCTION 
Feline immunodeficiency virus (FLY) infection causes a disease in cats similar to 
AIDS in humans. Like human immunodeficiency virus (HIY) and simian 
immunodeficiency virus (SLY), it is a T-lymphotropic lentivirus that persistently 
infects its natural host and causes loss of CD4+ T cells, finally resulting in a 
severe immunodeficiency (Brunner & Pedersen, 1989; Ackley et al., 1990; Dow 
1I9 
ef al., 1990; Torten ef al., 1991; Hoffmann-Fezer ef al., 1992). These similarities 
make FIV infection of cats a useful animal model for the evaluation of HIV 
vaccination strategies. 
Many of the vaccine strategies that have been explored to induce protective 
immunity against lentiviruses have been without or with limited success. 
Inactivated whole virus vaccines have been effective in the FIV system. Cats 
vaccinated with parafol'lnaldehyde fixed T cells (FL-4 cells) persistently infected 
with FIV, and cats vaccinated with parafol'lnaldehyde inactivated FIV derived 
from the same cells proved to be protected against homologous and to a lesser 
extent against heterologous FIV challenge infection (Yamamoto ef al., 1991, 
1993; Hosie ef al., 1995). Similar approaches with vaccine preparations derived 
from other cells were unsuccessful (Hosie ef al., 1992; Verschoor ef al., 1995). 
The most impressive protection against SIV infection in macaques has been 
obtained by vaccination with live attenuated virus (Daniel ef al., 1992; Clements 
ef al., 1995), but safety concerns (Dittmer et al., 1995) may limit the use of this 
approach. 
Live carriers like canary pox, BCG and attenuated Salmonella strains are 
being extensively evaluated as alternative lentivirus vaccine candidates. 
Attenuated Salmonella strains have been used successfully as live carriers to elicit 
mucosal and systemic humoral responses as well as cellular responses, including 
class I restricted cytotoxic T cells (CTL), against a number of bacterial (Wick ef 
al., 1993), viral (Tite et al., 1990; Charbit ef al., 1993; Schadel ef al., 1994; 
Valentine ef al., 1996) and protozoal (Aggarwal et al., 1990; Flynn ef al., 1990; 
Yang ef al., 1990; Gonzalez ef al., 1994) antigens. Induction of mucosal 
immunity may be of particular relevance to HIV -1 vaccine development, since 
the most common route of infection is via mucosal surfaces of the genital tract. 
Although attenuated Salmonella strains may present antigens to the 
immune system, the development of vaccines using Salmonella strains as live 
carriers has been hampered by low and/or unstable expression of heterologous 
antigens. To solve this problem we (Yan ef al., 1990; Yan, 1992; Tijhaar ef al., 
1994; E.I. Tijhaar, I.A. Karlas, z.x. Yan, T.F. Meyer, A.D.M.E. Osterhaus & 
F.R. Mooi, unpublished results) developed an expression system that allows 
abundant and stable expression of heterologous antigens by a bacterial 
population, even if antigen expression is toxic for individual bacteria. The 
system is based on an invertible promoter that randomly inverts. After switching 
to the "ON" position, it directs the expression of T7 RNA polymerase. The 
polymerase in turn directs expression of genes located under the control of a T7 
promoter present on another vector in the same cell. The bacterial population 
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consists therefore of two populations, one of which expresses the gene of interest 
due to the promoter inversion, while the major subpopulation does not produce 
the antigen. Not hindered by the expression of the heterologous antigen, the non-
producing population may disseminate within the host and segregate new antigen 
producers allowing a wide spread expression of the antigen in the body. 
Previously we have used this invertible promoter system to express the 
gag gene of FIV in Salmonella Iyphimllrillm (Tijhaar el al., 1997). Cats 
immunized intraperitoneally (i.p.) with these Salmonella Iyphimllrillm strains 
developed a clear antibody response to the Gag protein. Oral administration did 
not induce Gag-specific antibodies, but did prime the immune system, as became 
evident by the considerably faster and stronger response to Gag after challenge 
with FIV as compared to the control cats. However, none Of the thus immunized 
cats proved to be protected. In the present study we have extended the 
immunization regimen by co-administering Salmonella typhimllriufIl strains that 
express part of the env gene and subsequent boosting with recombinant Gag and 
Env proteins incorporated into immune stimulating complexes (iscom). Here we 
demonstrate that immunization with FIV -iscom, either alone or in combination 
with Salmonella Iyphillllll'illfll strains expressing FIV-Env and -Gag, resulted in 
the induction of higher specific plasma antibody titers. However, this did not 
correlate with reduced viral loads upon challenge. In contrast, repeated 
immunization with the FIV-Env and -Gag expressing Salmonella Iyphilllllrillm 
strains alone did result in lower mean cell associated FlV loads upon challenge. 
METHODS 
Bacterial strains and media 
The bacterial strains and their growth conditions have been described previously 
(Tijhaar et al. 1997). 
Construction of plasmids 
Construction of the invertible promoter plasmids pIP2 (=pYZ27bGP) and pIP4, 
and the T7 RNA polymerase controlled expression vectors pETMALp and 
pETMALgag, has been described previously (Yan, 1992; Tijhaar et al., 1997; 
E.J. Tijhaar, J.A. Karias, Z.X. Yan, T.F. Meyer, A.D.M.E. Osterhaus & F.R. 
Mooi, unpublished results). 
Vector pETMALc was created by deletion of co dons 9 to 26 of the malE 
gene of pETMALp, which code for the stretch of hydrophobic amino acids in 
the signal sequence of pre-maltose binding protein (MBP) that is essential for 
transport to the periplasm. This mutation was introduced because the toxicity of 
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cytoplasmatically localized MBP-fusiou proteins, as coded for by pETMALc, is 
usually less and the expression higher than of MBP-fusion proteins that are 
directed to the periplasm. The mutation was performed using the "Transformer 
Site-Directed Mutagenesis Kit" (catalog number K 1600-1; Clontech 
Laboratories Inc., Palo Alto, CA, USA). The oligo 5'-AAAACAGGTGCACGC 
GAAGAAGGTAAACTGG-3' was used for introducing the deletion, while oligo 
5'-ACCACGATGCCCGCAGCAATGGC-3' was used as the selection oligo. This 
oligo introduced a silent mutation in the ll-lactamase gene of pETMALp that 
destroys the PstI-site which allowed selection against unmutated plasm ids by 
linearisation with PstI prior to transformation. 
Western blot analysis of bacteria 
Western blots were performed as previously described (Tijhaar et al., 1997). 
Plasmid stability of bacterial strains during growth in thymocytes 
Thymocytes derived from a specified pathogen free (SPF) cat were stimulated 
for 3 days with 5 Ilglml concanavalin A (ConA) and subsequently maintained in 
culture medium (RPMI 1640 (GIBCO-BRL) supplemented with penicillin (100 
IVlml), streptomycin (100 Ilg/ml), L-glutamin (2 mM), and ll-mercaptoethanol 
(2 x 10-5 M)) containing 100 IVlml IL2 (Cetus). Prior to infection with the 
SL3261 strains, thymocytes were washed twice in RPMI 1640 without any 
additives. Bacteria from logarithmic growth cultures were harvested by 
centrifugation and washed twice with RPMI 1640. Approximately lOS bacteria 
were added to 106 thymocytes in a total volume of 1 ml RPM I 1640. 
Subsequently, cells were incubated for 2 hours at 37'C, during which period 
they were resuspended every 20 minutes. Finally the cells were washed twice in 
RPMI and suspended in 10 ml culture media supplemented with gentamicin (50 
Ilg/ml) to kill extracellular bacteria and IL2 (100 IVlml). After 24 hours at 
37"C, cells from 1 ml of culture were harvested, washed two times in PBS and 
lysed PBS containing 1 % Triton x-IOO to release intracellular bacteria. The 
bacteria were plated on media without antibiotics and colonies were allowed to 
form at 2S"C. Subsequently, at least 100 colonies of each sample were tested for 
resistance on plates containing ampicillin and kanamycin. The plasmid stability 
was expressed as the percentage bacteria that was still resistant to both 
antibiotics. 
Preparation of iscom 
FlV envelope glycoprotein iscom were prepared as described previously 
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(Rimmelzwaan et al., 1994) from lectin purified protein derived from BHK cells 
infected with the recombinant vaccinia virus vGR657x15. This recombinant 
vaccinia virus expressed a form of the envelope protein from which the cleavage 
site between the surface (SU) and transmembrane (TM) part of the protein had 
been deleted to facilitate incorporation in iscom. 
For the preparation of FIV Gag iscom, the complete coding sequence of 
the gag gene of molecular FIV clone 19k1 (Siebelink et ai., 1992) was cloned in 
frame with the bacterial expression vector pMALc (New England Biolabs Inc., 
Beverly, MA, USA) using peR. E.coli containing the resulting plasmid, 
expressed a MBP-Gag fusion protein after IPTG induction, which was affinity 
purified on an amylose column according to the procedure recommended by the 
manufacturer. The MBP-Gag fusion protein was coupled to palmatic acid (Reid, 
1992) and then incorporated into iscom, via this hydrophobic anchor, by a 
procedure similar to that described for the preparation of the FIV envelope 
iscom. 
lscom containing vaccinia derived SIV envelope glycoprotein and iscom 
containing SIV Gag derived from an MBP-Gag fusion protein, which were both 
a kind gift from E. Hulskotte, have been described elsewhere (Hulskotte et al., 
1995). 
Table 1. Immunization schedule 
Group 
A 
B 
C 
D 
Immunization at 
week: 0 and 4 
SL3261-F1V' 
SL3261-F1V 
SL3261-CtxB 
SL3261-CtxB 
Immunization at Challenge (Lm.) 
week: 10 and 13 week 15 
SL3261-F1V 30 CID50 F1V 19k1 
iscom-F1V§ 30 CID50 F1V 19k! 
iscom-FIV 30 CID50 F1V 19k! 
iscom-Srv'll 30 CID50 F1V 19k1 
Each cat received a total of 1011 bacteria by the ora! route and 109 by the Lp. route per 
immunization with SL3261. The iscom-immunized cats received 10 Ilg of each protein 
by the subcutaneous route. 'SL3261-F1V: equal amounts of SL3261 strains expressing 
the gag gene and strains expressing part of the ellv gene of F1V (l9kl). §iscom-F1V: F1V 
Env and Gag incorporated in iscom. 'Iliscom-SIV: SIV Env and Gag incorporated in 
iscom. 
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Immunization of cats and FIV challenge 
Immunizations were performed as shown in Table 1. Two Env-expressing 
strains (i.e. SL3261(pETMALenv + pIP2) and SL3261(pETMALenv + pIP4)) 
and two Gag-expressing strains (i.e. SL3261(pETMALgag + pIP2) and 
SL3261(pETMALgag + pIP4)) were used. Although only the plasmid 
combination of pETMALgag with pIP4 was stably maintained in the invasion 
assay (Tijhaar et ai., 1997), SL3261(pETMALgag + pIP2) was included in the 
vaccine formulation because of the higher expression levels obtained by this 
strain. The idea was that the combination with pIP2 would present a higher 
amount of antigen early in infection, while the combination with pIP4 would 
result in a lower but more stable expression. Equal amounts of the four different 
strains were used. For convenience this combination of Gag and Env expressing 
strains is in short referred to as SL3261-FIV. As a control the CtxB-expressing 
strain SL3261(pT7ctxB + pIP2) (Tijhaar et ai., 1997), in short referred to as 
SL3261-CtxB, was used. Per immunization each cat received a total of 5xl0Il 
bacteria by the oral route and 109 bacteria by the i.p. route. Preparation and 
administration of the bacteria was performed as described previously (Tijhaar et 
ai., 1997). The iscom-immunized cats received 10 Ilg of each protein by the 
subcutaneous route. 
All cats were challenged intramuscularly with thirty 50% cat infectious 
doses (CID50) of the homologous molecular FlV clone 19k1 (Siebelink et al., 
1992) two weeks after the last immunization. Plasma samples were taken 
immediately before the primary immunization and after 2, 4, 6, 9.5, 10.5, ll, 
13, 15, 17, 17.7, 18.5,20,22,26 and 32 weeks. 
Detection of FIV infection 
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized 
blood and cultured as previously described (Siebelink et ai., 1992). The presence 
of FIV antigen in the culture supernatant was detected using an FIV antigen 
capture ELISA (Siebelink et al., 1990). 
Semi-quantitative PCR of proviral DNA 
A nested PCR end-point titration was performed on chromosomal DNA 
prepared from PBMC taken 16 weeks post challenge (pc). Ten micro litre 
reaction product of the first PCR reaction was used as template in the second 
(nested) PCR. As a negative control chromosomal DNA isolated in parallel from 
uninfected cells was used. The primer combinations used in the first PCR 
reaction were GGCCCTCCACAGGCATATCC (corresponding to nucleotides 
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1014-1033) with GCATTTTATATCCTGGTGAGCC (nucleotides 1670-1692), 
and for the nested PCR reaction GGCAAGAGAAGGACTAGGAGG 
(nucleotides 1106 - 1126) with GCACAGCTCGAGGAGACTTAGC (nucleotides 
1440-1461). Both PCRs were "touch-down"-PCRs starting with two cycles at an 
annealing temperature of 70·C, followed by two cycles at 68, 66, 64, 62 and 
finally 25 cycles at 60·C. PCR samples were analyzed by electrophoresis on an 
1.5% agarose gel containing ethidiumbromide. The end-point was defined as the 
lowest concentration template DNA that resulted in a positive PCR with all 
higher concentrations being positive as well. 
Cell associated virus load: infectious center test 
The cell associated virus load in FIV challenged cats was determined as described 
previously (Siebelink ef al., 1995). In short, serial dilutions of PBMC samples 
from infected cats were co cultivated with ConA and IL-2 stimulated PBMC from 
an uninfected SPF cat. After three weeks the culture supernatants were tested for 
the presence of FIV antigen by ELISA (Siebelink ef al., 1990). The cell-
associated virus load was based on those dilutions that resulted in wells positive 
and negative for FIV antigen, assuming that one infected PBMC gave rise to 
antigen production after three weeks of cocultivatlon. 
ELISA 
The ELISAs to determine specific antibody responses against LPS from 
Salmonella fyphimllrium and against the MBP, were performed as described 
previously (Tijhaar ef al., 1997). 
Antibodies against the Gag proteins p24 and p17 were detected with a 
commercially available test kit, using recombinant p24 and p17 proteins (catalog 
number F1002-ABOI; European Veterinary Laboratory BV, Woerden, The 
Netherlands). 
An ELISA based on the detection of antibodies to the bacterial fusion 
proteins SUI and SU3 (see Fig. 1) was performed as described elsewhere (De 
Ronde ef al., 1994). Plasma samples were used in a 1:100 dilution for this 
ELISA. 
RESULTS 
Construction and characterization of pETMALc and pETMALenv 
The vector pETMALp (Table 2) contains the malE gene under control of a T7 
promoter. When present in bacteria that produce T7 RNA polymerase, large 
amounts of the MBP are expressed from this malE gene (Tijhaar ef al., 1997). 
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Fig. 1 Representalion of different MalE-ellv fusions and their relative expression levels in 
SL3261(pIP4). The top bar represents the ellv gene ofFIV encoding the envelope protein of FlV, 
including the leader (L), surface (SU) and transmembrane (TM) proteins. The hypervariable 
regions are represented as black boxes. The number of pluses are all arbitrary representation of the 
relative expression levels of the different malE-ellv fusions as determined by SOS-PAGE and 
Western blotting. The photo shows a stained gel of bacteriallysates subjected to SOS-PAGE. 
Lanes: l. molecular mass markers (in kOa); 2. SL3261; 3. SL3261(pETMALellv (=construct D) 
+ pIP4). The arrow head indicated the position of the MBP-Env fusion protein. The bacterial 
fusion products SU I and SU3 used in the EllV-ELISA are indicated as black bars. 
The pIP-vectors (Table 2), which contain the T7 RNA polymerase gene under 
control of an invertible promoter, allowed the continuous production of an 
MBP-Gag protein by a bacterial population (Tijhaar et al., 1997). The MBP-Gag 
protein was encoded by an in-frame fusion between the malE gene of pETMALp 
and the gag gene of FlY. Attempts to express parts of the FlY env gene using 
pETMALp were unsuccessful. In an attempt to reduce the toxicity of MBP-
fusion proteins, the region of malE coding for the hydrophobic part of the signal 
sequence was deleted, so that the protein would remain localized within the 
cytoplasm. Expression of MBP by bacteria containing pIP4 (Table 2) in 
combination with the mutated plasmid, designated pETMALc, was at least as 
abundant as that from the unmutated plasmid pETMALp (Fig. 2). However, 
expression of the KpnI-KpnI en v-fragment of the molecular clone FlY 19k1 
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Table 2. Main features of plasmids and bacterial strains used in this study 
Plasmid or strain Main features Reference 
plasmid 
pETMALp malE (MBP), T7 promoter, Amp® Tijhaar et al., 1997 
pETMALc t. signal seq. malE, T7 promoter, Amp® this study 
pETMALgag malE-gag (MBP-Gag), T7 promoter, Amp® Tijhaar et al., 1997 
pETMALenv malE-en v (MBP-Env), T7 promoter, Amp® Tijhaar et al., 1997 
pT7ctxB ctxB (CtxB), T7 promoter, Amp® Tijhaar et al., 1997 
pIP2/pIP4* T7 RNA polymerase gene, invertible Tijhaar et al., 1997 
promoter, Kan® 
strain 
SL326 I Salmonella t),phimurium aroA mutant Hoiseth et al. 1981 
SL3261-CtxB SL3261 (pT7 -CtxB + pIP2) Tijhaar et al., 1997 
SL3261-FIV equal amounts of' 
SL3261 (pETMALgag + pIP2) Tijhaar et al., 1997 
SL3261 (pETMALgag + pIP4) Tijhaar et al., 1997 
SL3261 (pETMALenv + pIP2) this study 
SL3261 (pETMALenv + pIP4) this study 
'Plasmid pIP4 is a lower copy number derivative of pIP2 (previously also designated 
p YZ27bGP), which directs lower expression levels of genes positioned under control of a T7 
promoter than pIP2 (Tijhaar et al., 1997). 
preMBP "--
MBP r 
1 2 3 4 5 
97 
68 
43 
29 
18 
14 
Fig. 2 Expression of MBP from malE with and without a functional signal sequence, using the 
two-plasmid invertible promoter system. Total bacteriallysates grown till late log phase at 37'C 
were subjected to SDS-PAGE followed by staining of the gel. Lanes: l. SL3261(pETMALc + 
pIP4); 2. SL3261(pETMALp + pIP4); 3. SL3261(pETMALp); 4. SL3261; 5. molecular mass 
markers (in kDa). 
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(Siebelink ef al., 1992) in frame with the malE gene of pETMALc (Fig. I: A) 
remained problematic. To determine which parts of the envelope gene were 
predominantly responsible for this lack of expression, different gene truncations 
were made (Fig. I: B, C and D). The malE fusion with the KpnI-BamHI env-
fragment was weIl expressed (Fig. I: B). Introduction of a frameshift by filling 
in the HindIII-site (Fig. I: C) resulted in a translational stop-codon within 7 
codons of this site. No expression could be observed from this truncated malE-
env fusion. The BclI-KpnI fragment (Fig. I: D) that codes for the variable 
regions V-3, V-4 and V-5 in which several neutralizing B cell epitopes are 
localized, was well expressed (Fig. 1). Therefore this plasmid, designated 
pETMALenv, was selected for immunization experiments. 
Before the immunization experiments were started, the plasmid stability of 
SL326 I strains after invasion of cat thymocytes was determined. Plasmid 
pETMALenv proved to be stable in combination with pIP2 as weIl as with pIP4 
(Table 3). 
Plasma antibody responses after immunization 
The day following the first Salmonella immunization (Table I), two out of ten 
cats appeared not to be feeling weIl, as they were much less active than usuaIly. 
Two to three days later these cats seemed to have recovered completely. No 
obvious side effects were observed following the Salmonella booster 
immunizations. AIl the cats developed plasma antibodies against Salmonella 
fyphimllrillm LPS, within two weeks after the first immunization (Fig. 3). 
Considerable differences were observed between individual cats. Two weeks 
after the second immunization titers ranged from 800 to 50,000. The cats 
immunized with the MBP-Env and -Gag expressing SL3261 strains (groups A 
and B) developed antibodies specific for the MBP moiety of the fusion protein 
within two weeks after the first immunization. Two weeks after the second 
immunization the plasma titers were around 10,000 for most of the cats of 
groups A and B. Despite of the strong antibody responses to the MBP-moiety, no 
clear responses were detected against the Env or Gag moieties of the MBP fusion 
proteins. After the third immunization with SL3261-FIV, Gag-specific responses 
were detected in two of the three cats of group A (Fig. 3). After the first 
immunization with iscom-FIV (groups B and C), anti-Gag titers rose faster in 
the group that had previously been immunized with SL3261-FIV (group B), as 
compared to the group that had received SL3261-CtxB (group C) (Fig. 3) 
indicating a priming effect of the Gag-expressing SL3261 strains. The second 
iscom-FIV immunization of groups Band C at week 13, resulted in a 
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Table 3. Plasmid stability after invasion of cat thymocytes 
Strain 
SL3261 (pETMALenv + pIP2) 
SL3261(pETMALenv + plP4) 
Plasmid stability 
93 ±7% 
92±3% 
'c;;;thy;;;~yte~ were infected with th-;' different b';;'terial strains and~~tut~d in the presence-.;r 
gentamycin to kill extracellular bacteria. After two days the percentage intracellular bacteria still 
resistant to both ampicillin and kanamycin was determined. Represented is the mean plasmid 
stability ± SD of three independent experiments. 
considerable increase in the anti-Gag response (Fig. 3). The titers in the plasma 
samples of cats that had not been primed with SL3261-FIV (group C) Wer~ 
similar to those that had (group B). Even after a fourth immunization with 
SL3261-FIV, the Gag-specific antibody titeeremained weak in the cats of group 
A. At the day of challenge only the plasma samples of the cats vaccinated twice 
with iscom-FIV (groups B and C) showed clear reactivity with the bacterial 
derived FIV envelope fusion protein SU3 (Fig. 4: O' weeks post Challenge}. No 
significant antibody response to SU3 was detected after a single iscorn-FIV 
immunization (results not shown). Cats of groups C and D showed an antibody 
response to MBP upon immunization with the respective iscom preparations; 
which contained MBP either as part of the Gag fusion protein (group C) or as a 
contaminant (group D) (Fig. 3). 
Plasma antibody responses after FlV challenge 
Two weeks after the fast immunization all cats were challenged with homologous 
molecularly cloned FIV (FIV 19k1), Gag-specific antibody titers in the plasma 
samples from cats vaccinated with iscom,FIV (groups Band C) rose within- three 
weeks pc. Cats of the control group (group D) and the group vaccinated four 
times with SL3261-FIV (group A) started to develop' Gag-specific antibodies 5· 
weeks pc. 
Within 2.5 weeks pc the antibody responses to bacterial derived' FlY Env 
fusion proteins, started to increase in the cats immunized with iscomcFIV 
(groups Band C)' (Fig. 4). At this time; both cats immunized with SL32M-
CtxB/iscom·FIV (group C) and one out of three cats immunized with· SL3261'-
FIV/iscom"FIV (group B), had also- developed' responses to SUI'. At 5 weeks pc 
the plasma samples of all the cats of groups Band C displayed plasma' antibodies 
specific for SUI and SU3. Both cats of the negative control group (D), developed 
I29' 
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antibodies specific for SU3 between 2 and 7 weeks pc and one cat also developed 
antibodies to SUI. In contrast, the cats only immunized with SL3261-FIY (group 
A) did not develop detectable antibody responses to SUI during the whole 16 
week period of the experiment. Only one cat (no. 1) of this group developed 
antibodies to SU3, but later than the control cats (group D). 
Development of viraemia after FIV challenge 
At 19 days pc FlY infected PBMC were detected in both cats of the control 
group (group D), in two out of three cats of group B and in one of the two cats 
of group C (Fig. 5). At this time no infected PBMC were detected in the cats 
immunized four times with SL3261-FlY (group A). At 25 days pc, FlY infected 
PBMC were detected in all cats, except for one cat of group A. At 110 days pc, 
FlY infected PBMC were demonstrated in all cats of groups B, C and D, but in 
only one cat of group A. The average cell-associated virus loads at this time 
point were 8, 217, 38 and 31 infected cells per 106 PBMC for groups A, B, C 
and D, respectively. PCR on chromosomal DNA isolated from PBMC taken at 
this time point demonstrated the presence of proviral FlY DNA in all cats (Fig. 
6). The overall lowest levels of proviral DNA were observed in the cats 
immunized four times with SL3261-FIY (group A). 
DISCUSSION 
In the present study we have shown that cats immunized four times with FIY-
Gag and -Env expressing Sallllonella fyphimllrilllll strains, developed lower 
mean cell associated viral loads upon homologous FlY challenge than the other 
groups of cats studied. Immunization with FlY -iscom, either alone or in 
combination with the recombinant Salmonella fyphimllrilllll, did not result in a 
decrease of cell associated FlY load upon challenge. Due to the relatively small 
group sizes, the differences observed between the four groups can only provide 
an indication of a protective effect of vaccination in the first group of cats. 
The Gag and Env proteins were expressed as fusions with MBP in the 
attenuated Salmonella fyphilllllrilllll aroA strain SL3261. The expression levels 
of the different env gene truncations indicated that a region located between the 
Bam HI- and Bell-site of env (Fig. 1) had a prohibitive effect on the expression 
Fig. 3 Development of antibody responses in cats after vaccination. Cats within the respective 
groups are represented by the same symbols in all graphs (filled triangles: cat no. I; open square: 
cat no. 2; filled circle: cat no. 3). The small arrows indicate the days of immunization and the large 
arrow indicates the day of challenge. 
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by SL3261. It is likely that the region coding for the highly hydrophobic 
putative leader of the SU protein is mainly responsible for this effect. Antibodies 
to MBP, Gag and Env were induced more efficiently when these proteins were 
incorporated into iscom than when presented by SL3261 (Fig. 3 and Fig. 4). In 
fact, three immunizations with SL3261-FIV were required to induce detectable 
titers of Gag-specific antibodies and even four immunizations failed to induce 
Env-specific antibodies. However, the MBP fusion proteins expressed by the 
SL3261 strains were presented to the immune system of these animals, since 
MBP-specific antibodies were detected within two weeks after the first 
immunization in five out of six cats immunized with SL326l-FlV (groups A and 
B; Fig. 3). Although after the second immunization still no Gag-specific 
antibodies could be detected, the immune system had clearly been primed for this 
protein by SL326l-FIV, as specific antibodies developed faster after the first 
iscom-FIV immunization in group B (SL326l-FIV/iscom-FlV) than in group C 
(SL326l-CtxB/iscom-FIV). Priming with SL326l-FIV apparently had no 
beneficial effect on the level of the MBP-, Gag- or Env (SUl/SU3)-specific 
plasma antibody responses (compare groups Band C; Fig. 3 and Fig. 4). 
None of the evaluated immunization strategies protected the cats from FIV 
infection upon homologous challenge, but the reduced mean cell-associated virus 
loads (Fig. 5), the reduced mean proviral DNA loads (Fig. 6) and the much 
weaker induction of antibodies against SUl/SU3 after challenge in the cats 
immunized four times with SL326l-FlV, as compared to cats of the other groups 
(Fig. 4), suggested that this immunization regimen, did have a protective effect. 
It is unlikely that the observed reduced FIV loads were the result of induced 
antibody responses, as no significant Env-specific antibodies and only weak Gag-
specific antibody titers were present at the time of challenge. Furthermore, no 
reduced virus load was observed in the iscom-FIV immunized cats, which had 
much higher Gag- and Env-specific plasma antibody titers. This is not surprising 
in the view of our recent observations, which showed that enhancement of FIV 
infection may occur after immunization with Env-iscom (Siebelink ef ai., 1995), 
which showed that the enhancement of FIV infection may occur after 
immunization with Env-iscom. It seems therefore more likely that, if indeed the 
cats of group A were partially protected, a cellular rather than a humoral 
Fig. 4 Development of antibody responses in cats after challenge. Represented are the OD450 
values obtained with plasma samples diluted I: 100. The same cats within a group are represented 
by the same symbols in all graphs (filled triangles: cat no. I; open square: cat no. 2; filled circle: 
cat no. 3). 
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immune response was at the basis of this protection. In our previous study cats 
immunized with a Salmonella strain only expressing the FIV gag gene had a 
comparable virus load after challenge as control cats (Tijhaar ef al .• 1997). The 
reduced virus load in cats immunized with Salmonella strains expressing the gag 
and env genes observed in this study. indicates that the en v-expressing 
Salmonella strains are mainly responsible for the observed reduced virus load. 
Interestingly. Flynn ef al. (1996) found that vaccine induced protection against 
FIV infection correlated with Env- but not Gag-specific CTL responses. 
Alternatively. the reduced virus load observed in this study is not (only) due to 
the en v-expressing Salmonella strains. but might be due to the increased number 
of immunizations. the different route of administration (oral QL i.p. in the 
previous study vs oral and i.p. in this study) or a combination of all. 
In conclusion. this study provided an indication of a protective effect of 
immunization with the Salmonella fyphimllrilllll recombinants expressing the 
FlV -Gag and -Env protein. However. further studies are required to evaluate the 
full potential of this approach for lentivirus vaccine development. 
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Cals were immunized three Ilmcs \\ilh different recombinant feline immunodeficiency lirus (FIV) candidate 
mcdoes. Recombinant "acdnla ,irus (rVV)·expressed em'elope glycoprotein \\ith (yGR657) or \\ithou( 
(,-GR6S7xlS) (he deal-age site and an FIV em"elope bacterial fusion Ilroteln (p·Galaclosldase-Em·) \\ere 
incorporated into immune-stimulating complexes or adjm"anted \\ith Qui! A. Allhough all immunized cats 
del'eloped antibodies against the ennlope protein, only the cats "acdnated "ilh the rVV·expressed em'elope 
glycoproteins del"eloped antibodies which neutralized FIV Infecllon of Crandell feline kidney cells. These 
antibodies failed to neutralize infection of IhymoC)'tes \lith a molecularly cloned homologous FIV. After the 
third immunization the cats were challenged "ith homologous Fl\'. Two weeks arler challenge the cell· 
associated ,iralload prond to be significantly higher In the cats immunized wilh ,-GR6S7 and ,-GR6S7xIS than 
in the other cats. The cats immunized nllh yGR6S7 and \'GR657xlS also de,"eloped antibodies against Ihe Gag 
proteins more rapidly Ihan the cats immunized \\ilh p·Galaclosldase-Em' or the control cals. This suggested 
that immunization nith rVV-expressed glycoprotein ofFIV results In enhanced Infectility ofFIV. It was shoml 
that the obsernd enhancement could be transferred to nahe cats "ith plasma collected atlhe day ofchallenge. 
Feline immunodeficiency virus (FlY) is a T-Iymphotropic 
lentivirus that causes feline AIDS, which is similar to AIDS in 
humans (I, 3, 9, 12, 20, 29, 39, 41, 45, 51). The similarities 
between FlY and human immunodeficiency virus (HIV) on the 
one hand and between the pathogeneses of the syndromes they 
cause on the other hand have led to the use of FIV infection of 
cats as an animal model to evaluate the potential of pre\'entive 
and therapeutic measures for HIV infection in humans. Since 
FlV infection is widespread among cats all O\'er the world, the 
development of preventive and therapeutic measures for feline 
AIDS is also of major veterinary importance. 
Different vaccination strategies for lentivirus infections have 
been evaluated wilh varying degrees of success. Most attempts 
to develop candidate vaccines against lentivirus infections were 
without success (for a review, see reference 22), Nevertheless, 
in some experiments chimpanzees were successfully vaccinated 
against HIV type I (HIV-l) (4) and macaques were success-
fully vaccinated against HIV-2 or simian immunodeficiency 
virus (SIV) infections with candidate whole inactivated virus, 
live attenuated virus, recombinant virus, subunit virus vaccines, 
or combinations of these candidate vaccines (6, 7, 17,21,28, 
30,32,38). The mechanisms by which protcctive immunity was 
established in these systems are not well understood at present, 
although there are indications for a major role of both virus-
neutralizing (VN) antibodies and cell-mediated immunity (10, 
24,31). However, contradictory data have also been obtaincd 
in some of these studies (2, 5, 16, 18,36). In the macaque SIV 
model it was shown that at least part of the protective immu-
nity induced could be attributed nottovirus·specifie but rather 
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to cell·specific antibodies (23, 46). In the SIV system it was 
recently shown that vaccine-induced protection against infec-
lion with SIV-infected cells correlated with the presence of a 
certain major histocompatibility complex class I genotype of 
the monkeys, indicating the invol\'ement of major histocom-
patibility complex class I-restricted cytotoxie T-Iymphocyte re-
sponses (11). 
Se\'cral approaches to develop a preventive vaccine against 
FIV infection have also pro\'en to be unsuccessful (16, 48). 
However, Yamamoto et at reported the induction of protec-
tive immunity in cats against homologous and to a lesser extent 
also to heterologous FlY Challenge, by vaccination with inae-
tivated whole virus or FlV-infected cells (49,50). This protec-
tive effect could be transferred to naive cats with plasma from 
vaccinated animals, indicating that antibodies may be at the 
basis of this protective immunity (13). It was shown that serum 
antibodies against FIV envelope glycoproteins, with different 
VN domains, correlated more with protcctive immunity than 
did antibodies to other viral proteins. 
FIV vaccines based on recombinant envelope proteins 
would have clear advantages over inactivated or attenuated 
virus vaccines. However, so far vaccination strategies using 
FlV purified envelope glycoproteins or fractions of these pro-
teins as immunogens have failed (16, 26). Here we rcport the 
results of a series of vaccination experiments in cats \\ith dif-
ferent envelope proteins of FlV, expressed by recombinant 
vaccinia viruses (rVV) or as a bacterial fusion protein and 
presented in the context of different adjuvant systems. The 
most striking finding of these studies is that vaccines containing 
intact envelope glycoprotein induced enhancement of infectiv-
ity rather than protective immunity against homologous FlV 
infection. The observed enhancement could be transferred to 
naive cats with the plasma of the vaccinated cats. 
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l\lATERlALS At,,{D METHODS 
Cell, and cballenge rlTlli. Pcdphera! blood mononuclear cells (PBMe) and 
th)m0C}1es ,wre deriwd from an S.week·old specific.pathogen.free (SPF) cat 
(42). These cell, ",-ere stimulated Ilith concanaH,lin A (5 I'-g/ml) in culture 
medium (RPMI 16--10 [GiBeO, Gaithersburg. Md.j. penidllin [100 IUlml]. strep' 
tomycin [100 I'-s/mlj, L·glutamine [2 mM]. 2·mercaptoethanol [2 x 10-5 Mj. 
interkukin·2 [100 IUfml]) and 1O~ fetal calf serum. After 3 days the cells "ere 
",-;u.hed and cultured further in culture medium. An FlV,su5Ceptlbk done of 
Crandell feline kidnq (CrFK) cdls, named CrfK lOW, was kindly prOlided by 
N. Pedersen (51), The FlV AMI9 strain \las i,olated from PB!\IC of a cat 
naturally infected \lith FIV (42). Concanavalin A· and inter!eukin·2·stimulated 
cell, were infected \lith FIV AMI9. When FlVantigen "as detected in culture 
supematant by enzyme·linked immunolorbent a~say (ELISA) (40), it" as filtered 
through a nO-nm.pore·s;u filter, aliquoted. and stored at -135'C 1his FIV 
stock "as titrated in \'r.-o. Groups of four SPF cats were inoculated intramu.<cU· 
larly "ith 05 ml of 1:100, 1:400, 1:1,600, 1:6AOO, or 1:25.600 dilution> of the FIV 
Stock. All cals recen-ing 1:100 and 1:400 dilution. became infected by 4 to 8 
"'<eks postinkction as sho"n bperocon\'ersion and lirus isolatio[\. Three of the 
four cats inoculated "ith 1:\.600--diluled FlV stock and one of the four cats 
inoculaled "'ith 1:6,400--diluted 510Ck became \irus isolation positil'e and ~ero· 
pruitile. One 50% cat infectious do,e (cro_<D) "as Iberefore eSlimated to b-e 05 
ml of a 1:3,200 dilution of the FlV stock. 
FlV AM6\: was isolated from raMCof a cat naturally infected "ith FlV and 
ad!lpted to replicate in CfFK 1010 cells as pre,ioullr de~ribed (43). fill' gene 
sequence homology of FlV AM6\: and FIVI9ki is 9~.8~. CrFK lOW cells "ere 
infected "ith FlV A-,\!6c. and after 6 days the culture medium lIas refreshed. 
After another 4 days of culture. "hen FlV antigen "as detected in the culture 
wl"'matant. it "a, filtered through a 2l0-nm·pon:·size filter and stored in 
aliquots at -l3Ye. This f1V stock "a, titrated in CrFK 1010 cell, and the 
highest d~ution (20 TClO..,,) "hieh con>hlently rewlted in dete(C!able antigen 
production Ililhin 8 day,> was med in tbe VN asHy {see bela","}. 
P~paratlon of (";lndldate fl\' ucclnes. The en' elope glrcoproteins of FIV 
A!\1J9 were e"qlrel.Sed b)' an rVV in BfIK cells either in their nalh-e form 
('GR657) or after delelion of the clealage sile behleen the surface (SU) and the 
tran,membrane (nl) proteins (IGR657d5) to facilitate incorporalion into im· 
mune·stimulating comple~e, (iscoms) (33). After lectin purification Ihe,.. pro· 
teim "ere im:orporated into iswms, \\hieh resulted in mo i>l:om prepJrations-----
\GR657 and \GR657.~15 ixoms-as pre,iou,ly de~rilxd (33). An 1.870-bp 
fragment of the enl.:lope gene lIas e"is~d from pBlues.::ript. containing the 
"ho!e em'dope gene, by using the reslriction ~Ill)mes BamBI and BgnJ (nucle· 
otide positions 350 and 2220, rc'lpectil\'ly) and sulxloned into BamHI.Ji!':e,ted 
pE.X I'eclor (Stratagene. La Jolia, Calif.). This\'ector allo .... ~ inducible e"'Pression 
of proteins as ~.gabctos.idase (p·Gal) fu,ion protdn. This protein "as partially 
purified as inclusion bodies, soIubililed, and mlwd ,,-j!h Quil A a, an adjunnt. 
SIV en\'do~ gl)'wprotein L«"Oms were prepared by E Hulskotte using a 
method similar 10 that used for the deal·age site.Jeleted BV enl'elope gl)co· 
protein L«Oms (19). 
Yacdnati<)fl and challfflgt InfKllon of (";lts. SlX groups of <;~"( SrF cats each 
"'ere vaccinated three time, su!xutaneou,ly acwrding to the folloOliog schedule: 
group I, \GR657 isooms; group 2, ,GR657:d5 L«"Oml; group 3, \GR657xI5 plus 
Qu~ A: group 4, ~·Ga!-FlV Em' plus Qui! A; group 5, SIV En .. iswm<;; and 
group 6, phosphate·buffered saline. The cats were vaccinated "ill! 10 [J.g of 
protein at "eek5 0, 4, and 10. Two "eek5latcr the cats were Challenged by the 
intramuscular route ",ilh 20 ClDw of F1V AMI9. pa~lc and plMma samples 
"ere collected ewry 2 weeks poslchal1enge (p.c.) during an B·week p;'r1od. 
Stcologlcal a'<;3fs. Antibodies against the Gag protdM p24 and 1'17 "ere 
detected "hI! a commercially a,-ailable test kil, using recombimnt p24 and pl7 
proteins (cata!og numb-er Fl002·AaOI; Europ;'an Veterinal)'laborat0I)' B.V., 
Wo;:rden, The Netherlands). Antibody titers were upre»ed as the oplka! den· 
sity at 450 nm (OO,w) value of the serum mUltiplied by Ihe dilution dilided by 
three times the OOw, value of the negatil·e control serum. 
Antibodies against the enwlope protein "ere detected by ELISA wing syn· 
thetic peptides and bade rial fusion proteins. representing different regions of the 
em\'lope protein asshmm in Fig. I. ~ S)llthetkpeptides "ere purcha>ed from 
Eurol"'an Vderinll)' laboratol)' B.V. (catalog numbers: SU peptide, EVS.{OO.. 
PE-003: TM peptide, EVS.{OO..PE·OO4). The first S)llthetk I"'ptide contains the 
immunodominant VN epilope "ithin variable region 3 spanning amino acid 
residues 3% to 412 of the surface protein of the Petaluma strain (SU peptide) 
(25). The se(ond peptide contains a B--cdl cpilope between amino add positions 
695 and 706 of the transmembrane protein o(tbe ~me FIV strain (Thl peptide). 
Antibody liters were calculated as de>l:rilxd for the Gag ELISA. 
An ELISA based on the det~ction of antibodies to a ,>eries of bacterial fusion 
protdn~ as shO\\n in Fig. I was performed as de>l:nbed else"here (8). 
\'N a5S3)s. VN serum antibodies "-ere determined in 1110 different VN assa}"S. 
The feline l)mphO\.')1e VN 35My was based on inhibition of infection of th)mo--
(:)Ie. "ith molecularly cloned FlV 19k1 as pre\iousl)' described (+I). The CrFK 
VN as..<ay wa, bMed on the inhibition of infection of CrFK 1010 cells "'llh FlV 
AM6c, "hichis adapted to replicate in the>e cells. For this assay CrFK IDIO cells 
(3.5 x IOl) were seeded Into a 96''\\"ell plale in 100 1'-1 of Oul~co modified 
F..agle medium supp!emenled "ith 5% fetal calf serum. The nnt day the cells 
"ere washed and incubated for 1 h at 37'C",ith Po1)brene (8[.Lg/ml) in Dulb-ecw 
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FIG. L Surface (SUI to SU6) and transmembrane (nil to nB) bacterial 
fusion products and SU and TM peptide, used in the EliSA to detect antibodie, 
against the enlelope protdn. The top bar repre~ents the emelope protein of 
FlV, including the leader (L), surface {SUI. and lJammembrane (nf) protein,. 
The black oo_\es represcot hyperl'Jriable region, in the emelope protein. Th~ 
different bacterial fu<;ion products and the peptide, are indicated a, bar5, 
modified Eagle medium supplemented "ilh 5<;l fetal calf serum. A rtll\lUre of 
equal volumes of the diluted (see abole) \ifU$ stock of FfV AM6c and mofold 
se.ia! dilutions ofhea\-inactr-ated serum "as incubated for I h at 3YC. Then the 
CrFK cell, "'ere "a,hed and incubated "ith the lirus·serum mh1ure at 37'C. 
After 2--1 h the CrFK cells \\ere "'Mbed mice and propagated in Dulbecco 
modified Eagle medium supplemented "ith 2 R feta!calf:s.erum. After 8 da}"$ the 
culture ,upernalant was tested for the presence of FIV anligen by ELISA ( .. 0). 
The neutralizing antibody titerwas expre>sed as the highest dilution of the serum 
still prelenling FIV antigen produclion in the culture supunatanl. 
Cell·a$!odat{d ,ims load: Inffftlou5 center ttst. Serially diluted PB!\IC S3m' 
ples (I x 10'.3 x 10\ and I x 10' cells) "ere prepared from cal> before and 
after challenge as prelioUlly de>l:ribed (42). These ceHs "ere c,-"ultilated "ith 
lOS concana,'alin A· and inter1eul.in·2·stimulated PB!\IC from an SPF cat in 
eight duplicate Ilells. After 3 "eeks the culture supernatant, "ue te,ted for 1he 
prelen,e of FlV antigen by ELISA. The number of infected cdll in the PB!\IC 
in \il"o was calculated from the in ,flro culture br assuming that one fnfc'ctedcell 
gale rise 10 antigen production after coculti'alion "i1h concanal·a!in A· and 
interkukin·2·stimulated rB!\IC from an SPF cal, "hen one or more culture, 
tested in eight duplicate well, \\.:re negati,\' for FIV antigen production. 
Pla5ma tramfu. A plasma pool lIas prep3red by mi.>Jng equal \'oJumes of the 
plMma ~mples derived from all the lacdnated cal. from groups 1 Jnd 2 at the 
day of challenge (plasma pool A). A se,ond pool (plalma pool a) "as prepared 
similarly b)" mi>Jng plMffia sa.mpks from all the cats of group 6 at the dJr of 
challenge. T",o groups of four SPF (al.", 10 weel.5 old. \\eighing ~h\'Cen SOD and 
1,150 g "ere used in the transfer e'P"riment. Cats of g.oup A and group B "ere 
injecled intral'enOUlly IIi1h 7 ml of plMma pool A and plasma pool B. relpec· 
til-~!y. Si~ hours later the cat, "'ere challenged by the intramuscular route "ith 20 
ClDw of FIV AMI9 as described abow. PBMC and plMma samples of the cats 
"ere,olleCied al wecklyinteflals and te,ted for,iremia bylirus i.oiation and for 
the del·e1opment of p!Mma antibodie, agaimt the Gag protein. 
RESULTS 
Dcwlopmcnt or FIV-specific plasma antibodies upon Yacd· 
nation, All plasma samples collected at the day of challenge 
were tested in the SU and TM peptide ELISA (Table I, week 
p.c. 0). AU the cats vaccinated with the vGR657 and 
\'GR657x15 iscoms (groups 1 and 2) had developed plasma 
antibody titers to these peptides, ranging from 200 to 25,000, 
whereas all the cats vaccinated with Quit A-adjuvanted 
vGR657xI5 (group 3) had developed antibody titers to at least 
one of the two pep tides ranging from 50 to 3,000. Fh'e of six 
cals vaccinated ,.nth the Qui! A·adjuvanted bacterial FIV en· 
velope fusion protein (group 4) had also developed serum 
antibody titers to the TM peptide, ranging from 50 to 3.000, 
whereas only one animal had developed a titerof3oo to the SU 
peptide. One cat of the two control groups, groups 5 and 6, 
showed an apparently nonspecific plasma antibody titer to the 
SU and TM peptides, which already existed before the start of 
the immunization procedure (not shown). Subsequently the 
TABLE 1. Antibody response against SU and TIt peptides in vaccinated Cilts at different times p.c." 
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~ SU p.;ptide ELISA le,ulll: no symbol, tiler < 200; ., liter berneen 200 and 1,(00; .. , titer bern·cen 1,000 and 5,ClOO; 
.. , titer berneen 5,000 and 25,000; __ ,tiler> 25,000. TIt peptide ELISA leru!ts: no S}mool, liler < 50; ., liter 
between 50 and 300; _, titer beNeen 300 and 3,000; .. , tiler berneen 3,000 and 10,000; __ , liler > 10,000. 
same plasma samples were tested in ELISA for antibody titers 
against the respective bacterial FlV envelope SU and Tl'\.·( 
fusion proteins (Table 2). Vaccination with the vOR657- and 
vGR657x15 iscoms (groups 1 and 2) resulted in high plasma 
antibody responses to all the SU and Th·( regions tested with 
the exception of the SUS and TMI regions, against which 
lower or no antibody levels were detected. Antibody levels 
induced with the native glycoprotein iscoms (group 1) and the 
cleavage site-deleted envelope iscoms (group 2) are compara-
ble_ The oyerall OD450 values induced with the cleavage site-
deleted FlV envelope glycoprotein adjuvanted with Quit A 
(group 3) were lower than those found in the cats of groups 1 
and 2. Vaccination with the j3-Gal-FiV envelope fusion pro-
tein adjuvanted with Qui! A failed to induce antibodies against 
the SUI. SU2, SU4, and SUS regions_ No significant levels of 
antibody to these fusion proteins were found in the cats of the 
two control groups (groups 5 and 6). 
All the plasma samples collected at the day of challenge 
were also tested in the two VN antibody assays. None of the 
samples exhibited VN activity in the feline lymphocyte VN 
assay (not sho\\'Jl). However, VN antibodies could be demon-
strated in cats of groups 1,2, and 3 in the CrFK VN assay (Fig. 
2). The VN titers in cats vaccinated with vOR657 iscoms 
(group 1) ranged from 160 to 640, with a mean titer of 506. 
Those of vOR657x15 iscom-vaccinated cats (group 2) ranged 
from 40 to 640 \\ith a mean of 206, which is not significantly 
different from the values found for group 1. VN plasma anti-
body liters of cats vaccinated \\ith the Qui! A-adjuvanted 
vGR657x15 protein varied from 10 to 40, with a mean titer of 
28, a value which is significantly lower than Ihat found for 
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TABLE 2. Lewis of antibody against envelope fragments in vaccinated cats at the day 
of cha1!engea 
Em-elope regions 
group ~, SO< SU2 SUJ SU, SUS SUO TMI TM2 TM3. 
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FlO. 2. Plasma VN antibody titers of the indi;idua\ Cats of the st.; diffuent 
vaoxination groups as measured in the CrFK VN M..<.3.y at the day of challenge. 
The titers [n the indhidual cats are indicated with different S)mbols. The meM 
liter per group [s indicated by a bar. 
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groups 1 and 2 (Student t test; P < 0.05). In cats vaccinated 
with the ~-Gal-FIY envelope fusion protein (group 4) and the 
cats of the control groups 5 and 6, no VN antibody response 
could be demonstrated at the day of challenge. 
As expected, none of the cats had developed plasma anti-
bodies to the FlV Gag protein at the day of challenge (Fig. 3). 
Kinetics of FIY-speclfic plasma antibodies after flY cbal-
lenge. Plasma antibody titers against the SU and TM peptides 
of most of the cats immunized with the recombinant FIV 
envelope proteins (groups Ito 4) increased 3· to lO-fold within 
4 weeks after challenge infection. Within 8 weeks all the cats, 
induding the control animals in groups 5 and 6, had developed 
anti-SU and anti-TM peptide plasma antibodies (Table 1). At 
8 weeks p.c. the SU peptide-specific antibody titers in the cats 
vaccinated with rVY-expressed FlV envelope glycoprotein 
were significantly higher than those of the nonvaccinated cats 
(Table 1; P < 0.05). 
~ 30 
f 
~ 20 
* 
10 
~o .. ,.,.l:s(d'Ia,~..-.;-o) 
= 2 ..... <spc 
_ ."w>.spc 
=6~pc 
= S",~lsPC 
o~I~~_~,~ 
2 3 4 5 6 
group number 
FIG, J. Kinetics of the plasma antibody titer de'-e!opmenl against the Gag 
protein, in cats from the different vaccination groups. Mean anti-Gag tilers at 
different limes after challenge are presented. 
Plasma antibodies to the FIV Gag protein could be detected 
4 weeks after challenge in all the cats vaccinated with rVV-
expressed FlY envelope glycoproteins (groups 1, 2, and 3) 
(Fig. 3). In the cats vaccinated with the f!-Gal-FIV envelope 
fusion protein (group 4) and in the cats of the two control 
groups, groups 5 and 6, it took about 2 weeks longer before 
FlV Gag-specific antibodies were detected. Not only was the 
induction of FlV Gag-specific antibodies in cats of groups 1 to 
3 faster, but also the 8·week p.c. plasma titers tended to be 
higher in these animals (Fig. 3). 
Cell·assoclated ,irus load. 1\\'0 weeks after infection FIV-
infected PBMe were demonstrated in all the cats of groups I 
and 2 and in four of six eats of group 3 (Fig. 4). The numbers 
of FIV-infected PUMC varied from 50 to 210, 30 to 1,000, and 
o to 106 per 10" PUMC, respectively. In the other three groups 
no infected PB!\'fCwere demonstrated at this time. Two weeks 
later. FlY-infected PBMC could be demonstrated in all the 
cats of all groups. Although a lower average FIV load was 
observed in cats of group 4 compared with that in the other 
groups, the differences observed between the groups proved 
not to be significant. 
Plasma transrer experlmenl. Pools of plasma collected at 
the day of challenge from the cats of groups 1 and 2 (pool A) 
Vlralload at 2 wks pc 
~ 10001 0 
n. 
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• \' • • 
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B 
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6 
FlG, 5. Kinetic; of numbers of FIV-infected celfi per [(1~ PB),!C in indr.idual 
cat, (indicat~d by different bu,) transferred \lith p!a.\ma pool A (groups 1 and 
2) or phsma pool B (group 6), mea.\ured owr 61leeks p.c. 
and from group 6 (pool B) were prepared, and VN titers were 
determined. The titers, measured in the CrFK VN assay, were 
320 and <10. respectively. Two groups of four SPF kittens 
were inoculated intravenously with 7 ml of plasma pool A or 
plasma pool B. No plasma VN antibodies could be detected 6 
h after the transfer. FIV could be demonstrated in PllMC of 
one of four cats of group A (20 infected cells per 10" PB;\-lC) 
but not in PBi\lC of cats of group B 2 weeks after challenge 
with 20 CrD5()s of FIV AMl9 (Fig. 5). Three weeks after 
challenge three of four catS of group A and two of four cats of 
group B exhibited cell-associated viremia, with significantly 
higher numbers of FIV-infected cells in the cats of group A (P 
< 0.05). The mean numbers of infected PBMC in the cats from 
groups A and B at 3 weeks p.c. were 115 and 6 per 106 PB!\IC. 
respectively (Fig. 5). At 4 weeks p.c. the mean numbers of 
FlV-infected cells were III and 16 per lOfj PBMC, respec-
tively. Five and six weeks after challenge FlV could be reiso-
lated from PBMe from all cats of both groups with no clear 
differences in cell-associated virus load. 
Four weeks after challenge, plasma antibodies to the Gag 
Viral road al4 wks pc 
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FIG. 4. Numbers' of F1V-infected celli per 10" PB~IC in th~ indi-.idual tats (indicated b)' different S)mools) of the different vac-cination g/Oups at 2 and 4 Ile~ks 
p.c. The me.an numbers of infected PB~lC per group .are indicated by a bar. 
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FIG. 6. Kinetic;; of plasma antibOOy tiler dewlopmen! agairullhe Gag protein in indr.idual cats (indicated by different bars) transferred "ilh plasma of pool A 
(groups I and 2) or plasma of pool B (group 6). 
protein could be detected in three of four cats of group A (with 
ELISA liters ranging from 170 to 800) and in none of the cats 
of group B (Fig. 6). At 5 weeks p.c. anti·FIV Gag plasma 
antibodies were demonstrated in all cats of group A (titers 
from 180 to 2,6(0) and in only two of four cats from group B 
(Iilers from 70 to 100). In the plasma samples collected from 
all the cats of both groups at 6 and 8 weeks p.c., antibodies 
against the Gag protein were demonstrated. The titers were 
significantly higher (P < 0.05) in the cats of group A than those 
in the cats of group B from 4 weeks p.c. onward. 
DISCUSSION 
The present paper describes the evaluation of the potential 
of different candidate FIV vaccines in a vaccination challenge 
experiment in SPF cats. The most striking finding was that 
immunization with rVV-expressed FlV glycoproteins, resulting 
in VN plasma antibodies, led to enhanced FlV infection upon 
challenge in these cats (groups 1, 2, and 3). This was demon-
strated by the more rapid development of PBMC-associated 
viremia and Gag·specific plasma antibodies. The enhancement 
effect could be transferred to naive cats "ith plasma collected 
from cats immunized \\ith these candidate vaccines. In con-
trast, cats immunized with an FIV envelope bacterial fusion 
protein (group 4) did not develop VN plasma antibodies and 
developed PBMC-associated viremia and Gag-specific pla~ma 
antibodies with the same kinetics as the Iwo control groups. 
Comparison of the antibody levels induced in the first three 
groups of cats at the day of challenge indicated that the im-
munogenicity of vGR657 and vGR657x15 incorporated into 
iscoms was higher than that ofvGR657xl5 presented with Quil 
A. Both VN plasma antibodies and plasma antibodies to the 
different SU regions proved to be higher in the first two groups 
(Fig. 2; Table 2). Plasma antibody leyels against most of the SU 
regions were lower or absent in group 4 at the day of challenge 
(Table 2). It is not clear why the presence of VN plasma 
antibodies at the day of challenge correlated not with protec-
tive immunity but rather with enhanced susceptibility to FIV 
infection, It should be noted, however, that the VN activity was 
demonstrable only in the CrFK VN assay and not in the feline 
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lymphocyte assay. The latter assay should probably be consid-
ered more relevant in terms of protective immunity a2ainst in 
vivo FlV infection since, in contrast to feline kidney cells, 
feline lymphocytes are natural targets for FlV infection. In the 
transfer experiment it was shown that the enhancement phe-
nomenon could be transferred to naive cats with the plasma of 
cats of groups 1 and 2. Although not formally proven, this 
indicated that the enhancement was mediated by FlV enve-
lope-specific antibodies. The mechanism of enhancement 
pro\'ed to be operational at relatively high dilutions: after 
plasma transfer, no VN antibody activity could be demon-
strated in the plasma of the kittens which subsequently showed 
enhanced FlV infectivity. It has also been shown for HIV-l 
that antibody-dependent enhancement (ADE) could still be 
demonstrated at high dilutions (up to 1:65,OOO), whereas VN 
antibody activity can rarely be demonstrated at dilutions higher 
than 1:1,000 (35). As no reliable systems are available at 
present to quantify or even detect FlV-enhancing antibodies in 
vitro, it should be realized that all FlV-neutralizing antibodies 
found, per definition, should be considered to be the net result 
of neutralization and enhancement of FlV infectivity mea-
sured in vitro. 
To date different mechanisms of ADE have been described 
for lentivirus infections. Complement- and Fe receptor-medi-
ated tIDEs have been shown to playa role in HIV-l. HlV-2. 
and SIV infections (14. 15,27,34,47), Recently, another mech-
anism of t\DE was described, in which antibodies neutralized 
or enhanced HIV-1, dependent on the phenotype of the virus 
involved (37). From our data it cannot be concluded which 
mechanism was involved in the obsen'ed enhancement of FIV 
infectivity. Indications for enhanced infectivity after FlV vac-
cination have been obsen'ed before (16). In the experiments of 
Yamamoto et al. (50) the presence of VN antibodies, demon-
strated in an FeTl cell (feline lymphoid cell line) VN assay. 
correlated with protective immunity rather than with enhance-
ment of infectivity. This immunity could be transferred to naive 
animals "ith plasma of immunized animals (13). The main 
difference between their vaccination approach ,lOd ours is that 
in our experiments recombinant envelope proteins were used 
whereas Yamamoto et al. used inactivated whole virus or virus-
infected cells as immunogens. Since transfcr experiments 
showed that probably plasma antibodies are involved in the 
observed mechanisms of enhancement and protection in both 
series of experiments, it may be speculated that the differences 
in configuration in which the FIV envelope glycoproteins were 
presented in both vaccines led to VN antibodies with different 
affinities. This may have had direct consequences for their in 
vivo effects. 
Furthermore, the cell substrates used for the production of 
challenge viruses may have contributed to the observed differ-
ences in outcome of the vaccination experiments. The chal-
lenge virus used in our experiments was propagated in primary 
feline lymphocytes, whereas the challenge viruses in the exper-
iments of Yamamoto et a!. were propagated in a feline T·cell 
line (50). Like in the HIY-1 system, T-cell line-adapted FlY 
may be neutralized more efficiently than virus isolates from 
primary lymphocyte cultures, which may result in neutraliza· 
tion of the virus in the presence of enhancing antibodies. Fur-
thennore, it may be speculated that, as was recently demon-
strated for HIV-l isolates from one individual (37), T-cel! 
line·adapted FlY is less susceptible to ADE. 
Taken together, it should be stressed that the mechanisms 
leading to the observed phenomenon of FlV enhancement 
upon vaccination and passive transfer are not fully understood 
at present. For the development of an effective FlY vaccine, 
the elucidation. of the underlying mechanisms may be crucial. 
This may also lead to a more rational strategy for the devel-
opment of HIY-1 vaccines. 
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CHAPTER 8 
Summarizing discussion 

Despite numerous efforts a safe and effective vaccine for the prevention of 
HIV -1 infection has not yet been developed. A number of lentivirus 
characteristics hinder the development of effective vaccines against these 
viruses. Their extreme variability, their persistence as provirus, which remains 
hidden for the immune system, and their initial replication at the mucosal sites 
are some of the major problems that an effective vaccine has to deal with. A 
vaccine that would induce an efficient local immune response would abrogate 
or limit viral replication at an early stage, thereby facilitating the task for the 
systemic immune system. Virus particles escaping the local immune response 
should preferably encounter a strong specific systemic response, which ideally 
should include effective VN antibodies and CTL which would allow the killing 
of infected cells early in the viral replication cycle. To reduce the emergence 
of escape mutants it would be advantageous if antiviral immunity would be 
based on a variety of preferably conserved epitopes. 
Our main efforts have focused on the development of lentivirus vaccines 
based on attenuated recombinant Salmonella strains. Attenuated Salmonella 
strains used as carrier show promise as Ientivirus vaccines as they are able to 
induce specific local and systemic immune responses including class I restricted 
CTL responses. They have the capacity to express large heterologous genes 
enabling them to present a large number of viral Band T cell epitopes. 
Furthermore, they will be inexpensive to produce and easy to administer 
(orally), which are both important features, especially for third world countries 
where an HIV vaccine is most needed. However, a major obstacle in the 
development of vaccines based on live recombinant Salmonella strains, is that 
the amount of heterologous antigen required to induce an adequate immune 
response is often toxic for the recombinant bacteria. Therefore an expression 
system was developed that allows the continuous production of antigen by a 
bacterial population in spite of toxicity for individual producing bacteria. The 
system is based on a temperature inducible PL promoter which inverts at 
random. This inversion is the result of recombination between two inverted 
repeats that border the promoter, by the site-specific recombinase Gin. The 
gene of interest is only expressed in one orientation of the promoter (ON-
orientation), but not in the other (OFF-orientation). Provided the inversion 
frequency of the PL promoter is low enough, only a minor part of the bacterial 
popUlation will produce toxic levels of antigen, leaving the major part of the 
population unaffected. Unaffected by antigen production, the non-producing 
population may disseminate within the host and segregate new antigen 
producers. In this way antigen production can continue ill vivo until the S. 
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typhimllrillm aroA mutant is cleared. In chapter 2 this expression system is 
evaluated using the Cholera toxin B subunit (CtxB) as a model antigen. Plasmid 
pYZI7 contains the ctxB gene under control of the invertible PL promoter. 
Restriction enzyme digest on pYZ17 DNA revealed that the fast majority of the 
PL promoters were in the OFF position, demonstrating selection against the ON 
form. BALB!c mice orally immunized with the Salmonella typhimllrillm aroA 
vaccine strain SL3261 harbouring pYZI7, induced high titres of CtxB specific 
IgG and IgA serum antibodies as well as secretory IgA in the gut. Nearly 100% 
of the bacteria stably maintained pYZl7 for several weeks in vivo. 
In a single CtxB producing cell, on average only a fraction of the PL 
promoters will be in the ON orientation. Therefore only a fraction of the ctxB 
gene copies will be expressed. We anticipated that antigen production could be 
increased considerably if a single promoter inversion would result in the 
expression of all the copies of the gene of interest. Therefore an improved 
invertible promoter expression system was developed and evaluated (chapter 3). 
This improved system consists of two different plasmids in one bacterial cell. 
One plasmid containing the gene of interest under control of a T7 promoter and 
the other containing the T7 RNA polymerase gene under control of the 
invertible PL promoter. In this configuration a single promoter inversion 
results in the production of T7 RNA polymerase, which in turn will direct 
expression of all the gene copies under control of the T7 promoter. Using this 
two-plasmid system, much higher levels of CtxB could be obtained than with 
pYZI7. The higher production levels resulted indeed in enhanced CtxB specific 
serum IgG and IgA responses and sIgA responses in the gut of BALB/c mice 
after oral administration. It also induced enhanced CtxB specific serum IgG 
responses following i. p. immunization. 
Following a promoter inversion, it will take longer before toxic 
production levels are obtained for a weakly toxic antigen than for more toxic 
antigens. Weakly toxic antigens will therefore allow a larger time span before 
cell division becomes impossible. In other words, weakly toxic antigens will 
tolerate a higher inversion frequency than more toxic antigens. To achieve 
optimal antigen expression, that is the maximum expression level that allows 
reasonably stable maintenance of the expression system, a series of different 
invertible promoter plasmids (pIPI to pIPS, see Fig. I of chapter 3) was 
constructed. These plasmids differed in the relative orientation of gin and 
c/857, the composition of the untranslated leader of gin, or their copy numbers, 
which can all in their own way affect the inversion frequency. Different 
inversion frequencies may be reflected in different percentages of antigen 
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expressing cells and thereby in different amounts of antigen produced by the 
bacterial population as a whole. This was initially demonstrated for expression 
of the gene fusion between gene-IO of bacteriophage T7 and a 580 bp ellv 
fragment from HIV-I. Of the intermediate copy number plasmids pIPl to -3, 
the highest expression of this gene fusion was revealed by pIPl, followed by 
pIP2 and finally pIP3. As expected, the low copy number plasmids pIP4 and 
pIP5 revealed less antigen production than their higher copy number 
counterparts pIP2 and pIP3, respectively. Similar observations were made for 
the maltose binding protein (MBP) production obtained with pIP3 and pIP5 
(chapter 3) and production of the MBP-Gag FlV fusion protein obtained with 
pIP2 to -5. (chapter 5). 
The two plasmid system can be used to produce toxic antigens. This was 
demonstrated for the gene-IO-env fusion protein. When induction of T7 RNA 
polymerase is under control of a fixed PL -promoter, so that protein production 
upon temperature induction will OCClll' in all the cells of a bacterial population, 
colonies could only be recovered when the PL promoter was not induced. 
However, when expression of the T7 RNA polymerase gene was under control 
of the invertible PL_promoter, a comparable number of colonies was recovered 
at inducing and non-inducing temperatures. In spite of this toxic antigen 
production, most combinations of pET3xa-env with the different pIP vectors 
were essentially stably maintained ill vivo, except for the combination with 
pIPI. This combination resulted in the highest antigen production levels, 
suggesting that the extreme instability observed with pIP I might be the result of 
toxic antigen production in close to or more than 50% of the bacteria. The 
plasmid stability after growth of S.rypililllllrilllll in cell lines was determined 
and appeared to correlate with ill vivo stability. Thus, an indication of plasmid 
stability ill vivo may be obtained before animal experiments are initiated by 
determining the stability in cell lines. 
Using the immunogenic maltose binding protein as a model antigen, it was 
demonstrated that the specific humoral response obtained after oral 
administration of SL3261 harbouring the invertible promoter system, was 
nearly forty times stronger than with a fixed promoter system (chapter 3, Fig. 
7). This is most likely due to the higher viability of the bacterial population that 
employs the invertible promoter system. The non-producing ·part of this 
popUlation will be able to actively infect the GALT and system lymphatics, 
meanwhile segregating new MBP producing bacteria. However, it is 
conceivable that the bacteria harbouring the fixed promoter system, become 
severely inhibited in their ability to invade the local and systemic lymphatics 
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soon after administration, as the vast majority of the bacteria loose viability 
within 45 minutes following exposure to a temperature of 37 0C ill vitro. 
Chapter 3 described to use of the invertible promoter system for the 
production of a viral (Env) and two bacterial (CtxB and MBP) proteins. The 
general applicability of the expression system for the continuous production of 
antigens at high levels, was further illustrated by the study described in chapter 
4. In this study the system was used to express high levels of the Tam1-1 and 
Tamsl-2 merozoite surface antigens of the parasite Theileria alllllliata by the 
Salmonella vaccine strain SL3261. Two days after infection of the macrophage 
cell line J774.16, the majority of these bacteria stably retained pIPS in 
combination with the Taml-l or Taml-2 containing plasmid. The stability in 
combination with plP2 was about half of that observed for pIPS. 
FlV infection of cats is considered a useful small-animal model for the 
evaluation of vaccine strategies relevant for controlling HlV -1 infections in 
humans. To evaluate the potential of recombinant Salmollella strains as 
candidate lentivirus vaccines, FlV antigens were expressed in SL3261 using the 
two plasmids system. Initially the ability of SL3261 as a carrier to present 
heterologous antigens to the feline immune system was determined. Salmollella 
typhimurium aroA strain SL3261 expressing the MBP-FlV Gag fusion protein 
and CtxB as a control, proved to be immunogenic in cats, as high specific 
serum antibody titres to Salmollella LPS, CtxB and MBP developed after a 
single immunization. Specific serum antibodies against Gag developed after a 
second i.p. immunization. No Gag specific antibodies were induced in the orally 
immunized cat, but this cat was primed for Gag by this immunization 
procedure as demonstrated by the faster development of Gag specific antibodies 
after FlV challenge of this cat compared to the control cats. It is unlikely that 
this faster antibody response is the result of enhancing antibodies acting at 
levels below the detection limit, as it is unlikely that antibodies against the 
capsid proteins will induce enhancement of infectivity. Also, the viral loads 33 
days post challenge in the cat orally immunized with the MBP-Gag expressing 
Salmonella was not higher than that of the control cats. Although this study 
demonstrated the ability of Salmonella to present antigens to the feline immune 
system, the immunisation failed to protect the cats against a challenge with 
homologous· molecular cloned FlV. The vaccination schedule was therefore 
extended. Two experimental FlV vaccines were tested, either alone or in 
combination. One vaccine (SL3261-FlV) incorporated SL3261 strains 
expressing Gag, as well as strains expressing part of the envelope protein (Env) 
of FlV. The other vaccine was composed of bacterial derived FlV -Gag and 
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recombinant vaccinia virus derived FIV-Env proteins incorporated in immune 
stimulating complexes (iscom-FIV). Cats of group A received four 
immunisations with SL3261-FIV and cats of group B two immunisations with 
SL3261-FIV, followed by two immunizations with iscom-FIV. Cats of group C 
were immunised twice with the CtxB expressingSL3261 strain (SL3261-CtxB) 
followed by two immunisations with iscom-FIV. The cats of group D, which 
served as a negative control, were immunized twice with SL3261-CtxB and 
twice with iscom in which the Gag and Env proteins of SIV had been 
incorporated (iscom-SIV). It was hoped that the SL3261 and iscom 
immunisation would complement each other. Both are able to induce class I 
restricted CTL, but may do so by different routes. The induction of CD8+ 
CTLs by iscoms is most likely a result of entry into the endogenous pathway of 
antigen processing and presentation 7, while SL3261 may have access to an 
alternative route of class I restricted presentation, described for particulate 
antigens (for review see ref. 4) that requires phagocytotic APCs. Furthermore, 
the glycosilated vaccinia derived Env protein in the iscom preparation, may 
present additional VN epitopes that are absent from the non-glycosilated Env 
produced by SL3261. Specific antibodies were induced much more efficiently 
by immunisation with iscom-FIV than by immunisation with SL3261-FIV. 
Repeated immunisations with the last, did not induce detectable Env-specific 
antibody responses and only weak Gag-specific responses. However, cats that 
had previously been immunized with SL3261-FIV were primed, as Gag-specific 
antibodies developed faster in these cats after immunisation with iscom-FIV, 
compared to cats previously immunized with SL3261-CtxB. Two weeks after 
the last immunisation all the cats were FIV -challenged. At this time point all the 
cats that had received iscom-FIV had developed considerable serum antibody 
responses to Gag and Env, while these responses were weak or undetectable in 
the cats immunized four times with SL3261-FIV. Seven weeks after FIV-
challenge the Env-specific antibody responses had increased considerably in the 
cats of all groups, apart from the group immunised four times with SL3261. By 
sixteen weeks post challenge only one cat of this group had developed a 
considerable anti-Env response, comparable with that of the negative control 
cats. The overall virus load, as determined by the number of FIV infected 
PBMC and by PCR end-point titration, was lowest in group A at all time 
points. Taken together, these data strongly suggests that the cats immunized 
four times with SL3261-FIV were partially protected against FIV-challenge. It 
is unlikely that the reduced virus load in this group was a result of VN 
antibodies, as no significant Env-specific antibody titres were detected and only 
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weak Gag-specific titres. Furthermore, in spite of much higher specific serum 
antibody titres in the cats immunised with iscom-FIV, no reduced virus load 
was observed in these cats. It seems therefore more likely that a cellular 
response is at the basis of the observed reduced virus load. The cats of the 
previous study, immunized only with SL3261-Gag, were not protected against 
FIV-challenge, suggesting that SL3261-Env contributed to the observed partial 
protection. These results are in accordance with the observation that Env but 
not Gag-specific CTL responses correspond with protection against FIV 
infection I. Care should be taken in the interpretation of these resnlts, however, 
as the group sizes were small and the used immunisation schedules not identical. 
In chapter 7 the evaluation of different FIV envelope preparations 
incorporated in iscoms is described. Two different recombinant vaccinia virus 
derived glycosilated envelope proteins and a non-glycosilated bacterially 
produced b-galactosidase-Env fusion protein were compared. Both glycosilated 
proteins were identical except that one was expressed from an env gene in 
which the region encoding the cleavage site between the surface and the 
transmembrane proteins, had been deleted to facilitate incorporation of the FIV 
SU protein into iscom. Env was prepared using a recombinant vaccinia virus 
expression system. The different envelope proteins incorporated into iscom, 
and the relevant control preparations - cleavage site deleted FIV glycoproteins 
mixed with Quil A, and a SIV iscom preparation - were used to immunise cats. 
The highest Env specific serum antibody responses and VN antibody responses 
were induced by the iscoms preparations that contained the vaccinia virus 
derived envelope proteins, with no significant difference between the envelope 
proteins with and without cleavage site. In accordance with earlier studies3 the 
responses were considerably weaker when Env was not incorporated in iscom, 
but just mixed with Quil A. The b-galactosidase-Env fusion protein iscom 
preparation was least effective in the induction of Env-specific antibodies and 
failed to induce detectable levels of VN antibodies. All vaccine preparations 
failed to protect cats against FlV challenge. More striking, the preparations that 
induced VN antibodies detectable in the CrFK VN assay even enhanced FIV 
infectivity. This enhancement effect could be transferred with plasma of the 
vaccinated cats, indicating that it was mediated by antibodies. 
Although iscom-FIV induced antibodies much more effectively than 
SL3261-FIV, it had no protective effect against FIV infection of cats. SL3261-
FIV, on the other hand, did not induce detectable antibody responses to Env and 
induced only weak responses to Gag, but the data suggest that cats immunised 
four times with this vaccine were partly protected against FlV infection. A 
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number of studies support the view that the use of attenuated Salmonella strains 
as carries for heterologous antigens favours the induction of a Type-I immune 
response8, whiCh is characterised by a dominant cellular response, as opposed 
to a Type-2 response which favours the development of antibody responses. In 
HIV -I infected individuals the switch from a dominant Type-l immune 
response to a dominant Type-2 response is associated with a fast progression 
towards AIDS. It may be speculated that the immunization with the Env- and 
Gag-expressing SL3261 strains has driven the immune system to the more 
favourable Type-l response, while the immunization with iscom-FIV, directed 
the immune system to the less favourable Type-2 response. This hypothesis is in 
accordance with the relatively low cell-associated virus load and with the weak 
induction of antibodies against SUI and SU3 in the cats immunized four times 
with the Gag- and Env-expressing SL3261 strains upon FIV challenge. It would 
also explain why the antibody response to Gag following the first iscom-FIV 
immunization is faster, but not stronger in cats primed with SL3261-FIV 
(group C) compared to unprimed cats (group B). The second iscom-FIV 
immunisation may have driven the immune system further toward a Type-2 
response, thereby undoing any potentially protective effect from the SL3261-
FIV priming. 
Concluding remarks 
The invertible promoter system described in this thesis is very universal. In 
principle it allows the continuous expression of every gene that can be 
expressed with the T7 RNA polymerase/T7 promoter systems described by 
Studier et al.5 and Tabor6, even if gene expression is toxic. In fact, due to the 
high transcription levels obtained, expression of most genes employing the T7 
RNA polymerase system will be toxic for the expressing bacteria5. In its 
current form the invertible promoter system should be considered as a 
prototype. The antibiotic resistance genes present on the plasmids, make its use 
in a human vaccine unacceptable. Only low copy numbers of the T7 RNA 
polymerase gene are needed. Therefore the T7 RNA, polymerase gene and its 
invertible promoter can be integrated into the chromosome, obviating the need 
of antibiotic selection pressure to stably maintain the gene. To obtain high 
production levels of the antigen of interest, the corresponding gene should be 
present on a high copy number plasmid. To allow stable maintenance of this 
plasmid in the absence of antibiotic selection pressure, the ampicillin resistance 
gene can be replaced by an essential genes that has been deleted in the carrier 
strain. For this purpose the well characterised asd-system described by 
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Nakayama et al.2 can be used. Both modifications have the additional advantage 
that they will further stabilise the expression system. 
Although none of the vaccine strategies tested in this study fully protected 
cats against FlV infection upon challenge, the reduced virus load observed in 
cats immunized four times with SL3261-FlV compared to control cats is 
encouraging. More extended vaccine studies using attenuated Salll10nelia strains 
as carriers will have to demonstrate the true significance of this approach for 
lentivirus vaccine development. Whatever the outcome of these studies, the 
ability of the invertible promoter system to allow the abundant expression of 
(toxic) heterologous antigens by recombinant Salmonella strains, may greatly 
facilitate the evaluation of these live carriers as candidate vaccines against a 
variety of other pathogens. 
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Samenvatting 
Ondanks grote inspanning is er tot op heden nog geen veilig en effectief vaccin 
ter voorkoming van HIV -1 infecties ontwikkeld. Een aantal eigenschappen van 
lentivirussen, zoals hun extreme variabiliteit en hun vermogen om als provirus 
"onzichtbaar" voor het immuunsysteem te persisteren, bemoeilijken de 
ontwikkeling van een dergeJijk vaccin. Een vaccin dat in staat is een effektieve 
mucosale immuunrespons te induceren, zal in een vroeg stadium replicatie van 
het binnenkomende virus kunnen beperken of zelfs voorkomen. Een sterke 
systemische immuunrespons, bestaande uit cytotoxische T- cellen (CTL) die een 
geYnfecteerde eel vroeg in de replicatiecyclus kunnen vernietigen, alsmede virus-
neutraliserende (VN) antilichamen, moeten dan de virussen uitschakelen die aan 
de mucosale immuunrespons ontsnapt zijn. Om het onstaan van zogenaamde 
"escape"-mutanten zoveel mogelijk te voorkomen, zou de antivirale immuniteit 
op een aantal, bij voorkeur geconserveerde, epitopen gebaseerd dienen te zijn. 
Het in dit proefschrift beschreven onderzoek heeft zich allereerst 
geconcentreerd op de ontwikkeling van lentivirusvaccins gebaseerd op 
geattenueerde recombinant Salmonella stammen. Deze stammen koloniseren na 
orale toediening de lymfoYde weefsels van het darmkanaal (de GALT) en 
vervolgens de systemische lymphoYde organen. Geattenueerde Salmonella 
stammen zijn veelbelovend als "dragers" voor lentivirus-antigenen, omdat zij in 
staat zijn specifieke lokale en systemische immuunresponsen, waaronder klasse I 
gerestrikteerde CTLs, te induceren. Ook zijn ze in staat grote heterologe genen, 
met veel virale B en T cel epitopen, tot expressie te brengen. Verder zullen dit 
soort vaccins relatief goedkoop geproduceerd en eenvoudig (oraal) toegediend 
kunnen worden. Deze laatste twee eigenschappen zijn met name van belang voor 
Derde-Wereld landen, waar een HIV-vaecin het meest nodig is. Om een 
voldoende sterke specifieke immuunrespons tegen het heterologe antigeen te 
indueeren l)lOet doorgaans eehter veel van het antigeen door de baeterien 
geprodueeerd worden. De prod uk tie van deze hoeveelheden is vaak toxiseh voor 
de baeterien, hetgeen resulteert in een te sterke attenuatie van de bacterien en/of 
instabiliteit van de antigeenproduktie. Beiden resulteren in de presentatie van 
suboptimale hoeveelheden antigeen aan het immuunsysteem. Er is daarom een 
expressiesysteem ontwikkeld dat een bacteriele populatie in staat stelt 
voortdurend grote hoeveelheden heteroloog antigeen te produeeren, ondanks dat 
dit toxiseh is voor de individuele produeerende baeterien. Het systeem is 
gebaseerd op een temperatuur-indueeerbare PL promoter die van orientatie kan 
veranderen. Deze inversie is het resultaat van reeombinatie tussen twee "inverted 
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repeats" waartussen de PL promoter gesitueerd is. Slechts in een orientatie van 
de PL promoter (AAN-orientatie), maar niet in de andere (UIT-orientatie), zal 
het heterologe gen tot expressie komen. De essentie van het systeem is, dat slechts 
een minderheid van de bacterien toxische hoeveelheden antigeen produceert. 
Hierdoor blijft het grootste deel van de populatie onaangetast. Dew niet 
producerende bacterien zijn in staat de infectie voort te zetten en zullen door 
promoter inversies voortdurend nieuwe antigeen producerende bacterien 
voortbrengen. Op deze wijze kan de presentatie van antigeen aan het 
immuunsysteem voortgezet worden, tot de geattenueerdeSalmonelia stam 
uiteindelijk uit het lichaam verdwijnt. In hoofdstuk 2 van dit proefschrift is de B 
subunit van Cholera toxine (CtxB) gebruikt om dit expressiesysteem te 
evalueren. Plasmide pYZ17 bezit het ctxB gen onder de controle van de 
inverteerbare PL promoter. Restriktieenzym analyse van p YZ17 DNA wees uit 
dat het merendeel van de PL promoters zich in de UIT -orienta tie beyond. Er 
vindt dus selectie plaats tegen de AAN-orientatie. Een Salmonella vaccin-stam dat 
pYZ17 bevatte werd vervolgens via een maagsonde aan BALB/c muizen 
toegediend. Deze muizen ontwikkelden hoge titers CtxB-specifiek IgO en IgA in 
hun sera en tevens secretoir IgA in de darmen. Bijna 100% van de bacterien 
behield p YZ 17 gedurende enkele weken in vivo. 
In een CtxB producerende bacterie zal doorgaans slechts een deel van de 
PL promoters de AAN-orientatie hebben. Daarom zal slechts een deel van de 
ctxB genen in zo'n bacterie aan de CtxB produktie bijdragen. Als een enkele 
promoterinversie in de expressie van aile ctxB genen binnen die bacterie zou 
resulteren, dan zou de CtxB produktie aanzienlijk vergroot kunnen worden. In 
hoofdstuk 3 is een expressiesysteem beschreven dat dit mogelijk maakt. Dit 
verbeterde expressiesysteem bestaat uit twee verschillende plasmiden. Een van de 
plasmiden bezit het ctxB gen onder controle van een T7 promoter. Het andere 
plasmide bevat het T7 RNA polymerase gen onder controle van de inverteerbare 
PL promoter. Door deze configuratie zal een enkele promoter inversie in een 
bacterie leiden tot de produktie van T7 RNA polymerase. Dit zal op zijn beurt 
resulteren in de expl'essie van aile ctxB genen binnen deze bacterie. Dit 2-
plasmiden systeem resulteerde inderdaad in een veel hogere CtxB-produktie dan 
met p YZ17 verkregen kon worden. De hogere produktie 1eidde na orale 
toediening tot aanzienlijk hogere CtxB-specifieke IgO en IgA titers in de sera, en 
sIOA titers in de darmen van BALB/c muizen. 
Om de algemene toepasbaarheid van het verbeterde inverteerbare 
promoter (IP) expressiesysteem te demonstreren, werden een ander bacterieel 
antigeen (het maltose bindend protei'ne (MBP)), een viraal antigeen (een deel van 
164 
het HIV-I envelopeiwit gefuseerd met het gen-lO eiwit) en twee protozoaire 
antigenen (de Taml-l en Taml-2 merozoYet oppervlakte antigenen van Theileria 
ann Illata (hoofdstuk 4)) tot expressie gebracht. Met het IP-systeem konden al 
deze genen continu en in grote hoeveelheden geproduceerd worden. Wordt 
expressie van T7 RNA polymerase echter gecontroleerd door een gefixeerde 
promoter, zodat antigeen produktie na temperatuur induktie in aile cellen van de 
bacteriele populatie plaats vindt, dan kunnen de bacterien aileen groeien bij een 
temperatuur waarbij de PL promoter onderdrukt blijft. 
Het immunogene MBP werd als model antigeen gebruikt om het voordeel 
van het IP-systeem voor vaccinatiedoeleinden te demonstreren. Na orale 
immunisatie van muizen werd een bijna 40 maal sterker MBP-specifieke 
antilichaam respons met het IP-systeem verkregen, dan met het gefixeerde 
promoter systeem. Vervolgens werd het IP-systeem gebruikt om het Gag eiwit 
van het feline immunodeficientie virus (FIV) als fusieeiwit met MBP tot 
expressie te brengen. Salmonella stammen die dit fusieeiwit of, als een controle, 
ctxB expresseerden bleken immunogeen in katten. Een enkele immunisatie 
resulteerde in hoge specifieke antilichaamresponsen tegen Salmonella LPS, CtxB 
en MBP. Tevens werden na een tweede i.p. immunisatie ook FIV Gag specifieke 
antilichamen geYnduceerd. Orale immunisatie induceerde geen Gag-specifieke 
antilichaam respons, maar resulteerde wei in Gag-specifieke "priming". 
Of schoon dit experiment aantoonde dat Salmonella in staat is antigenen aan het 
immuunsysteem van katten te presenteren, beschermde de immunisatie de katten 
niet tegen een experimentele infectie met FlV. Het vaccinatieschema werd 
daarom uitgebreid. Naast Gag producerende Salmonella stammen werden tevens 
FIV-Env producerende stammen toegediend. Bovendien kregen de katten dit 
Salmonella-FlY vaccin zowel oraal als i.p. toegediend. Een ander vaccin bestond 
uit recombinant FIV-Gag en FIV-Env geYncorporeerd in immuun stimulerende 
complexen (iscom). Na FIV -infectie was aileen in de groep katten die vier maal 
met het Salmonella-FlY vaccin geYmmuniseerd was, de virus titer lager dan in de 
controle groep. Verder was na FIV -infectie de Env-specifieke 
antilichaamrespons in deze groep veel zwakker dan de overige groepen. Deze 
resultaten suggereren dat de vier immunisaties met Salmonella-FlY een zekere 
mate van bescherming tegen infectie met FlV induceerden. 
Het laatste dee I van het proefschrift beschrijft de evaluatie van 
verschillende subunitvaccins gebaseerd op FIV -envelopeiwitten. Geglycosyleerd 
envelopeiwit met of zonder de klievingsplaats en een bacterieel geproduceerd 
ongeglycosiJeerd FIV -envelop fusieeiwit, werden geYncorporeerd in iscoms of 
gemengd met QuilA als adjuvant. Al deze vaccins induceerden Env-specifieke 
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antilichamen in katten, maar er bestonden duidelijke verschillen tussen de 
responsen gernduceerd door enerzijds de geglycosileerde eiwitten en anderzijds 
het ongeglycosileerde envelopeiwit. Zo induceerden uitsluitend de 
geglycosileerde eiwitten antilichamen die in staat waren FIV-infectie van een 
kattenier cellijn te neutraliseren. Verder herkenden de antilichamen ge'induceerd 
met de geglycosileerde eiwitten meer verschillende regio's van het envelopeiwit. 
Na infectie met FIV bleek in de katten die met de geglycosileerde eiwitten 
ge'immuniseerd waren, eerder virus in het bloed aantoonbaar, dan bij de katten 
van de andere groepen. Deze versnelde infectie kon met plasma van de 
gevaccineerde dieren worden overgebracht naar na'ive katten. 
Geen van de vaccinstrategien beschreven in dit proefschrift was in staat 
katten volledig tegen een experimentele FlV infectie te beschermen. Het is echter 
bemoedigend te zien dat de virustiter na experimentele FlV-infectie lager was in 
de groep katten die vier maal met Salmonella-FlY ge'immuniseerd was, dan in 
de controle groep. Meer uitgebreide vaccinstudies waarin Salmonella stammen 
als dragers van lentivirus antigenen gebruikt worden zullen het uiteindelijke 
belang van deze benadering voor de ontwikkeling van lentivirus vaccins moeten 
demonstreren. Het vermogen van het inverteerbare promoter systeem om 
continu grote hoeveelheden (toxisch) antigeen door recombinante Salmonella 
stammen te laten produceren, zal de evaluatie van deze levende dragers als 
candidaat vaccins tegen lentivirussen en andere pathogenen aanzienlijk 
vereenvoudigen. 
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